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Abstract 
Epidemiological studies suggest that the availability of methyl-donor nutrients may 
influence the risk of cervical cancer and of cancer progression. This effect may be mediated 
by altered DNA instability and aberrant DNA methylation. The aim of this study was to 
develop and validate an appropriate in vitro model of methyl donor depleted cervical cancer 
cells and to use this model to investigate effects of methyl donor depletion on cell processes 
relevant to cancer risk and progression.  
The human cervical cancer cell lines, C4-II and SiHa were selected for study. Cells 
were grown in complete medium and in medium depleted of folate alone and in medium 
depleted of methionine and folate. Growth rate, intracellular folate, intracellular methionine, 
and extracellular homocysteine were measured to validate the cervical cancer cell model of 
methyl donor depletion. The depleted cells showed >20-fold reduction of intracellular folate 
concentration in both cell models and a 60% reduction of methionine concentration in C4-II 
cells. Methyl donor depletion led to a greater reduction in the growth rate of C4-II than SiHa 
cells. Extracellular homocysteine was significantly raised by methyl donor depletion 
compared with controls.  
Global DNA methylation was measured using a flow cytometric method. Combined 
depletion of folate and methionine led to an 18% reduction in global DNA methylation in C4-
II cells but had no significant effect in SiHa cells; accordingly, only C4-II cells were used for 
further study. The expression of DNA methyl transferases (DNMTs) was measured using 
semi quantitative RT-PCR. Methyl donor depletion led to a significant down-regulation of 
DNMT3a and DNMT3b, which showed a 2.62 (P= 0.024) and 3.60-fold (P= 0.001) reduction 
in expression respectively. Total DNMT activity was increased by folate and methionine 
depletion cells (P= 0.001), although there are concerns about the quality of the assay used. 
Effects of folate and methionine depletion on cell growth, and DNMT3a and DNMT3b 
expression were reversed by transferring depleted cells to growth in complete medium.  
Gene microarray analysis was carried out in order to identify genes and pathways 
affected by methyl donor depletion. A high proportion of genes associated with cell death, 
cell communication, and cell motion were up-regulated whilst a high proportion of genes 
associated with regulation of the cell cycle, cytoskeleton organisation, and chromosome 
organisation were down-regulated. Despite findings from the gene microarray were 
suggestive of effects on cell migration rate this was not found to be significantly influenced 
by methyl donor depletion, using the scratch assay.  
Methyl donor status reversibly influences DNMT expression in cervical cancer cells in 
vitro, which may explain effects on global hypomethylation. Alterations in expression of other 
genes in response to methyl donor depletion are suggestive of cancer-promoting effects. 
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Chapter 1 Introduction 
 
Micronutrient deficiency is known to play an important role in the development of many 
conditions including night blindness, anaemia, and peripheral neuropathy. Additionally, there 
is evidence that some micronutrients have an important influence on the risk of cancer at 
various sites (Jacobs et al., 2003; Powers, 2005; Park et al., 2007). There are various 
factors which seem to be important for cancer risk and cancer progression such as smoking, 
infection, and diet. A few nutrients have been clearly shown to have a role in determining 
cancer risk (García-Closas et al., 2005); there is particular interest in the role of methyl 
donors because of their importance to DNA synthesis/repair and DNA methylation, which are 
known to influence carcinogenesis (Duthie et al., 2004; Kim, 2005). 
1.1 Cancer 
This thesis described and investigation of methyl-donor deficiency on aspect of DNA 
methylation, gene expression and the cervical cancer phenotype. The interpretation of our 
findings necessitated an understanding of those processes thought to be especially pertinent 
to the cancer process. This understanding is informed by the work of Hanahan and 
Weinberg (2000 and 2011) who proposed hallmarks of cancer to characterise the cancer 
process (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). The hallmarks of cancer 
are summarized below. 
 
I. Sustaining proliferative signalling 
Normal tissues work to ensure a balance between cell death and proliferation 
through cell cycle signals. In contrast, cancer cells have their own signals and deregulate the 
cell cycle (Collins et al., 1997). Our understanding of the mechanisms of cell signalling in 
normal cells is fairly limited, research into cell signalling in cancer cells is better understood. 
Cancer cells may organize their own growth factor ligands to produce autocrine proliferative 
stimulation or send the stimulated signal to normal cells to send back the various supporting 
growth factors (Bhowmick et al., 2004; Cheng et al., 2008). Cancer cells may also increase 
their receptor proteins in order to access more signals and operate an independent 
downstream signalling pathway within the cells. This hallmark is likely to involve the 
activation of downstream pathways such as the mitogen activated protein (MAP)-kinase 
pathway and phosphoinositide 3-kinase (PI3-kinase) (Castellano & Downward, 2011). 
Cancer cells also have mechanisms which disrupt the intrinsic negative-feedback, therefore, 
they can sustain proliferative signals. Moreover, the elevation of oncogenic signals from 
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RAS, MYC, and RAF in cancer cells leads to cell adaptation by disabling senescence- or 
apoptosis-inducing circuitry (Lowe et al., 2004; Evan & d'Adda di Fagagna, 2009; Collado & 
Serrano, 2010). 
 
II. Evading growth suppressors 
To sustain growth stimulating signals, the cancer cells do not operate to negatively 
regulate cell proliferation. Two well-known key tumour suppressors, RB (retinoblastoma-
associated) and TP53, play an important role in this. Generally, the RB and/or TP53 pathway 
is defective in cancer cells (Kastan & Bartek, 2004). In addition, the loss of contact inhibition 
can disrupt growth suppressors; this has occupied researchers for about the last four 
decades of research, but the mechanism is only just being understood. Moreover, 
interference in the TGF-β pathway (antiproliferative effect) is reported to promote 
malignancy (Derynck et al., 2001). 
III. Resisting cell death 
Cancer cells evolve their ability to limit apoptosis, commonly by the functional loss of 
the TP53 tumour suppressor gene (Fridman & Lowe, 2003). For the same purpose, cancer 
cells may increase their expression of antiapoptotic regulators such as Bcl-2 and Bcl-xL, and 
also up-regulate survival signals (IGF1/2) (Shortt & Johnstone, 2012). A defect in autophagy 
is also a mechanism to drive cancer cells to resist cell death. Autophagy is a self-
degradation process which is up-regulated by stress signals such as growth factor 
deprivation, starvation, and pathogen infection (He & Klionsky, 2009). In addition, necrotic 
cancer cells can release proinflammatory signals to the surrounding microenvironment, 
which promote angiogenesis, proliferation, and invasion, such as IL-1α to facilitate cancer 
progression (Apte et al., 2006). 
IV. Enabling replicative immortality 
Immortalization is the ability to proliferate without evidence of senescence or crisis. 
There is evidence that unlimited proliferation results from telomeres protecting the end of the 
chromosomes (Shay & Wright, 2000; Blasco, 2005) and the presence of telomerase (DNA 
polymerase which adds telomere segments) is associated with a resistance to entering 
senescence and crisis/apoptosis (Reddel, 2000). 
V. Inducing angiogenesis 
To support their metabolism, in terms of receiving nutrients and oxygen or removing 
waste products, cancer cells generate neovasculature. Important angiogenesis factors are 
vascular endothelial growth factor-A (VEGF-A) and thrombospondin-1 (THBS-1).  VEGF-A is 
an angiogenetic inducer which is up-regulated by hypoxia and oncogenic signals (Carmeliet, 
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2005; Gabhann & Popel, 2008; Ferrara, 2009). The VEGF ligands can be activated by 
extracellular matrix-degrading proteases such as MMP-9 (Kessenbrock et al., 2010). TSP-1 
is an angiogenetic inhibitor which binds to transmembrane receptor and counterbalances 
proangiogenic stimuli (Kazerounian et al., 2008).  The chronic up-regulation of fibroblast 
growth factor (FGF) is also one of the proangiogenic signals (Baeriswyl & Christofori, 2009). 
 
VI. Activating invasion and metastasis 
The key factor in this hallmark is the cell-to-cell adhesion molecule, E-cadherin. This 
molecule supports the assembly of epithelial cell sheets. The down-regulation of E-cadherin 
indicates the promotion of invasion and metastasis (Cavallaro & Christofori, 2004; Berx & 
van Roy, 2009). The genes expressing cell-to-cell and cell-to-ECM adhesion molecules, 
which support cytostasis, are typically down-regulated in this hallmark. In contrast, genes 
which encode adhesion molecules involved in cell migration, are up-regulated such as N-
cadherin in the migrating neuron (Hazan et al., 2000). 
VII. Reprogramming energy metabolism 
In order to supply sufficient energy for unlimited proliferative potential and rapid 
division, cancer cells need to adapt themselves to deal with an estimated 18-fold higher 
requirement of ATP by an up-regulation of glucose transporters (GLUT1) (DeBerardinis et 
al., 2008; Hsu & Sabatini, 2008; Jones & Thompson, 2009). An increased Ras oncoprotein 
and hypoxia in cancer cells also leads to an increase in HIF1α and HIF2α transcription 
factors in order to up-regulate glycolysis (Kroemer & Pouyssegur, 2008; Semenza, 2010b; 
Semenza, 2010a). 
VIII. Evading immune destruction 
Basically, the immune system has a responsibility to destroy pathogens or foreign 
bodies in the body. In a similar way to pathogens, cancer cells should be recognised and 
eliminated by the immune system. However, the existence of cancer cells at all somehow 
indicates that cancer cells can avoid elimination (Dunn et al., 2002; Schreiber et al., 2011). 
Cancer susceptibility is not only limited to the immunocompromised patients with virus-
induced cancer, but occurs in non-virus-induced cancers. According to tumour-host 
immunological interactions, the immune system of the host can be destroyed by highly 
immunogenic cancer cells. 
All 8 hallmarks are coordinated to maintain cancer cell characteristics such as the 
alteration of genes in the Wnt signalling pathway, which leads to changes in cell motility and 
also is linked to changes in the expression of other genes important to carcinogenesis. 
Figure 1 illustrates the integrated circuits from individual signals. The 4 sub-circuits show an 
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interconnection between signalling pathways in cancer cells. Individual sub-circuits are 
comprised of multiple hallmark capabilities and lead to the main characteristics of cancer 
cells. Characteristics of cancer cells at specific sites do not necessarily include all of the 
hallmarks summarised above. Furthermore, cervical cancer has the added complexity of 
requiring the presence of the human papillomavirus (HPV).  
The details concealed within the circuits in figure 1 are examined in some depth 
when discussing the findings of our microarray study.  
 
Figure 1: Integrated circuits derived from multiple hallmark capabilities 
(Hanahan & Weinberg, 2011) 
This figure identifies particular cellular functions and expresses these as signalling 
pathways, which Hanahan & Weinberg visualise as circuits. This figure focuses on 
some of the circuits which proved important in the gene microarray study of methyl 
donor depleted cells.  
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1.2 Cervical Cancer 
1.2.1 Epidemiology 
In the 1930s cervical cancer was the most common cancer in American women 
(Schoell et al., 1999). Recent cancer statistics indicate that (figure 2), cervical cancer is the 
third most diagnosed cancer and the fourth major cause of cancer death in women 
worldwide, accounting for 9% (529,800) of new cancer cases and 8% (275,100) of total 
cancer deaths among females (Jemal et al., 2011). Chronologically, the world burden of 
cervical cancer has improved; specifically, since the introduction of the Papanicolaou (Pap) 
smear for screening pre-invasive cervical cancer, the incidence has decreased in developed 
countries (Garner, 2003).  
Cervical cancer used to have a relatively high incidence in middle-aged women, but 
now the peak incidence has shifted toward younger women. In European countries, twenty 
years ago the highest rate of incidence was in women aged between 44 and 49 years, 
whereas in Latin America, Asia and Africa  the peak occurred between the ages of 50 and 
55 (1987). In 2006, data from Cancer Research UK reported that the highest incidence of 
cervical cancer in UK occurred between the ages of 30-40years  (CancerresearchUK, 2009). 
Trends in cervical cancer incidence in most Latin American countries, in African countries, 
and in several Asian countries, have not decreased in the way they have in developed 
countries because of a lack of effective screening programs. About 80% of new cases each 
year are in developing countries (Powers, 2005). 
1.2.2 Pathology 
Cervical cancer can be divided into two types: squamous cell carcinomas (SCC) 
which are the transformation of squamous epithelial cells of ectocervix, and 
adenocarcinomas (AC) which are transformation of glandular epithelial cells of endocervix. 
According to the International Federation of Gynecology of Obstetrics (FICO), cervical 
cancer can be classified by four stages from the less severe level I to the most severe level 
IV. In the context of Bethesda criteria, abnormality of cervical cells can be classified into 
various grades of cervical intraepithelial neoplasia (CIN). CIN 1 (grade I) is a mild dysplasia 
or a low grade squamous intraepithelial lesion (LSIL), which deeply expands into 1/3 of the 
layer of epithelial cells. CIN 2 (grade II) is a moderate dysplasia, which expands for 2/3 of 
epithelial cells. And CIN 3 (grade III) is a severe dysplasia or a high grade squamous 
intraepithelial lesion (HSIL), which expands into more than 2/3 of the epithelial cell layer. 
Women who have dysplasia grade far beyond the CIN 3 are diagnosed as having cervical 
cancer (figure 3). 
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Figure 2: Incidence and mortality rate of cervical cancer update 2011 
(Jemal et al., 2011) 
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Figure 3: Diagram of CIN progression to invasive cancer 
Adapted from (Lowy & Schiller, 2006) 
 
 
Although CIN 1 is the first stage for development of cervical cancer, not all women 
who are diagnosed with CIN 1 develop cervical cancer. The follow-up study in USA of Ostor 
in 1993, found that more than fifty percent of cases of CIN 1 could regress to normal. This 
study also reported that 32% of stage CIN 1 persisted while the progression of CIN 1 to CIN 
3 was 11% and 1% of cases progressed to invasive cancer (Ostor, 1993). The progression 
from CIN 1 to CIN 3 may take a long time or not depending on the individual. Furthermore 
even though the grade of CIN is classified on the basis of a cytological classification system, 
it can be difficult to be certain about the diagnosis of the earliest stage of abnormality, CIN1. 
1.2.3 Causation 
There are several established risk factors for cervical cancer. Owing to many 
chemical carcinogens in tobacco, smoking is associated with an increased risk of several 
kinds of cancer including cervical cancer. Carcinogens cause DNA damage and mutations 
Basal 
epithelium 
Surface of 
epithelium 
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which lead to cancer. A short communication suggested that both smokers and even non-
smokers who are passive smokers are at risk of cancer (Whidden, 1994). In 2006 The 
International Collaboration of Epidemiological Studies of Cervical Cancer reported their 
analysis of 23 studies, and stated that current smokers were inclined to have a greater risk 
of squamous cell carcinoma of the cervix than women who had never smoked (Relative Risk 
(RR) = 1.60 (95% CI: 1.48–1.73), p<0.001). Women who smoke a greater number of 
cigarettes per day (≥ 15) tend to be at higher risk for cervical cancer than never smokers 
(RR= 1.98 (95% CI: 1.78–2.21), (Appleby et al., 2006). However, early studies of risk factors 
for cervical cancer did not take HPV infection into account, which would alter relative risks 
from other factors. 
Parity appears also to influence the risk of cervical cancer. A case-control study in 
four Latin American countries during 1986-1987 found that women with 12 or more live births 
have a four-fold increased risk over women with one or never live births and the relative risk 
for those with 14 or more pregnancies was 5.1(95% CI: 2.7–9.7) (Brinton et al., 1989). This 
study also suggested that the high risk of parity for cervical cancer may because of the 
greater risk of a trauma lesion of the cervix during delivery. The increase in risk does not 
seem to be restricted to only women with very high parity. In 2002, Muñoz et al reported 
results of a cross-cultural study. They gathered parity data from ten case-control studies 
carried out in populations at different risk of cervical carcinoma in eight countries: high risk-
Morocco, Brazil, Peru, Paraguay, and Colombia; intermediate risk-Thailand and Philippines; 
and low risk-Spain. The Odd Ratios for seven or more pregnancies compared with 
nulliparous women was 3.8 (95% CI: 2.7-5.5) and was 2.3 (95% CI: 1.6-3.2) when compared 
with one or two pregnancies (Muñoz et al., 2002). 
Oral contraceptive (OC) use is also a risk factor for cervical cancer. Brinton and 
colleagues conducted a case-control study in Panama, Costa Rica, Columbia and Mexico. 
They demonstrated that long-term users have a higher risk of cervical cancer especially of 
adenocarcinomas (Brinton et al., 1990). There was also a report from the Oxford Family 
Planning Association contraceptive study, which conducted a cohort study of 17000 women 
incorporated within a nested case-control study, which demonstrated that users of various 
OCs had a slightly increased risk for all types of cervical neoplasia compared with non-
users; the Odd Ratio (OR) was 1.40  (95% CI 1.00-1.96). They also pointed out that Odds 
Ratios were highest for invasive carcinoma (OR=4.44, 95% CI 1.04-31.6) and lowest for 
dysplasia (OR=1.07, 95% CI 0.69-1.66). The increasing risk associated with OC use 
appeared to be specific to the group of long-term users of OCs (Zondervan et al., 1996). 
Moreover, a report from 24 epidemiological studies (26 countries worldwide) from the 
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International Collaboration of Epidemiological Studies of Cervical Cancer in 2007, concluded 
that the greater duration of use of combined oral contraceptives, the greater the risk of 
cancer (relative risk = 1.90, 95% CI 1.69–2.13) for five or more years use versus never use 
(Appleby et al., 2007). 
The major risk factor for cervical cancer is infection with human papillomavirus 
(HPV). Many groups have established the importance of HPV which was summarized in the 
publication of Stanley (Stanley, 2006). There are: 
(1) 90-100% of cervical cancer cases have HPV detected. The frequent detection 
were HPV16 (40-60%) and HPV (10-20%) (Lowy et al., 1994). 
(2) HPV DNA can be found in 90% of high grade CIN. HPV-induced lesion was the 
major cause of cytologic abnormalities (Kiviat & Koutsky, 1993).  
(3) Prospective studies show that HPV infections bring about CIN and its progression 
  (4) Primary human keratinocytes can be immortalized by High risk types HPV (HR-
HPVs)  
 
HPV is a DNA virus, which usually infects the epithelium of the host cell. There are at 
least 200 types of HPV and these are usually classified by the potential to induce malignant 
transformation. High risk types HPV (HR-HPV) include HPV16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 73 and 82. The probable high-risk types are HPV26, 53, and 66. The low-
risk types are HPV6, 11, 40, 42, 43, 44, 54, 61, 70, 72, and 81 (Muñoz et al., 2003).  
The expression of E6 and E7 oncogenes of HPV has a major role in cervical cancer 
causation through inactivating cell cycle regulators. E6 inhibits tumor suppressor protein 
function by binding to p53 and induces the degradation of the protein, whereas E7 promotes 
cell growth by binding to retinoblastoma (Rb) gene product (Howley, 1991). Normally, Rb 
forms complexes with the transcription factor, E2F-1, and functions as transcriptional 
repressor. E7-Rb binding leads to the dissociation of Rb-E2F-1 complex, which makes 
transcription factor E2F-1 free for action as a transcriptional activator. A high level of E2F-1 
causes the up-regulation of S-phase genes (Boulet et al., 2007). 
However, despite the evident importance of HPV infection as a cause of cervical 
cancer, not every woman who acquires an HPV infection develops cervical cancer. Clearly, 
other factors must be important in not only determining whether a woman acquires an HPV 
infection but whether an HPV infection persists. Dietary factors may be important. There 
have been several studies of the role of nutrients in cancer not only in the case of cancer 
formation, but also in the case of cancer progression and recurrence. In 1996, The American 
Cancer Society estimated that diet was responsible for one third of cancer deaths in United 
States (The American Cancer Society Advisory Committee on Diet & Cancer, 1996). 
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Potischman and Brinton (1996) also suggested the role of diet on cervical carcinogenesis 
(Potischman & Brinton, 1996). 
1.2.4 Diet as a modulator of cervical cancer risk 
The evidence linking dietary behaviour with cervical cancer risk is quite limited. Early 
studies failed to take account of the importance of HPV infection as a causal factor, and 
therefore, results from these studies may be confounded and need to be considered 
cautiously.  
To evaluate the association of dietary factors with the risk of invasive cervical cancer, 
a case-control study of nutrients in the diet and plasma biomarkers of status and risk of in 
situ cervical cancer was conducted among Australian women. They found that high intakes 
of β-carotene, folate and vitamin C are associated with a lower risk of cervical cancer (Brock 
et al., 1988). In 1991, a case-control study in four Latin American countries was carried out 
by interviewing 748 cases and 1,411 controls, about diet consumption and other important 
details such as sexual behavior and medical history. This study found that women who have 
a high consumption of fruit and fruit juice tend to have a low risk of invasive cervical cancer. 
They also  found that a high intake of vitamin C, β-carotene, and other carotenoids was 
associated with a decrease risk of the cancer (Herrero et al., 1991). In the US, a case-
control study focusing on vitamin C and folate demonstrated an inverse association between 
dietary and serum folate and vitamin C and cervical intraepithelial neoplasia. Moreover, 
investigation of vitamin C in CIN women also gave the same result as folate (VanEenwyk et 
al., 1992). 
It has been suggested that the inverse association between intakes or plasma 
concentrations of some nutrients and cervical cancer risk may be explained by their 
antioxidant function in diminishing the damage caused by reactive oxygen species (ROS). 
ROS are products of normal cell metabolism and are generated daily in both normal and 
abnormal cells. The oxidation of DNA bases can lead to altered cellular function and 
increased risk of mutations. Nutrients which act as anti-oxidants include vitamin A, vitamin C 
and vitamin E but studies of their protective role in carcinogenesis have not generated 
consistent results (Goodman et al., 2004). Furthermore, effects of confounding factors have 
not always been taken into account. For example, in the case of vitamin C, although vitamin 
C status has been reported to be associated with risk of all grades of cervical neoplasia, 
vitamin C status is also known to be lower in smokers than nonsmokers. Given that smoking 
is also a risk factor for cervical cancer, the relationship between low vitamin C status and 
cervical cancer may be confounded by smoking status. Moreover, the epidemiological 
studies of vitamin C may be limited by its instability in blood (Potischman, 1993).   
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In their review, Potischman and Brinton summarized studies of the role of nutrition in 
cervical cancer risk at that time, concluded that a low intake of vitamin C, carotenoids, 
vitamin E and folate may be associated with an increased risk of cervical neoplasia. A low 
concentration of vitamin C and carotenoids may be associated with both pre-invasive and 
invasive cervical cancer, whereas folate may have an effect only on preneoplastic cervical 
lesions. However, in this review, the author pointed out that most studies did not take other 
factor risks into account and especially lacked information about HPV infection. Overall, it 
can be cautiously proposed that nutritional factors play an important etiologic role in cervical 
carcinogenesis (Potischman & Brinton, 1996). 
More recently García-Closas et al. (2005) tried to summarise findings regarding the 
role of diet in cervical cancer risk by conducting a systematic review and classification of all 
studies published between 1995 and 2003 with a consideration of HPV infection.  The 
authors concluded that a sufficiency of nutrients such as vitamins C, E, beta-and alpha-
carotene, and lycopene, may have a possible protective effect on HPV persistence. 
Nutrients including folate, retinol, vitamins C and B12 and vitamin E may have a possible 
protective effect on cervical neoplasia (García-Closas et al., 2005). 
There has been particular interest in the possible role of folate as a determinant of 
cervical cancer risk (Piyathilake, 2007). Some studies have focused on folate and HPV 
infection/persistence (Sedjo et al., 2002; Piyathilake et al., 2004) and some studies have 
considered the role of folate in DNA methylation and gene expression (Narayan et al., 2003; 
Flatley et al., 2009; Liu et al., 2011). The relevance of folate to cervical cancer will be 
discussed below.   
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1.3 Folate 
1.3.1 Folate metabolism  
Folate is a water soluble B vitamin. Although humans cannot synthesise folate, we 
are able to find folate in many foods such as nuts, beans, green leafy vegetables, fruits and 
liver (mainly in the form of polyglutamates). Low dietary folate intake has been associated 
with conditions such as neural tube defects (Czeizel & Dudas, 1992; Pitkin, 2007), Down’s 
syndrome (James et al., 1999; Patterson, 2008), and cancer (Eichholzer et al., 2001; Kim, 
2007). Folate fortification of flour has been introduced into several countries including USA, 
Canada, and Australia, with the specific purpose of reducing the incidence of neural tube 
defects. Current dietary reference values (DRVs) for the UK state that the amount of folate 
required to meet the requirements of 97.5% of the UK population is 200µg/day for adults and 
that women should take 400µg/day. The Recommended Dietary Allowance (RDAs) for the 
USA and the Joint Food and Agriculture Organization of the United Nation/World Health 
Organization Nation (FAO/WHO) is set at 400µg/day for adults and 600µg/day for pregnant 
women (Geissler & Powers, 2011). 
Folate is a term used to describe a group of naturally-occurring compounds, whereas 
folic acid is the synthetic form. If we look into the structure of folate, we will find that folate is 
composed of a pteridine ring, para-aminobenzoic acid, and glutamic acid residues 
(figure 4). Within the complex of its structure, folate can be related to more than 150 
compounds by modifying the pteridine ring and forming a polyglutamate tail (Shane, 2010). 
Food folates can be absorbed in the proximal jejunum and the efficiency of absorption 
seems to be dependent on the hydrolysis of the polyglutamate chain. Once taken up into the 
enterocyte folate can be converted to dihydrofolate (DHF) and tetrahydrofolate (THF) by 
dihydrofolate reductase (DHFR). There are many forms of pteroylmonoglutamates including 
5-formylTHF, 5,10-methenylTHF, 5,10-methyleneTHF, 5-methylTHF, 10-formylTHF, and 
tetrahydrofolate (THF) (figure 5). 
Pteroylmonoglutamates, mostly in the form of 5-methylTHF, are transported to the 
liver from which they are distributed to other tissues (Halsted, 1980). 5-methylTHF is taken 
up into tissues via folate receptors or reduced folate carriers. After being taken up into cells, 
pteroylmonoglutamates are converted by folylpolyglutamate synthetases (FPGS) to form 
folylpolyglutamate derivatives.The major function of folate is as a one-carbon carrier, which 
plays an important role in several biochemical reactions (figure 6). 
There are two main features of this one-carbon cycle, which underpin the 
biochemical basis for a role of methyl donors in cancer prevention. These are DNA 
synthesis/repair and DNA methylation. 
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Figure 4: Structure of folate 
(Stokstad & Koch, 1967) 
 
Figure 5: Structure of important folate coenzymes 
(Liu et al., 2010) 
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Figure 6: Methyl cycle showing two important mechanisms involved in one-carbon 
metabolism. 
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1.3.2 Importance of folate in DNA Synthesis and Repair 
Folate is essential for DNA synthesis and repair. In this case, tetrahydrofolate acts as 
methyl carrier for both purine and pyrimidine synthesis. In de novo process of purine 
synthesis, there are two steps in which folate is involved: the addition of carbon in the 
positions 2 and 8 of the purine ring.  The first step is the process to add 8-carbon atom to 
glycinamide ribonucleotide by N10-formyl-THF to form formylglycinamide ribonucleotide 
(figure 7) and then, the ring of purine forms. The second step is the addition of 2-carbon 
atom to aminoimidazolecarboxamide ribonucleotide by N10-formyl-THF to form 
formylaminoimidazolecarboxamide ribonucleotide (figure 8), and after that, inosine 
monophosphate (IMP) is formed. IMP is the precursor of adenosine monophosphate (AMP) 
and guanosine monophosphate (GMP); therefore, purine nucleotides are produced.  
In pyrimidine synthesis (figure 9), N5,N10-methylene-THF is one-carbon donor, which 
helps transfer a methyl group from deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP) in a reaction catalysed by thymidylate synthase. After N5,N10-
methylene-THF has donated a methyl group, it will be converted into DHF in order to start a 
cycle of one-carbon donor again. 
If folate is limiting, there will be an accumulation of dUMP. Moreover, there will be 
limited formation of both purine nucleotides and dTMP, so an imbalance of nucleotides will 
result. Consequently, the cell attempts to remove misincorporated uracil nucleotide by 
developing DNA strand breaks, but this can cause genetic instability and increase cancer 
risk. Folate-deficient chinese hamster ovary (CHO) cells were shown to have a 10-fold 
greater frequency of chromosomal aberrations in mitotic cells (Libbus et al., 1990). In a study 
of lymphocytes in culture, DNA strand breaks and uracil misincorporation increased as a 
result of folate depletion (Duthie & Hawdon, 1998). Duthie et al. (2002) reviewed the impact 
of folate deficiency on DNA stability. She cultured CHO cells in folate-deficient media and 
found that cellular uracil increased; the misincorporation of uracil also increased threefold. 
Moreover, when folate-deficient human colonocytes were exposed to an alkylating agent 
(which integrates into DNA and disrupts the cross-linking of DNA strands), these cells were 
unable to repair DNA strand breakage (Duthie et al., 2002). In his review, Ames (2001) 
reported that folate deficiency led to an increased uracil misincorporation into DNA (4 
million/cell) and subsequent chromosome break in 10% of US population. He associated this 
observation with an increase in  colon cancer risk (Ames, 2001).  
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1.3.3 Importance of folate to DNA methylation 
1.3.3.1 DNA methylation 
In general, methyl transfer can take place onto several types of biomolecules such as 
proteins, lipids, hormones, RNA, and DNA. Methylation is important for several cell activities, 
for example, noradrenaline accepts a methyl group to form adrenaline, lipids accept a methyl 
group to turn into phospholipids, guanidoacetic acid accepts a methyl group to produce 
creatine, and DNA can be found in the form of methylated DNA. DNA methylation is 
considered to be part of an ancient component of a protection mechanism which recognized 
parasitic viral DNA sequence integration into the genome. This methyl mark serves to be a 
suppressed or deleted location in order to establish normal genome function. DNA 
methylation now has been reported to have additional functions such as X-chromosome 
inactivation, imprinting, and transcriptional regulation.  
Cytosine is a target for methylation (figure 10) when it forms part of a dinucleotide 
with guanine (CpG). CpG dinucleotides are distributed unevenly throughout DNA (0.75-1% 
of human genome). However, there are regions, often in the promoter regions of genes, 
which are rich in CpG, called CpG islands. Normally, 70-90% of CpG dinucleotides are 
methylated (Ehrlich et al., 1982), but CpG islands are unmethylated. Recently, it was 
reported that CpG island “shores” are another important region for DNA methylation. CpG 
island shores are CpG-containing regions which are up to 2kb away from CpG islands and 
located at tissue-specific differential methylated sites in normal tissue (Irizarry et al., 2009). 
 
1.3.3.2 Folate and DNA methylation 
(Please refer to figure 5). Folate is relevant to methylation via its role in the SAM-
SAH cycle. DNA methylation is the addition of a methyl group onto the cytosine ring in DNA. 
Methionine, in the form of S-adenosyl methionine (S-AdoMet or SAM), is a methyl donor. 
By using methyltransferases, a methyl group transfers from SAM to a methyl acceptor, after 
which SAM itself is converted into S-adenosyl-homocysteine (SAH). SAH will cleave into 
homocysteine and adenosine. If homocysteine accepts a methyl group, for example, from 
methyl-tetrahydrofolate (methyl-THF), it will be remethylated to methionine and complete a 
cycle (figure 5). Considering the role of folate as a methyl donor, the SAM-SAH cycle is 
expected to be impaired in the absence of folate.  
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Figure 7: Purine synthesis: adding 8-carbon atom to purine ring 
 
Figure 8: Purine synthesis: adding 2-carbon atom to purine ring 
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Figure 9: Folate is involved in pyrimidine synthesis  
 
 
 
 
Figure 10: The position of methylation at a cytosine base 
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Studies of folate and methylation have been conducted in various systems. In their in 
vitro study, Stempak et al. (2005) reported that global DNA methylation was decreased in 
folate-deficient untransformed cells (NIH/3T3 and CHO-KI cell lines), but not significantly 
changed in folate-deficient transformed cells (HCT116 and Caco-2 colon cancer cell lines). 
In their study of Min mice to investigate the effect of DNMT1 deficiency on DNA methylation 
in folate-depletion, Trasler et al. found no change in global DNA methylation (Trasler et al., 
2003). Sohn et al.(2003) conducted a study to determine the effect of folate deficiency in rats 
and found that although plasma homocysteine was increased, and colonic SAM 
concentration was decreased, there was no change in colonic DNA methylation (Sohn et al., 
2003). Kotsopoulos et al. (2008) also conducted a study in folate-deficient rats. Rats were 
fed a folate-deficient diet (0 mg folic acid/kg rat) from weanling to young adulthood for 8 
weeks and then supplemented with 2mg/kg (control diet) at puberty for 22 weeks. There was 
a significant increase in global DNA methylation in the liver of 34-48% at adulthood. On the 
other hand, rats fed with a folate-deficient diet throughout their life until adulthood, and rats 
fed with the control diet until puberty and then changed to folate-deficent diet until 30 weeks 
of age, showed no change in their hepatic genomic DNA methylation. This suggested that 
the timing in exposure of folate deficiency influences epigenomic programming (Kotsopoulos 
et al., 2008). 
Some studies have been conducted in humans either depleted of folate or given folic 
acid supplements. For example, in order to link plasma folate status with the DNA 
methylation profile in gastric cancer samples, Fang et al.  (Fang et al., 1997) found a 
decrease in global DNA methylation in association with low plasma folate status and related 
this to gastric carcinogenesis. In 1998, Cravo et al. set up a controlled, cross-over study to 
evaluate the effect of folate supplementation on global DNA methylation in 20 patients with 
colonic adenomas. They found that supplementation with folic acid (5 mg/day) increased 
global DNA methylation in 7 of 20 patients who had one polyp (Cravo et al., 1998). This 
however was a very small study and the folic acid dose was high, and so the generalisability 
of their findings is not certain.  Jacob et al. (1998) conducted a study to determine the effect 
of folate status on DNA methylation in healthy postmenopausal women. Women aged 
between 49-63 years were fed for 5 weeks with a low folate diet (56 µg/day) followed by 
repletion with 111 µg/day of folic acid for 4 weeks and then 286-516 µg/day for 3 weeks. 
They found a decrease in plasma folate concentration, a lowering of lymphocyte DNA 
methylation, and an increase of plasma homocysteine in the first two time periods. After 
repletion with 286-516 µg/day of folic acid the lymphocyte DNA methylation level was 
normalised and plasma homocysteine decreased with 516 µg/day, but not with 286 µg/day 
of folic acid (Jacob et al., 1998).  Moreover, in 2000, Rampersaud and colleagues studied 
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the effect of folate depletion on DNA methylation of leukocytes in elderly women (60-85 
years) by investigation of the incorporation level of 3H-methyl group into DNA. They 
demonstrated that elderly women who consumed a folate-depleted diet (118 µg folate/day) 
for 7 weeks had a low level of DNA methylation compared with those consuming a folate 
adequate diet (P=0.0025) (Rampersaud et al., 2000). However, in this study, the 7-week 
repletion with 200 or 415µg folate/day after depletion did not change the DNA methylation 
level. Research so far suggests that folate status has variable effects on DNA methylation 
dependent on pathological stage, cell type, and age. 
1.3.3.3 DNA methylation and gene expression 
DNA methylation occurs in order to regulate gene expression to “switch on” or 
“switch off” genes, which is important for cell function. For example, (1) methylation of 
cytosine inhibits access of transcription factors to DNA via methylation-binding proteins, 
therefore inhibiting transcription (figure 11), and also, (2) methylation can change the DNA 
structure in the context of chromatin remodeling, which is important for regulating 
transcription (figure 12). By influencing the epigenetic modification of histones in chromatin, 
it is known that histone modification can determine whether chromatin is in the “opened” or 
“closed” configuration, which determines whether transcription is allowed or not. 
Aberrant DNA methylation, both hypo- and hypermethylation, is considered a cause 
of abnormal expression of genes. This may be undermethylation of the entire genome 
(hypomethylation) or hypermethylation in CpG-rich regions (islands), often locating upstream 
of promoter regions. Approximately sixty percent of human genes have CpG-rich regions 
(Antequera & Bird, 1993), not only housekeeping genes but also genes with tissue-specific 
pattern of expression. 
Specifically in relation to hypomethylation, there is interest in decreased global DNA 
methylation, which results in decreased ability to maintain a normal level of DNA replication 
and DNA repair. Uncontrolled replication and repair of DNA brings about mutations. Gene 
mutation can affect a protein’s efficiency. Sometimes, mutation may influence the 
transformation of a proto-oncogene to an oncogene, such evidence is critical in terms of 
tumorigenesis and oncogenesis (please refer to figure 12). DNA hypomethylation is mostly 
found in highly repeated DNA sequences (Hoffmann & Schulz, 2005; Weisenberger et al., 
2005), which include tandem centromeric satellites, juxtacentromeric (centromere-adjacent) 
satellite 2, interspersed Alu and long interspersed element (LINE)-1 (Ehrlich, 2009). 
Hypomethylation of satellite DNA (Sat2) of chromosome 1 was found in about 45% of 25 
breast adenocarcinomas (Narayan et al., 1998). LINE-1 DNA hypomethylation was also 
found in cancers such as cervical cancer (Shuangshoti et al., 2007) and colorectal cancer 
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(Estécio et al., 2007). Gene specific hypomethylation can also be found in cancer.  For 
example, urokinase (uPA) which is a serine protease, was found to be hypomethylated and 
overexpressed in breast cancers (Pakneshan et al., 2004). 
On the other hand, in the case of hypermethylation, we are interested in an increase 
of DNA methylation, which has been shown to lead to gene silencing.  With regard to 
transcription, hypermethylation will obstruct transcription factor binding, so that transcription 
cannot occur and in turn a gene is silenced (please refer to figure 11). When tumour 
suppressor genes are silenced this invariably leads to unlimited division of cells. In cancer, 
hypermethylation usually occurs on specific genes which play an important role in cancer 
pathways. For example, hypermethylation at the 5’-end of the Rb gene, which is important to 
regulation of the cell cycle, was found in blood and tumour cells of 21 retinoblastoma 
patients (Greger et al., 1989). Regarding genes involved in DNA mismatch repair, 
hypermethylation at the 5’ CpG island of hMLH1 was found in colorectal mucosa and 
primary sporadic colorectal tumour specimens (Herman et al., 1998). Promoter methylation 
of the DNA repair gene, O6-methylguanine DNA methyltransferase (MGMT), was found in 
about 40% of colorectal carcinoma patients (Esteller et al., 1999). In the Wnt signalling 
pathway,  colorectal cancer is often associated with  promoter DNA hypermethylation in one 
or more genes, including  APC, β-catenin, AXIN2, TCF4 and WISP3 (Thorstensen et al., 
2005). 
The process of DNA methylation is dependent on the activity of a group of enzymes 
called DNA methyltransferases, which are responsible for transferring a methyl group onto 
DNA. 
1.4 DNA methyltransferase (DNMT) 
1.4.1 DNA methyltransferase (DNMT) 
The DNA methylation process is catalysed by DNA methyltransferases (DNMTs).  
DNMTs catalyse the donation of methyl groups from S-adenosylmethionine (SAM) to the C5 
of cytosine nucleotide. Together with the availability of methyl donors, factors influencing 
their expression and activity might be expected to influence DNA methylation.   
There are 3 distinct enzymatically active forms of DNMTs: DNMT1, DNMT3a, and 
DNMT3b. Also there is one related protein called DNMT3L which is lacking catalytic activity. 
DNMT1 is classified as a DNA maintenance enzyme, preferring hemi-methylated CpG sites 
as substrate over unmethylated DNA. This enzyme is located at the replication fork to 
maintain parental methylation during the synthesis of daughter strand DNA in S phase.   
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Figure 11: Hypermethylation on CpG rich-region at a promoter site 
This inhibits the binding of transcription factor (TF), switches off some genes to 
further transcription such as tumor suppressor genes. 
  
Figure 12: Global hypomethylation on CpG-rich regions 
This can change the morphology of chromatin, which turns from a condensed 
structure to an open structure and allowed some genes such as oncogenes to switch 
on. 
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Knocked down DNMT1 of human colorectal carcinoma cells led to loss of cell proliferation 
and progressive cell death (Chen et al., 2007). The mRNA expression level of DNMT1 is 
dynamically changed during the cell cycle, being the highest in S phase of proliferating cells 
(Lee et al., 1996). Besides playing a maintenance role, other functions are unclear. 
However, Clements et al. examined the function of DNMT1 in the form of inactive catalytic 
methyltransferase and found that there were target genes for which DNMT1 functions as a 
transcriptional repressor (Clements et al., 2012). This repressive function may relate to a 
role for scaffolding target genes which induce a deficiency of the active histone mark. 
On the other hand, DNMT3a and 3b, which are reserved as de novo DNA 
methyltransferases, mostly catalyse the addition of methyl-groups to unmethylated CpG 
sites on both strands of the DNA (Fatemi et al., 2002). However, there is evidence showing 
that DNMT1 also has a de novo function and works together with DNMT3a (Fatemi et al., 
2002). DNMT3a and 3b are stably located at chromatin containing methylated DNA  (Jeong 
et al., 2009). Yanagisawa et al. (Yanagisawa et al., 2002) proposed that, like DNMT1, 
DNMT3a and 3b have multiple transcriptional start points (TSPs) which are controlled by 
multiple promoters. These promoters are in the form of CpG-rich and CpG-poor regions, 
which may comprise distinct transcription regulation. 
Regarding gene expression, Robertson et al. (2000), from his work in MCF7 breast 
cancer cells, suggested that DNMT1 and DNMT3b are down-regulated during G0/G1 of the 
cell cycle while DNMT3a sustains its expression level throughout the whole cell cycle. The 
change in DNMT expression during different phases of the cancer cell cycle suggested that 
there are determinants of DNMT expression which in turn influence DNA methylation, 
leading to development of cancer (Ahluwalia et al., 2001). 
 
1.4.2 Regulation of DNA methyltransferases  
The regulation of DNMT activity is not well understood but various post-
transcriptional and post-translational modifications as well as the interaction with non-coding 
RNA (ncRNA) and non-coding microRNA (miRNA), are thought to modify stability including 
methylation (Denis et al., 2011).  
Regarding DNMT1, three miRNAs, which are miR-148, miR-152 and miR-126, 
showed their ability to down-regulate DNMT1. Moreover, it has been reported in human 
colorectal HT-29 cells that mutation of APC (adenomatous poliposis coli) led to an 
upregulation of DNMT1 promoter activity and mRNA (Campbell & Szyf, 2003). The activity of 
DNMT1 was regulated via post-translational mechanisms through phosphorylation, 
methylation, acetylation and sumoylation-small ubiquitin-like modifiers (Denis et al., 2011). It 
has been shown that sumoylation of DNMT1 led to an increase of its activity in HCT116 
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cancer cell lines (Lee & Muller, 2009). In addition, a histone methyltransferase, SET7, has 
been suggested to regulate protein stability of DNMT1. SET7 methylated Lys-142 of DNMT1 
resulted in the promotion of proteosomal degradation and also enhanced the absence of 
lysine-specific demethylase 1 (LSD1). Thus the overexpression of SET7 resulted in a 
reduction of DNMT1 expression (Estève et al., 2009). 
Post-transcriptional modification of DNMT3a and 3b via an interaction with miR-29s, 
led to a down-regulation of their mRNA level (Fabbri et al., 2007). Additionally, it has been 
reported that DNMT3b was also down-regulated by miR-148 (Duursma et al., 2008). On the 
other hand, Hu-antigen R (HuR) seemed to enhance the stability of DNMT3b mRNA (López 
de Silanes et al., 2009). DNMT3a is also regulated by post-translational mechanisms 
through sumoylation of a Pro-Trp-Trp-Pro motif which is located in the N-terminal region. 
This sumoylation modifies DNMT3a ability to interact with other components such as HDACs 
and results in the disruption of its ability to repress the transcription of reporter genes (Ling 
et al., 2004). 
 
DNMTs interact with several components at the regulatory domain such as other 
DNMTs, histone deacetylase 1 and 2, the Rb and E2F1 transcription factors, and 
proliferating cell nuclear antigen (PCNA). All of those components can act as 
activators/suppressors of methylation. Abnormal interactions resulting from any alteration of 
those components influence DNMTs functions (Robertson, 2001).  
1.4.3 Dietary determinants of DNA methyltransferase expression /activity 
 Several nutrients have been found to affect DNMTs expression/activity such as 
choline, selenium, and folate. Regarding choline, rats fed a choline-deficient diet showed an 
up-regulation of DNMT1 gene expression in fetal liver, and choline supplemented diets led to 
a decrease in DNMT3a gene expression (Vacheva et al., 2007). This group also found a 
significant correlation between DNMT1 mRNA level and 5-methylcytosine content in fetal 
liver DNA (r =0.66, P<0.02). Fiala et al. (1998) determined the effect of selenium compounds 
benzyl selenocyanate (BSC), 1,4-phenylenebis(methylene)selenocyanate (p-XSC), and 
sodium selenite) on DNMTs activity and found that the DNMTs activity of cell lysate from  
both human colonic carcinoma cells and human colon carcinoma cell lines (HCT116) was 
inhibited by selenium compounds. The concentrations of selenite, BSC, and p-XSC which 
could decrease DNMTs activity by 50% were 3.8, 8.1, and 5.2 mM, respectively (Fiala et al., 
1998). However, this study was an in vitro model and the relevance to the in vivo situation is 
not clear.  In contrast, a study in Fischer-344 rats fed a selenium-deficient diet up to 70 days 
from weaning found no change in hepatic DNMTs activity although the activity tended to 
decrease in colon (P<0.06)(Ross & Davis, 2006). A study in the liver of F344 rats fed a folate 
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deficient diet (Ghoshal et al., 2006) demonstrated that folate and methyl donor deficiency led 
to a decrease in mRNA and protein of DNMT1, an increase in DNMT3a mRNA, and an 
increase in MBD1-3 mRNA. They also found an elevation of protein of MBD 1, 2, and 4 in 
folate and methyl deficient rats. In their mouse model of folate deficiency, Ding et al. (2012) 
demonstrated an elevation in DNMT1, 3a, and 3b expression in endometrial cells during 
pregnancy (Ding et al., 2012). 
 
1.4.4 DNA methyltransferase expression/activity as determinants of DNA methylation 
profile 
Since aberrant DNMTs expression/function may lead to an abnormal methylation 
level, some studies have suggested that aberrant DNMT expression influences DNA 
methylation profile, but results are not consistent (Fatemi et al., 2002; Sawada et al., 2007). 
There is still no clarity about the relationship between DNMT expression and DNA 
methylation profile.  
Some research has reported a link between DNMT expression and DNA methylation 
profile. For example, disruption of DNMT1 expression led to hypomethylation of mouse 
embryonic stem (ES) cells (Li et al., 1992). A study in colorectal and stomach cancer 
samples found an association between overexpression of DNMT1 and DNMT3b and cancer. 
Overexpression of DNMT1 mRNA was associated with a CpG island methylator phenotype 
(CIMP), but overexpression of DNMT3b was not related to CIMP or DNA hypomethylation of 
pericentromeric satellite regions (Kanai et al., 2001). This is important because the cancer 
phenotype is associated with a concentration of methylation at CpG islands and 
pericentromeric satellite regions seem to be the mutation target site (Hansen et al., 1999; 
Saito et al., 2002). In their investigation of 67 hepatocellular carcinomas (HCCs), Saito et al. 
(2001) found that the mRNA level of DNMT1 and DNMT3a of noncancerous liver tissues 
was higher than HCCs. DNA hypomethylation of pericentromeric satellite regions was 
detected in both noncancerous liver tissues and HCCs. The CpG island hypermethylation of 
p16, methylated in tumour1, 2, 12, 25, and 31 genes was greater in HCCs than 
noncancerous liver tissues. DNA hypomethylation of pericentromeric satellite regions led to 
a centromeric decondensation and increased chromosome recombination resulted in 
chromosome instability (Saito et al., 2001). 
In addition, the examination of DNA methylation and DNMT expression in a mouse 
prostate cancer model suggested that even though the overexpression of all DNMTs was 
seen in all stages of transgenic adenocarcinoma of mouse prostate (TRAMP), 
hypermethylation of specific genes was only seen in early and late stage of tumorigenesis 
and only related to the overexpression of DNMT1. Also, the overexpression of DNMTs 
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protein was not associated with genomic hypomethylation or specific gene hypermethylation 
(Morey Kinney et al., 2008). A study in human prostate cancer, which reported both an 
increase and decrease of DNA methylation level at CpG sites compared to normal prostate, 
demonstrated that those alterations were associated with the overexpression of DNMT3a 
and 3b (Kobayashi et al., 2011). 
 In their review Wild and Flanagan (Wild & Flanagan, 2010) suggested that the DNA 
methylation profile was associated with both an alteration in DNMT expression and a change 
in their activity and function. However, Choi et al. (Choi et al., 2003) demonstrated that 
DNMT1 activity was not correlated with its expression.   
1.4.5 DNA methyltransferases and cancer 
There are numerous observational studies reporting overexpression of DNMTs in 
tumour tissues. An immunohistochemical examination of DNMT1 in cervical cancer samples 
demonstrated that DNMT1 was increased in low-grade CIN and was even higher in high-
grade CIN, but the level was decreased in invasive stage. This suggested that the increased 
DNMT1 was associated with the early stage of cervical carcinogenesis (Sawada et al., 
2007). In their hepatocellular carcinoma study, Oh et al. found that all DNMTs were up-
regulated (RT-PCR) and the expression level was progressively increased from normal livers 
through chronic hepatitis, cirrhosis to HCCs (Oh et al., 2007). The overexpression of DNMT1 
was also found in gastric cancer samples using immunohistochemistry and correlated with 
hypermethylation at CpG islands of the human MutL homologue 1 (hMLH1), E-cadherin, and 
thrombospondin-1 (THBS-1) (Etoh et al., 2004) . There is also some evidence that 
overexpression of  DNMTs may influence liver cancer progression (Choi et al., 2003). 
Robertson et al. (Robertson et al., 1999) demonstrated that the expression of all 
DNMTs in normal tissue was coordinated. Unlike normal tissues, most tumour cells 
presented with a significantly increased DNMT3b expression, but only very modest 
increases in DNMT1 and DNMT3a. This suggested that the alteration of DNMT3b 
expression had a specific influence on tumor development. Ahluwalia et al. found an 
increased level of DNMT1 and DNMT3b transcripts in ovarian cancer cell lines and they 
suggested that DNMT activity was increased in association with the progression of 
cancer(Ahluwalia et al., 2001). Beaulieu et al. indicated that DNMT3b has a site selectivity, 
which plays an important role in regulation of gene expression, associated to cancer 
survival, and the down regulation of DNMT3b led to cancer cell apoptosis (Beaulieu et al., 
2002).  
1.4.6 DNA methylation, gene expression and cervical cancer 
Although cervical cancer has not been a major focus of interest in terms of 
associations between epigenetic determinants of gene expression, there is a modest 
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literature which can be discussed. In 1994, Kim et al. studied the relationship between 
various grades of cervical neoplasia and DNA hypomethylation status in 41 patients with 
abnormal cervical epithelial cells. They found that DNA hypomethylation level increased with 
the grade of cervical neoplasia. DNA hypomethylation increased from normal cervical tissue 
to cervical neoplasia and cancer by threefold and sevenfold, respectively. In other words, the 
more severe the progress of the disease, the greater the level of DNA hypomethylation (Kim 
et al., 1994b). Also, in 1998, Fowler et al. further described the above relationship by 
conducting a study in 83 patients with various grades of cervical neoplasia. They found that 
the largest increase in hypomethylation appeared in the early stage of cervical neoplasia and 
then was stable through CIN3, and then increased again when the disease progressed to 
cancer (Fowler et al., 1998). A more recent study (Flatley et al., 2009) also showed 
significantly more hypomethylation in cervical cell DNA from women with cervical cancer 
than in those women with neoplasia or normal cytology. 
Regarding hypermethylation, in 2001, Virmani et al studied aberrant promoter 
hypermethylation in cervical cancer in 73 patients and 10 cervical cancer cell lines. They 
found that the rate of DNA methylation in cervical cell DNA from cancer patients was greater 
than controls, moreover, the pattern of methylation of 6 genes important in DNA replication 
and cell division, p16, RARB, FHIT, GSTP1, MGMT, and hMLH1, was altered. They showed 
that the frequency of methylation in those 6 genes was greater than 20%, except hMLH1. 
Methylation is a tumour-associated event as RARB and GSTP1 methylation were found in 
early stage cellular abnormality, p16 and MGMT methylation were found in the intermediate 
stage, and FHIT methylation was found in the late stage (Virmani et al., 2001). Narayan et al 
(2003) also studied hypermethylation of 16 gene promoters in 82 tumour biopsies derived 
from primary invasive cervical cancers and 8 cervical cancer cell lines. They found that 
CDH1, DAPK, RARB and HIC1 gene promoters have a high level of methylation in cancer 
compared to normal cervical cells. The percentage of promoter methylation of CDH1, DAPK, 
RARB and HIC1 gene in cervical cancer cases was 51.1%, 43.3%, 33.3%, and 22.2%, 
respectively (Narayan et al., 2003). In this study, they included cervical cancer cell lines to 
investigate the reversible effect of methylation by treatment with the hypo-methylating agent, 
5-aza-2’-deoxycytidine, and found that expression of those genes with a previously 
hypermethylated promoter, was up-regulated. In addition, Flatley et al (2009) conducted a 
cross-sectional study in various grades of CIN in 308 women. They demonstrated that six of 
seven selected tumor suppressor genes showed a trend towards an increased promoter 
methylation from normal cervical cells towards cancer. Among those genes, three genes 
(CDH1, DAPK, and HIC1) showed a significant increase in promoter methylation from cells 
with normal cytology through neoplasia to cervical cancer (P< 0.05). Although it is generally 
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accepted that promoter methylation leads to gene silencing this need not always be the 
case. Recently, Guenin et al (2012) conducted a study of promoter methylation profile and 
expression pattern of stem cell (SC) genes during cervical carcinogenesis and they 
demonstrated that an increase in hypermethylation of undifferentiated cell transcription factor 
1 (UTF1) promoter was associated with lesion severity. In this study, the hypermethylation of 
this promoter resulted in the increase of mRNA and protein expression. They also reported 
that the disruption of methylation using 5-aza-2’-deoxycytidine was related to a decrease in 
UTF1 gene methylation and expression in epithelial cancer cell lines (Guenin et al., 2012). 
This study suggests that the hypermethylated promoter does not necessarily result in gene 
silencing. 
All of the above suggests that folate might play an important role in maintaining 
normal cellular metabolism and thereby influence cancer risk. A fall in folate intake will 
reduce folate status in tissues. This may lead to an altered methylation status of DNA, which 
may be DNMT-mediated. There also will be dNTP pool imbalance in folate deficiency, which 
will disrupt DNA repair. Finally, this may bring about the alteration of gene expression such 
as DNA methyltransferase, the disruption of DNA integrity, and an increase in DNA damage.  
These changes can increase cancer risk. These considerations are illustrated in figure 13. 
1.5 Folate as a modulator of cervical cancer risk 
1.5.1 Folate and history of cervical cancer 
A number of studies have examined the association between folate status and 
cervical cancer risk. In 1973, Whitehead et al. found that abnormal cervical cells were similar 
in appearance to those of megaloblastic anemia seen in folate and vitamin B12 deficiency. 
They also reported observations correlating folate status with cervical neoplasia in 22 
women using oral contraceptives. After they gave folic acid to eight women with cervical 
abnormality, who also took oral contraceptives, for three weeks, all of the women showed an 
improvement in abnormal cytology (Whitehead et al., 1973). However, this study was not 
robust because of the small number of subjects and the lack of a control group. In 1982, 
Butterworth et al. set up an experiment by giving oral folic acid supplement or placebo 
(ascorbic acid) for three months to 47 women who had mild or moderate cervical 
intraepithelial neoplasia and who also used oral contraceptive. They found that the cytology 
of women who received a folic supplement appeared to be better than the women in the 
placebo group (P<0.05). Therefore, they concluded that folate could decrease the severity of 
CIN. They also demonstrated that red blood cell folate concentrations of oral contraceptive 
users are lower than non-users (Butterworth et al., 1982). However, ten years later, in 1991, 
Potischman et al. conducted a case-control study in order to further examine the role of 
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folate. By collecting serum sample from 330 cases (varying stages of neoplasia and cervical 
cancer) and 555 controls (normal cervical cytology), they found that the concentration of 
folate was no different between the groups. Therefore, they concluded that folate is not 
correlated with the stage of cervical neoplasia (Potischman et al., 1991). In a nested-case 
control conducted by Alberg et al. (2000), there was no association between serum folate 
status and cervical cancer (Alberg et al., 2000).  
However, the determination of folate status using serum or plasma folate may be 
confounded by recent dietary intake. Moreover, these early studies of the role of folate on 
cervical neoplasia produced mixed results. In 2001, Weinstein et al. conducted a case-
control study in the United States in order to examine the relationship between serum and 
red blood cell (RBC) folate and incidence of invasive cervical cancer. In this study, they tried 
to control for all potential confounders such as age, smoking, oral contraceptive use, Pap 
smear history, and detection of HPV. Folate status was measured using four assays. The 
mean result for serum folate showed a lower concentration in cervical cancer cases than 
controls. For RBC folate, microbiological and radiobinding assays showed an Odds Ratio for 
cervical cancer for low versus high folate status of 1.2 (95% confidence interval (CI) 0.6-2.2) 
and 1.5 (95% confidence interval (CI) 0.8-2.7), respectively, which was not statistically 
significant (Weinstein et al., 2001). 
1.5.2 MTHFR polymorphisms and cervical cancer 
There are several studies investigating the metabolism of folate in the context of 
polymorphism in the methylene tetrahydrofolate reductase (MTHFR). MTHFR is an enzyme 
used to convert 5,10-methylenetrahydrofolate to 5-methyltetrahydrofolate, which is the key 
methyl donor for producing methionine.  Thus, this enzyme influences folate metabolism and 
methylation in cells. Decreased activity of MTHFR can occur via two single nucleotide 
polymorphisms (SNPs) in the MTHFR gene: (1) changing from C to T at the position of 677 
(C677T), and, (2) changing from A to C at the position of 1298 (A1298C). Both SNPs bring 
about an amino acid change in the enzyme, and may modify enzyme configuration, which 
has an influence on substrate binding. The prevalence of these genotype variants of MTHFR 
is different between populations; C677T polymorphism has a low frequency in sub-Saharan 
Africa and Northern Canada, whereas a high frequency is found in Southern Europe and 
South America. 
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Figure 13: Effects of folate in cancer risk 
(Rampersaud et al., 2002) 
Folate deficiency led to an alteration of DNA synthesis and methylation process. 
 
 
 
 
 
 
31 
 
In 2001, Goodman et al. conducted a multiethnic case-control study of 150 cases and 179 
controls in Hawaii to find variations in allele frequencies. They found that the CT-genotype 
and TT-genotype MTHFR had twofold [OR, 2.0; 95% confidence interval (CI), 1.1-3.7] and 
threefold risk (OR, 2.9; 95% CI, 1.0-8.8) of CIN, respectively, compare to CC-genotype. 
They also demonstrated that women who had the variant T allele (CT or TT) with low folate 
intake had more risk of cervical dysplasia than those women with the CC alleles and high 
folate intake (OR, 5.0; 95% CI, 2.0-12.2). Moreover, the risk from HPV infection in CIN also 
had strong impact among women carrying the TT-genotype or CT-genotype (OR, 46.6; 95% 
CI, 15.9-136.2) (Goodman et al., 2001). On the other hand, in 2002, Gerhard et al. 
conducted a study in USA into the association between the MTHFR polymorphic variation 
(C677T and A1298C) and invasive cervical cancer by using family-based 
transmission/disequilibrium test (TDT) in 102 families of women who had invasive cervical 
cancer. They found that there was no influence of the prevalence of these two MTHFR 
variants (Gerhard et al., 2003). This study did not use a traditional case-control study design, 
which can generate false-positives due to the difficulty in properly matching cases and 
controls. In addition, the study in Korea of Kang et al. (2005) also failed to find an increase in 
cervical cancer risk in association with the MTHFR C677T polymorphism in 82 cervical 
cancer specimens (Kang et al., 2005). 
1.5.3 Folate and the natural history HPV 
Because of the well-accepted importance of HPV infection as a risk factor for cervical 
cancer, factors which influence susceptibility to infection, and HPV clearance, are relevant to 
cervical cancer risk. In the context of folate and HPV risk of cervical cancer, there is 
evidence to suggest that the role of folate status and DNA methylation may be important for 
HPV gene expression in host cells. The chromosome fragile site which is sensitive to folate 
deficiency coincides with an HPV-16 integrating site in primary cervical carcinomas (Wilke et 
al., 1996). In 2004, Piyathilake et al. conducted a study of the association between folate 
status and high risk-HPV infection in a cohort of 345 women who were at risk of the 
progression of CIN. After 24 months with at least three consecutive visits HPV test and the 
measurement of folate status, they found that women having high folate status tended to 
show a negative result for the HR-HPV test (OR: 2.50; 95% CI, 1.18-5.30; P = 0.02) 
(Piyathilake et al., 2004). In 2007, this group conducted research in the same population to 
find out whether circulating folate concentration influenced the risk of CIN in high stage 
cytological abnormality (CIN ≥ 2) in women with HR-HPV. They found that HPV-16 infected 
women who also had low red blood cell folate, were more likely to show high CIN stage than 
non HPV-16 infected women who had high red blood cell folate (odds ratio 9, 95% 
confidence interval 3.3-24.8) (Piyathilake et al., 2007). In their recent study, Flatley and 
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colleagues demonstrated that folate status was significantly lower in women with HR-HPV 
infection than those with no infection (P=0.031)(Flatley et al., 2009). A further study in 100 
human cervical biopsy samples including normal, SIL, and cervical cancer (Pathak et al., 
2012) also found that low folate status modulated the risk of HPV infection and cervical 
cancer.  
 Overall, these findings suggest that folate status may modulate cervical cancer risk 
and/or progression, through effects on one-carbon metabolism. However, in the one-carbon 
cycle, folate is not the sole methyl donor. Other intermediates in the cycle, including dietary 
methionine and betaine, may be important determinants of DNA methylation and therefore 
gene expression. 
1.6 Methionine as a methyl donor 
Methionine is an essential amino acid which can be found in any protein products 
such as egg white, chicken breast, and fish. Methionine plays an important role in protein 
synthesis. Methionine itself is also required for cell growth and serves as one of the methyl 
donors which is essential for methylation processes. Figure 5 indicates the co-operation 
between folate, choline, and methionine in methyl donor function. Methionine biosynthesis 
occurs through 2 pathways. The first pathway involves the remethylation of homocysteine 
with 5-methyltetrahydrofolate, which requires the vitamin B12-dependent enzyme 5-
methyltetrahydrofolate-homocysteine methyltransferase. The second pathway is the 
remethylation of homocysteine with betaine, which is a product of choline metabolism; this 
reaction is catalysed by betaine-homocysteine methyltransferase. All of these methyl donors 
work in harmony to supply methyl groups for cellular metabolism and the availability of one 
methyl donor can affect the requirement for other methyl donors (Niculescu & Zeisel, 2002). 
Several studies have demonstrated that folate and choline deficiency lead to a lowering in 
hepatic methionine and SAM (Finkelstein et al., 1982; Zeisel et al., 1989; Pomfret et al., 
1990). In addition, it has been shown that a defect in the transmethylation of folate or choline 
leads to a perturbation in the other. Either choline depletion or choline and methionine 
depletion resulted in a decrease in hepatic folate concentration (Horne et al., 1989; Selhub 
et al., 1991). Severe folate deficiency also led to a significant depletion of hepatic choline 
and phosphocholine concentration (Kim et al., 1994a). 
There has been no study linking methionine status with cervical cancer. However, 
there have been a few in vitro studies conducted in various cell types. Kokkinakis et al. 
(2004) developed a methionine deficient model in central nervous system tumor cell lines in 
order to investigate the expression level of several genes. After Western blot confirmation, 
they found that methionine stress led to changes in genes in cell cycle checkpoints and 
proapoptotic pathways. This research group also used a methionine-depleted model in 
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pancreatic tumour cell lines. Their results suggested that methionine deficiency led to a 
disruption of mitosis and enhanced cell cycle arrest and increased the number of micronuclei 
cells (Kokkinakis et al., 2005). In 2009, Najim et al. also used a methionine-depleted model 
of central nervous system tumor cell lines and reported that glutathione was increased and 
O6-methylguanine-DNA-methyltransferase (MGMT) activity, which plays an important role in 
DNA repair, was decreased  in Daoy cells (Najim et al., 2009).  
Studies of combined methyl donor deficiency have been conducted mostly in animal 
models. For example, Duthie et al. (2000) studied the effect of deficiency in a combination of 
methyl donors (methionine and choline, and folate, methionine and choline) in Male Hooded-
Lister rats. After 10 weeks of feeding methyl-deficient diets, they found DNA strand breakage 
in colonocytes, but no significant change in global DNA methylation of colonic scrapings 
(Duthie et al., 2000b). Progribny et al. (2004) also investigated the effects of methionine-
choline-folate-deficiency in male weanling F344 rats. They reported DNA hypomethylation 
and an increase in DNA methyltransferase of rat liver after 36 weeks of depletion, but found 
no effect on pancreas, spleen, kidney, and thymus. This suggested that the alteration of 
DNA methylation was specific to hepatocarcinogenesis (Pogribny et al., 2004). In addition, 
Ghoshal et al. (2006) demonstrated an alteration of DNA methylation machinery in the liver 
of F344 rats which were fed with a folate-methionine-choline deficient diet (Ghoshal et al., 
2006). These studies suggested that effects of combined folate-methionine-choline 
deficiency targeted the liver. However, an effect of a combined folate-methionine-choline 
deficient diet was also found in the brains of F344 rats, but in the opposite direction to effects 
seen in the liver. In brain, global DNA methylation was increased, as detected by an 
increase in the genomic 5-methylcytosine content. This global DNA hypermethylation was 
also associated with an increase in protein expression of DNMT3a and methyl-CpG-binding 
protein 2 (Pogribny et al., 2008). Although combined folate-methionine-choline deficiency 
has been studied in a number of groups, there has been no study of the combination of only 
folate and methionine deficiency before. 
According to the evidence cited above there are plausible reasons why folate and 
methionine status may influence cervical cancer risk and progression. Low folate status 
affects one-carbon transferring processes, which are required for nucleotide synthesis/repair 
and methylation. Low methionine status also affects the distribution of folate derivatives and 
disturbs methylation processes.  A combined methyl donor deficiency may maximize the 
effects of methyl donor depletion on cells. Therefore, low folate and methionine status may 
lead to reduced DNA stability and disturbed DNA or histone methylation. Consequently, 
fragile sites may occur in DNA which cause difficulty in repair, and which might allow greater 
ease of entry of pathogenic DNA such as high-risk HPV. Moreover, normal cell division is 
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affected not only by an HPV-gene expression mechanism itself, but also by incorporation of 
unusual DNA methylation profile in the host cell, which occurs in folate deficiency. Since 
abnormal DNA methylation can cause “switch on” or “switch off” of regulatory genes, HPV 
persistence or HPV latency stage in the host cell may occur differently depending on DNA 
methylation level and therefore HPV DNA expression. 
As folate and methionine both serve as methyl donors, this study was conducted to 
determine the effects of folate deficiency alone or in combination with methionine depletion, 
on the global DNA methylation level of cervical cancer cells. Since the DNA methylation 
process is catalysed by DNA methyltransferase, DNMTs expression was also examined to 
investigate the association between DNA methylation level and gene expression. As 
aberrant DNA methylation is an epigenetic process which may lead to an alteration of gene 
expression profile and might lead to several changes in phenotype, cell characteristics 
resulting from the effects of folate and methionine deficiency were also examined. 
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1.7 Hypothesis, aim, and objectives 
1.7.1 Hypothesis 
 Methyl-donor depletion alters DNA methylation status and DNA methyltransferase 
expression. Furthermore, it is hypothesised that methyl-donor depletion will lead to an 
alteration of global gene expression, which affects the phenotype of cervical cancer cells. 
 
1.7.2 Aim 
 The overall aim of this study is to examine how methyl donor status influences DNA 
methylation, DNA methyltransferase gene expression, global gene expression, and cervical 
cancer phenotype. 
 
1.7.3 Objectives 
1. To develop the methyl donor depleted model using cervical cancer cell lines. 
2. To validate the methyl donor depleted model by examining intracellular folate 
concentration, intracellular methionine concentration, and extracellular homocysteine. 
3. To investigate the effects of methyl donor on; 
 - DNA methylation status 
 - DNA methyltransferases expression 
 - DNA methyltransferase activity 
 - global gene expression 
 - phenotype of cervical cancer cells  
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Cell lines 
Cervical cancer C4-II cells were obtained from HPA Culture Collections, United 
Kingdom. The cells are derived from a cervical carcinoma of a 41 year old Caucasian 
female. C4-II cells have been reported to contain human papilloma virus 18 (HPV-18) DNA 
sequences and to express HPV-18 RNA. C4-II is the most similar to cervical cancer biopsies 
in gene expression when comparing with other kinds of cervical cancer cell lines (Carlson et 
al., 2007). 
SiHa is a cervical cancer cell line which was established from fragments of a primary 
tissue sample obtained after surgery from a CIN II -grade Japanese patient. SiHa is reported 
to harbor an integrated human papillomavirus type 16 genome (HPV-16, 1 to 2 copies per 
cell). 
NIH 3T3 fibroblast cells were used as a positive control in the immunocytochemistry 
method for methylcytosine. 
2.1.2 Media 
A. Waymouth MB 752/1: GIBCO, UK (Cat. No. 31220072) was used for the normal 
culture of C4-II. This medium contains sufficient nutrients for cell growth. It is described 
in the text as complete medium or F+M+ medium (900nM of folic acid and 300µM of 
methionine).The medium was prepared by supplementation with 10% fetal calf serum 
gold (FCS Gold: PAA, Cat. No. A15-151), 200 nM L-glutamine, and 1% 
penicillin/streptomycin antibiotics (GIBCO, Cat. No. 15140-122) 
B. Waymouth MB folate and methionine-free medium: GIBCO, UK (Cat. No. 04196306) 
was used for folate and methionine depletion of cells. It is described in the text as 
depleted medium or folate and methionine-depleted medium or F-M- medium. The 
medium was supplemented with 10%FCS Gold, 200 nM L-glutamine, and 1% 
penicillin/streptomycin antibiotics. This medium contained a low concentration of folate 
and methionine from FCS (12-30 nM of folate and ~20 µM of methionine). 
C. Dulbecco’s Minimum Essential Medium (DMEM): GIBCO, UK (Cat. No. 22320022) 
was used for normal culture of NIH 3T3 cells (control cell for immunocytochemistry) and 
initial culture of SiHa 
D. Waymouth MB folate and methionine-free medium + 900 nM folinic acid (folinic acid 
calcium salt hydrate: SIGMA CAS No. 1492-18-8, MW= 511.50) was used for the folate 
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repletion experiment. It is described in the text as methionine-depleted medium or F+M- 
medium. 
E. Waymouth MB folate and methionine-free medium + 300 µM L-methionine (L-
methionine: SIGMA CAS 63-68-3, MW=149.21) was used for the methionine repletion 
experiment. It is described in the text as folate-depleted medium or F-M+ medium. 
 
2.1.3 Cell culture 
Centrifuge (Sorvall RT6000B refrigerated centrifuge, USA) 
Culture flasks and plates (Nunc) 
FCS Gold (foetal calf serum gold: PAA, Cat. No. A15-151) 
Folinic acid (folinic acid calcium salt hydrate, SIGMA: CAS 1492-18-8) 
Haemocytometer 
Hand tally counter 
L-Glutamine (200 nM L-Glutamine: GIBCO) 
L-Methionine (SIGMA: CAS 63-63-3) 
Microscope (Diaphot: Nikon, Japan) 
PBS pH 7.3±0.2 (phosphate buffered saline tablets: OXOID, England) 
Penicillin/ Streptomycin (1% Penicillin/Streptomycin: GIBCO, Cat. No. 15140-122) 
Trypan blue stain 0.4% (GIBCO) 
Trypsin-EDTA (0.25% trypsin-EDTA: GIBCO) 
 
2.1.4 Measurement of intracellular folate 
Beckman coulter folate access Kit (Beckman coulter, UK) 
Centrifuge (MIKRO 22R: Hettich Zentrifugen, Germany) 
Precellyse®24 lysis and homogenization machine (Bertin technologies, France) 
Sonicator (UCD-200TM: Bioruptor diagenode, Belgium) 
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2.1.5 Measurement of intracellular methionine 
Biochrom Amino Acid Analyser30 (Biochrom, UK) 
Centrifuge (MIKRO 22R: Hettich Zentrifugen, Germany) 
Precellyse®24 lysis and homogenization machine (Bertin technologies, France) 
Sonicator (UCD-200TM: Bioruptor diagenode, Belgium) 
 
2.1.6 Measurement of homocysteine 
Centrifuge (MIKRO 22R: Hettich Zentrifugen, Germany) 
Heat box (FALC supplied by Scientific Ltd. UK) 
HPLC Analysis of homocysteine kit (order no. 45000: CHROMSYSTEMS, Germany) 
HPLC module (Gilson model no. 811C, USA) 
Precellyse®24 lysis and homogenization machine (Bertin technologies, France) 
Sonicator (UCD-200TM: Bioruptor diagenode, Belgium) 
 
2.1.7 Determination of DNA methylation 
2.1.7.1 DNA methyl acceptor assay 
2.1.7.1.1 DNA extraction 
Centrifuge (MIKRO 22R: Hettich Zentrifugen, Germany) 
Heat box (FALC supplied by Scientific Ltd. UK) 
Nanodrop spectrophotometer (Labtech international, UK) 
QIAamp® DNA Mini kit (QIAGEN: cat no. 51304) 
 
2.1.7.1.2 [3H]-SAM donor assay 
Absolute ethanol (BDH, EC 200-578-6) 
Beckman counter LS 6500 multi-purpose scintillation counter 
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CpG methyltransferase (M.SssI 20000 unit/ml: Bio Labs , M00226M) 
DTT (dithiotreitol: SIGMA D9779-5G CAS no. 3483-12-3MW 154.2) 
EDTA (Ethylene diamine tetraacetic acid disodium salt solution: SIGMA E7889) 
3H-SAM (250 µCi-9.25 MBq [10.0 Ci/mmol in 0.455 ml of 10mM H2SO4: EtOH 9:1] S-
[methyl]-3H: Perkin Elmer, USA) 
Incubator, centrifuge, micropipette, microfuge tube 
Methylated control (100 µg/ml CpG methylated Jurkat genomic DNA: N4002S BioLabs) 
NaCl (sodium chloride: BDH AnalaR product no. 102415K MW 58.44) 
Plastic box and scintillation vial 
SAM (S-adenosylmethionine: BioLabs, 32 mM 10%ethanol in H2SO4, #B90035) 
Scintillation fluid (ULTIMA GOLD High flash-point LSC-cocktail for aq. and non-aq. 
Samples: Perkin Elmer) 
Sodium phosphate monobasic (SIGMA CAS no. 7558-80-7 MW 119.98 g/mol) 
TE buffer (Tris-EDTA buffer solution pH 8.0: Fluka) 
Tris (Tris (hydroxymethyl) methylamine: BDH GPR EC no. 201-064-4 MW 121.14) 
Unmethylated control (100 µg/ml 5-Azadc treated Jurkat genomic DNA: N4003S, BioLabs) 
Whatman ion-exchange filter paper (wipe out: 90mmØ circle cat no. 1001090, spot: 2.3 
cm Ø grade DE81 cat no. 3658-023) 
 
2.1.7.2 Immunocytochemistry of 5-methylcytosine 
Blocking solution (0.2% fish gelatin + 0.3M glycine in PBS) 
Broad-tipped Forceps, point-tipped forceps, fine-tipped forceps 
Cell of interest (C4-II cell lines, Positive control is NIH 3T3 cells) 
Citric acid (SIGMA, CAS no. 5949-29-1, FW=210.1) 
Culture slide (Lab-Tek® Chamber slide Cat. No. 177399) 
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DAB chromogen solution (mixture of substrate buffer, diaminobenzidine tetrahydrochloric 
acid, and hydrogen peroxide: reagent D1, D2, and D3 of Histostatin®-Plus Kits, respectively) 
DAB Staining kit (Histostatin®-Plus Kits Invitrogen®2nd Generation Cat no. 85-9643) 
Enzyme conjugate (streptavidin-peroxidase conjugate: reagent C of Histostatin®-Plus Kits 
Invitrogen) 
Fish gelatin (gelatin from cod water fish skin: SIGMA, G7765-250ML) 
Formaldehyde (formaldehyde solution for molecular biology 36.5%: SIGMA CAS no. 50-00-
0) 
Glycine (Fisher Biotech, USA CAS no. 56-40-6 FW=75.07) 
Haematoxylin counterstain (Heamatoxylin Gill II: Surgipath, product code 01521E) 
Hydrochloric acid (36%: Fisher Scientific, CAS. No. 7647-01-0, FW=36.46) 
Hydrogen peroxide (SIGMA, CAS no. 7722-84-1) 
Microscope (Nikon ECLIPSE e400) 
Mounting medium (Clearmount ™ Mounting Solution: ZYMED®Laboratories invitrogen 
Immunodetection) 
PBS pH 7.3±0.2 (phosphate buffered saline tablets: OXOID, England) 
Permeabilizing solution (0.2% (v/v) Triton X-100 in PBS) 
Primary antibody (anti 5-methylcytosine mouse mAb: MERCK 162 33 D3) 
Primary antibody diluents (0.1% tween 20 in PBS) 
Secondary antibody (biotinylated secondary antibody: reagent B of Histostatin®-Plus Kits 
Invitrogen) 
Tissue culture medium appropriate for the cells 
 
2.1.7.3 Flow cytometric analysis of 5-methylcytosine 
5-azadeoxycytidine (SIGMA) 
BSA (Albumin from bovine serum: SIGMA EC 232-936-2) 
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Cell of interest (C4-II and SiHa cell lines) 
Centrifuge (Sorvall RT6000B refrigerated centrifuge, USA) 
Donkey serum (SIGMA D9663 PA-TEC-0005) 
FACS tube (5 ml Polystyrene Round Bottom tube 12x75 mm : Becton Dickinson 352058) 
FACS CALIBUR flow cytometer (Becton Dickinson) 
FCS (FCS Gold: PAA, Cat. No. A15-151) 
Formaldehyde (formaldehyde solution for molecular biology 36.5%: SIGMA CAS no. 50-00-
0) 
Haemocytometer 
Hydrochloric acid (36%: Fisher Scientific, CAS. No. 7647-01-0, FW=36.46) 
Isotype control Ab negative control (mouse IgG1: AbD SEROTEC MCA928) 
Methanol (Fisher Scientific: CAS. No. 67-56-1, FW=32.04) 
PBS (phosphate buffered saline tablets: OXOID, England) 
Primary antibody (anti 5-methylcytosine mouse mAb: MERCK 162 33 D3) 
Secondary antibody (anti-mouse IgG: Alexa fluor 488 donkey anti-mouse IgG (H+L), 
Invitrogen A21202) 
Sodium borate pH8.5 (SIGMA CAS 1303-96-4)  
Tissue culture medium appropriate for the cells 
Tween20 (Polyoxyethylene sorbitan monolaurate: SIGMA P7949 CAS 9005-64-5) 
Water bath 
 
2.1.8 RNA extraction 
Absolute ethanol (BDH, EC 200-578-6) 
Bevelled Filter Tips (sterile): RNase, DNase, DNA and pyrogen free 
Herarus PICO17 centrifuge (Thermo scientific, UK) 
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Micropipette (Gilson, USA) 
Nanodrop spectrophotometer (Labtech international, UK) 
Precellyse®24 lysis and homogenization machine (Bertin technologies, France) 
Precellyse tube 
RNase-free DNase I (New England Biolabs: cat no. M0303S) 
RNase-free DNase set (QIAGEN: cat no. 79254) 
RNeasy® Mini kit (QIAGEN: cat. no. 74104)  
Sodium Hydroxide solution (20mM: for experimental space cleaning) 
 
2.1.9 cDNA synthesis 
0.2ml single thin wall PCR tubes (Starlab, Germany: Cat. No. 1 1402 4300) 
5X First-Strand Buffer (Invitrogen: Cat. No. 18080-044) 
Centrifuge: GmCLAB® for PCR tube (Gilson, USA) 
dNTP mix (Invitrogen: Cat no. 18427-013) 
DTT (Dithiothreitol:Invitrogen) 
Nuclease-Free water (Ambion: Cat. No. AM9937)  
PCR machine: G-strom (Catcombe, UK) 
Random primers (Promega, USA: Cat. no. C1181) 
RNase OUT™Ribonuclease Inhibitor Recombinant (Invitrogen: Cat no. 10777-019)  
SuperScipt™III Reverse transciptase (RT) (Invitrogen: Cat no.18080-044) 
 
2.1.10 DNMTs gene expression by qRT-PCR 
Bevelled Filter Tips (sterile): RNase, DNase, DNA and pyrogen free 
Fast optical 96 well reaction plate: Micro AMP® with Barcode 0.1 ml (Applied 
Biosystems, Singapore) 
43 
 
Mini Plate Spinner (Labnet MPS1000) 
Optical adhesive film: Micro Amp™ (Applied Biosystems, USA) 
Primers (SIGMA, USA) 
Probes (Applied Biosystems, USA) 
StepOne Plus™Real-Time PCR (Applied Biosystems, USA) 
TaqMan®: Fast Universal PCR Master Mix (2X) No AmpErase®UNG (Invitrogen, USA: 
cat no. 4367846) 
 
2.1.11Gene expression analysis by microarray 
Agilent 2100 Bioanalyzer (Agilent Technologies, Germany) 
Agilent RNA 6000 Nano Kit (Agilent Technologies, Germany) 
David Bioinformatics Resource 6.7 
GeneChip® 3’IVT Express Kit (Affymetrix, UK) 
GeneChip® Command Console® Software (Affymetrix,UK) 
GeneChip® Fluidics Station 450 (Affymetrix,UK) 
GeneChip® Human Genome U133 Plus 2.0 Array (Affymetrix, UK) 
GeneChip® Hybridisation Oven 640 (Affymetrix, UK)  
GeneChip® Hybridisation, wash, and Stain kit (Affymetrix, UK) 
GeneChip® Scanner 3000 enabled for high-Resolution Scanning (Affymetrix,UK) 
GeneSpring Software version11 (Agilent Technologies, Germany) 
Herarus PICO17 centrifuge (Thermo scientific, UK) 
Micropipette Thermal Cycler with heated Lid 
Nanodrop spectrophotometer (Labtech international, UK) 
RNase-free microfugetube 
Vortex Mixer multiple  
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2.1.12 Nuclear extraction 
Centrifuge (MIKRO 22R: Hettich Zentrifugen, Germany) 
NE-PER® Extraction Reagents (Thermo Scientific, USA: Cat no. 78833) 
Protease Inhibitor Cocktail Tablet (Complete Mini in Easy Pack, Roche Applied Science, 
USA: Cat no. 04 693 124 001) 
 
2.1.13 Protein quantification 
96-well plate 
Bio-Rad Bradford Reagent (Bio-Rad, UK: cat no. 500-0205) 
Microplate reader (BioTek FLX800, USA) 
Protein standard BSA liquid 2mg/ml (Sigma, UK: CAS number 9048-46-8, Cat no. P0834) 
 
2.1.14 DNMT activity 
EpiQuik™ DNA Methyltransferase Activity/Inhibition Assay Kit (Epigentek, USA) 
Incubator 
Microplate reader (BioTek FLX800, USA) 
Multichannel micropipette 
 
2.1.15 Cell migration  
96-well culture plate (Nunc™ Cell Culture MicroWell Plates: Thermo scientific, UK) 
CellTiter 96®Aqueous One Solution Cell Proliferation Assay (Promega: Cat no. G3580) 
ImageJ Software 
LAS software 
Leica DMI AF600LX time-lapse microscope (USA) 
Leica DMIL microscope (USA) 
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Microplate reader (BioTek FLX800, USA) 
Mitomycin C (SIGMA) 
Motic Image plus 2.0ML Software 
 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cell Thawing 
Growth of the cell lines was initiated by propagation of the cells received from HPA. 
Cells were moved from vial to a new 50-ml tube and 11 ml normal (complete) medium were 
added to the cells and the suspension centrifuged at room temperature for 5 min. at 150xg. 
The supernatant was discarded and the cell pellet was suspended in 4 ml of normal medium. 
Cells were counted and checked under a microscope for viability (see section 2.2.1.3). Then, 
11 ml of fresh and warm normal medium were added into new T75 flask and the cell 
suspension was transferred into the flask. Cells were cultured in a humidified incubator at 
37oC with 5% carbon dioxide. Cell growth and cell characteristics were observed each day. 
The cells were subcultured when they reached 70-80% confluence. 
2.2.1.2 Subculture 
Cells were split when they reached 70-80% confluence. The culture medium was 
discarded and cells were washed with 10 ml. PBS. Then, 2 ml. of trypsin-EDTA were added 
into the culture flask and incubated in CO2 incubator for about 8 min. Detached cells were 
checked under a microscope. Fresh warm normal medium was added into the culture flask 
and the cell suspension transferred to a new tube. Cells were centrifuged at room 
temperature for 5 min. at 150xg. The supernatant was discarded and cell pellet was 
suspended with 4 ml of fresh and warm normal medium. Then, 14 ml of fresh and warm 
normal medium were added into a new flask and 1 ml of the cell suspension was transferred 
into the flask (split 1:4 or 1.5x106 cells of C4-II for 4-day culture in T75-flask : total cells may 
be 10000-30000 cell/cm2 and split 1:3-1:10 for SiHa cell). Cells were cultured in a humidified 
incubator at 37oC with 5% carbon dioxide. Cell growth was observed daily according to 
confluence and cell morphology. 
2.2.1.3 Counting 
Viable cells were counted by mixing 20µl of cell suspension with 20µl Trypan Blue in a 
microfuge tube and 20µl were taken for counting using  a haemocytometer (dead cells 
appear blue). Cells were counted in 4 big corner squares (please see figure 14: area 1, 2, 
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4, and 5) under 10x objective of microscope. The haemocytometer was designed so that the 
number of cells in one set of big corner squares was equivalent to the number of cells x 104 
per ml. 
Cell number = (the sum of cells/4) x 2 x 104 cell/ml 
(The number of cells was divided by 4 to produce an average and multiplied by 2 to 
adjust for the 1: 2 dilution in trypan blue)                                                                             
Percentage viability = (no. viable cells/total cells) x100 
2.2.1.4 Cryopreservation 
Cell line stocks were frozen in liquid nitrogen. Cells were harvested when they 
reached 70-80% confluence. The culture medium was discarded and cells were washed with 
10 ml. PBS. Then, 2 ml. of trypsin-EDTA were added to the culture flask and incubated in 
CO2 incubator for about 8 min. Detached cells were checked under a microscope. Fresh and 
warm medium was added into the culture flask. The cell suspension was transferred to a 
new tube and cells were centrifuged at room temperature for 5 min. at 150xg. Supernatant 
was discarded and cell pellet was suspended with fresh and warm medium. Viable cells 
were counted (see 2.2.1.3). Then, DMSO was added to the cell suspension at 1:9 ratio of 
DMSO: cell suspension. The cell suspension was pipetted into a cryotube and frozen in a 
cryobox at -20oC overnight to slow the decrease in temperature before storage in liquid 
nitrogen. 
2.2.2 Determination of growth rate 
Cells were split when they reached 70-80% confluence. The culture medium was 
discarded and cells were washed with 10 ml PBS. Then, 2 ml of trypsin-EDTA were added to 
the culture flask and incubated in CO2 incubator for about 8 min. Detached cells were 
checked under a microscope. Fresh and warm medium was added into culture flask. The 
cell suspension was transferred to a new tube and centrifuged at room temperature for 5 
min. at 150xg. The supernatant was discarded and the cell pellet was suspended in 4 ml of 
fresh warm medium. Viable cells were counted (see 2.2.1.3). Then, 2.5 ml of fresh and warm 
medium were added into each well of a 6-well plate or 15 ml of fresh and warm medium 
were added into each T75-flask and the cell suspension transferred into each culture 
container (starting cell density 0.192 x106 cell/ well in 6-well plate or 1.5 x 106 cell/flask: total 
cell may be 10000-30000 cell/cm2). Cells were cultured in a humidified incubator at 37oC 
with 5% carbon dioxide. Cell growth was observed daily and 1-3  wells of culture plates or 
one flask was selected for counting every 3-5 days for 12- 20 days. 
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Figure 14: The haemocytometer gridline 
 (Phelan, 1998) 
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2.2.3 Measurement of intracellular folate 
More than 5 million cells were harvested at day 4, 8 and 12 of culture for C4-II cells, 
and at 2nd, 4th, and 6th passage (week 2, 4, and 6) for SiHa. Cells were trypsinised and 
washed with PBS. The cells were suspended with 500 µl of 0.5% (w/v) ascorbic acid in 
water. Cell lysates of the cell suspension were prepared by cell disruption using a sonicator 
(high pulse: 10 min.) followed by 2 cycles of precellys (1 cycle: 6000 rpm/pulse: 2 x 30 sec / 
pause: 20 sec). The supernatants were separated by centrifugation at 16000xg for 10 min at 
4oC. The cell suspensions were diluted into 1:10 ratio in separate tubes and all diluted 
suspensions and non-diluted suspensions were kept at -80oC until analysis. Intracellular 
folate was measured in units of ng/ml by using an automated competitive folate protein 
binding assay (Beckman Access Kit) in the Department of Human Metabolism at the 
University of Sheffield. Intracellular folate concentration was expressed as pmol/106 cells for 
C4-II and pmol/106 cells for SiHa cells. 
2.2.4 Measurement of intracellular methionine 
More than 20 million cells were harvested at day 4, 8 and 12 of culture for C4-II cells. 
Cells were trypsinised and washed with PBS. The cells were suspended with 300 µl of PBS. 
Cell lysates of the cell suspension were prepared by cell disruption using a sonicator (high 
pulse: 10 min.) followed by 2 cycles of precellys (6000 rpm/pulse: 2 x 30 sec / pause: 20 
sec). The supernatants were separated by centrifugation at 16000xg for 10 min at 4oC and 
kept at -80oC until analysis. Methionine was measured using Biochrom 30 amino acid 
analyzer at the Department of Clinical Chemistry, Sheffield Children Hospital, using a Biosys 
software v2.05 and analysed using EZChrom Elite software v3.4. The intracellular 
methionine was presented in nmol/L and expressed as pmol/106 cells. 
2.2.5 Measurement of homocysteine 
Intracellular and extracellular homocysteine concentrations were determined by 
reverse-phase high-performance liquid chromatography using CHROMSYSTEMS HPLC Kit. 
Briefly, cell lysates (cell lysate preparation is the same as for the intracellular methionine 
measurement) and cultured medium were pipetted into a light protected reaction vial and 
incubated with internal standard and reducing reagent at room temperature for 10 min. 
Precipitation reagent was added and centrifuged at 9000xg for 5-7 min. The supernatant 
was transferred to a new light protected reaction vial. Derivatisation mix was added to the 
supernatant and incubated at 50-55oC for 10 min. Prepared samples were injected onto the 
HPLC system. Absorbance of eluted compounds was monitored using λex =385 nm and λem 
= 515 nm. The retention time of the internal standard and homocysteine at a flow rate of 1.5 
ml/min were taken as 3.3-3.5 min and 3.9-4.5 min, respectively. Chromatograms were 
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recorded with UniPoint™ LC System Software Version 5.1 with quantification accomplished 
by automatic peak area integration. Calibrator, control I, and control II with internal standard 
were used to identify the elution peaks and for calculation of homocysteine concentration. 
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A sample  = Peak area/height of substance A in the chromatogram of the sample 
A calibrator  = Peak area/height of substance A in the chromatogram of the 
calibrator 
IS sample  = Peak area/height of substance Internal standard in the 
chromatogram of the sample 
IS calibrator  = Peak area/height of substance Internal standard in the 
chromatogram of the calibrator 
C calibrator  = The concentration C of substance A in the calibrator (14.8 µmol/l) 
 
2.2.6 DNA extraction 
DNA was extracted by QIAamp®DNA Mini kit from QIAGEN (cat no. 51304) by 
following the manufacturer’s protocol. Briefly, the cell pellet was removed from -20oC freezer 
and thawed. Then, 180 µl of buffer ATL was added in to the cell pellet followed by 20 µl of 
proteinase K. The cell suspension was mixed by vortexing and incubated at 56oC for 1-2 
hours. Then, 200 µl of buffer AL were added followed by further incubation at 70oC for 10 
min. After that, 200 µl of ethanol (96-100%) were added and the DNA mixture was applied to 
the QIAamp spin column. The column was centrifuged at 6000xg for 1 min. The filtrate was 
discarded and buffer AW1 was added and the column was centrifuged again at 6000xg for 1 
min. The filtrate was discarded and Buffer AW2 was added and the column was centrifuged 
at 16000xgfor 3 min. The filtrate was discarded and TE buffer was added and the sample 
incubated at room temperature for 5 min, followed by a centrifugation at 16000xg for 1 min. 
The filtrate consisted of a DNA suspension; DNA was quantified and the purity determined 
using the Nanodrop spectrophotometer. The DNA had an absorbance ratio of A260:A280 
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between 1.8 and 2.2. The DNA concentration was determined as the mean of three 
independent spectrophotometric readings. 
2.2.7 Determination of global DNA methylation 
2.2.7.1 DNA methyl acceptor assay 
The modified method of Balaghi and Wagner (Balaghi & Wagner, 1993) was used. 
DNA suspension containing 0.5 µg of genomic DNA was prepared in triplicate from cells at 
day 4, 12, 20, and 24 of culture for C4-II and at day 8 of SiHa cells after 6 passages. The 
DNA was incubated with 0.455 µCi of [3H]-methyl-S-adenosylmethionine , 3 units of CpG 
methyltransferase and 6 µl of methylation buffer ( pH 8.0: 50 mM tris, 600 mM NaCl, 50 mM 
EDTA, 5 mM DTT) in a total volume of 30 µl for 1 hour at 30oC. The incubation mixtures 
were spotted onto Whatman DE-81 ion exchange filter paper. After the papers were dried, 
the papers were washed 3 times with 0.5 M sodium phosphate buffer pH 7.0 for 10 min each 
followed by 10-minute washing with water. Then, the papers were washed with 70% ethanol 
2 times and washed with absolute ethanol 2 times. The papers were dried for 30 min placed 
into scintillation vials and 5 ml of scintillation fluid was added. The radioactivity retained on 
the papers was measured by scintillation counting for 10 min. each. For a positive control, 
0.5 µg of 5-azadeoxycytidine-treated Jurkat genomic DNA (5-azadeoxycytidine treatment 
demethylates DNA) was used instead of the cell DNA. For a negative control, 0.5 µg of CpG 
methylated Jurkat genomic DNA was used. The disintegration per minute (DPM) result 
reflected the [3H]-methyl incorporation into DNA. To calculate sample DNA hypomethylation, 
blank DPM (the mixture lacking CpG methyltransferase) was subtracted from sample DPM 
and reported as DPM/1 µg of DNA. 
2.2.7.2 Immunocytochemistry of 5-methylcytosine 
Cells were grown in T25 or T75 flasks, trypsinised and then were seeded onto 4-well 
slide chambers and incubated at 370C/ 5%CO2 for 24 hours, 8 days and 15 days. On the 
indicated day, cells were washed twice with cold PBS and fixed with p-formaldehyde for 
20min and washed twice with PBS. Then, cells were permeabilized with 0.2%triton X-100 in 
PBS for 10 min and washed 3 times with PBS. For antigen retrieval, the cultured slide was 
placed into 0.01M citric acid pH 6.0 and heated at full power in a microwave oven for 12 min 
and rinsed with deionized water. The slide was then placed into 3.5N HCl for 15 min followed 
by rinsing with deionized water. Endogenous peroxidases were quenched with a solution of 
3% hydrogen peroxide in methanol for 10 min and washed 3 times with PBS. The slide was 
then incubated with blocking solution (0.2% fish gelatin and 0.3 M glycine in PBS) for 30 min 
at room temperature to block nonspecific staining. After draining off the solution, the slide 
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was incubated with 5 µg/ml of primary antibody (anti 5-methylcytosine mouse monoclonal 
antibody) for 1 hour at room temperature. This antibody is known to recognize 5-
methylcytosine in methylated DNA or RNA in NIH 3T3 cells, which were used as a positive 
control. After washing 3 times with PBS, the secondary antibody (biotinylated secondary 
antibody: reagent B of Histostatin®-Plus Kits Invitrogen) was added for 10 min. The slide 
was then washed 3 times with PBS and incubated with enzyme conjugate solution 
(streptavidin-peroxidase conjugate: reagent C of Histostatin®-Plus Kits Invitrogen) for 10 
min, and then washed 3 times with PBS. For staining, DAB chromogen solution was added 
for 3-10 min and rinsed with deionized water. For counterstaining, Gill’s Haematoxylin was 
used for 15 seconds and rinsed with Scott’s Tap water. Finally, the mounting medium was 
placed on the cell surface until completely dried. Cells were visualized using Nikon ECLIPSE 
e400 microscope. NIH 3T3 cells with and without primary antibody were used as a positive 
and negative control, respectively. Cells positive for 5-methylcytosine had DAB brown 
stained nuclei, negative cells were haematoxylin blue counterstained. 
2.2.7.3 Flow cytometric analysis of DNA methylation 
More than 5x106 trypsinised cells were collected into 6 ml of appropriate medium in a 
50ml centrifuge tube and pelleted by centrifugation (150xg). The supernatant was decanted 
and cells were washed twice by resuspending in 10ml of washing solution (PBST/BSA: 0.1% 
tween20, 1%BSA in PBS) and pelleted by centrifugation. The cell pellet was resuspended in 
5ml of 4%formaldehyde for 30 min at 37oC and cooled at 4oC for 10 min for fixation.  Cells 
were incubated with 9 volumes of 88%methanol/12%PBS at -20oC for 30 min. Cell pellets 
were centrifuged and the supernatants were discarded. The cells were washed twice by 
centrifugation in 10ml PBST/BSA.  Antigen retrieval was performed by incubating each cell 
pellet in 5ml of 2N HCl for 30 min at 37oC and pelleting by centrifugation, and resuspending 
in 5ml of 0.1M sodium borate pH8.5 for 5 min at room temperature. Cells were washed twice 
by centrifugation in washing solution. The cells were blocked in blocking solution (10%FCS 
or donkey serum in PBST/BSA) overnight at 40C. Cells were counted and aliquots of 0.5x106 
cells placed into FACS tubes. Cell aliquots were immunostained with primary antibody anit-5 
methylcytosine (100µl of a 1:250 dilution of anti 5-mc in PBST/BSA) OR 10µl IgG1 isotype 
control + 90µl PBST/BSA per tube and incubated at 37oC for 45 min. Cells were washed 3 
times by centrifugation in washing solution. Secondary antibody was added (100µl of 1:1000 
of 2oantibody in PBS+5% BSA solution) and incubated at 37oC for 45min in the dark. Cells 
were washed 3 times by resuspending pellet in washing solution and pellet by centrifugation. 
Cells were kept at 40C before analysis by BD FACSCalibur™. Appropriate controls were 
utilized and included unstained cells, secondary antibody alone and 5-Aza, 2-deoxycytidine 
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treated cells for a negative control. Nonspecific antibody binding was monitored with a 
mouse IgG1 isotype. Data analysis was run by BD CELLQuest software. 
2.2.8 RNA extraction 
RNA was extracted by RNeasy® Mini kit from QIAGEN. The 500 µl of PBS was 
added in to the cell pellet followed by homogenizing by precellys (6000 rpm, 2x30 sec-pulse, 
20 sec-puase). Then, 350 µl of RLT buffer was added to the cell lysate and mixed by 
vortexing. Then, 1 volume of 70% ethanol was added to the homogenized lysate and mixed 
by pipetting. After that, the sample was applied to the RNeasy spin column. The column was 
centrifuged at 10000xg for 15 seconds. The filtrate was discarded and buffer RW1 was 
added and the column was centrifuged again at 10000xg for 15 seconds. The filtrate was 
discarded and DNase mix (The RNase-Free DNase Set, QIAGEN cat. no. 79254) was 
added. The column was incubated at room temperature for 15 min. The buffer RW1 was 
added and the column was centrifuged again at 10000xg for 15 seconds. The filtrate was 
discarded and 500 µl of RPE buffer was added and the column was centrifuged again at 
10000xg for 15 seconds. The filtrate was discarded and 500 µl of RPE buffer was added and 
the column was centrifuged again at 10000xg for 2 min. The filtrated was discarded and 30-
50 µl of RNase-free water was added. The column was incubated at room temperature for 
10 min. followed by a centrifugation at 10000xg for 1 min. The filtrate consisted of a RNA 
suspension; ice-cold RNA suspension was quantified and the purity determined using the 
Nanodrop spectrophotometer. The RNA had an absorbance ratio of A260:A280 between 1.8 
and 2.2. The RNA concentration was determined as the mean of three independent 
spectrophotometric readings. However, the absorbance ratio of A260:A280 does not indicate 
whether the RNA suspension was contaminated by DNA. 
To remove the remaining genomic DNA from RNA, DNase digestion (DNase 1: 
RNase-free, New England Biolabs, M0303S) was done again. Briefly, the 2-10 µg of RNA 
suspensions were added by 2 unit of DNase I in the total reaction volume of 100 µl and 
incubate at 370C for 10 minutes. The one µl of 0.5M EDTA (5mM in final concentration) was 
added to prevent the RNA from degradation and incubated at 750C for 10 minutes in order to 
inactivate the DNase I activity.  The treatment was stopped by placing the tube on ice. The 
RNA suspension was cleaned to remove the protein and excess salt by following the RNA 
cleanup protocol of QIAGEN. Following this, the 350 µl of RLT buffer was added to the cell 
lysate and mixed by vortexing. Then, 250 µl of absolute ethanol was added to the RNA 
suspension and mixed by pipetting. After that, the sample was applied to the RNeasy spin 
column. The column was centrifuged at 10000xg for 15 seconds. The filtrate was discarded 
and 500 µl of RPE buffer was added and the column was centrifuged at 10000xg for 15 
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seconds. The filtrate was discarded and 500 µl of RPE buffer was added and the column 
was centrifuged again at 10000xg for 2 min. The filtrate was discarded and 30-50 µl of 
RNase-free water was added. The column was incubated at room temperature for 10 min. 
followed by a centrifugation at 10000xg for 1 min. The filtrate can be re-loaded into the 
column and centrifuged at the same speed again in order to increase the RNA yield. RNA 
was quantified again and the purity determined using the Nanodrop spectrophotometer. RNA 
with an absorbance ratio of A260:A280 between 1.8 was used for further work.  
2.2.9 cDNA synthesis 
Each first-strand cDNA synthesis was carried out using the SuperScript™ III Reverse 
Transcriptase (Invitrogen, USA) according to the manufacturer’s recommendations for 
random primer. The cDNA synthesis was performed on 1.5-2 µg of total RNA in a volume of 
20µl. In brief, 50 ng of random hexamer (Promega, USA) and 0.5mM of dNTP mix 
(Invitrogen, USA) were added to RNA sample. The mixture was heated at 65oC for 5 min 
and incubated on ice for at least 1 min. Then, the master mix, which is comprised of 5X first-
strand buffer (Invitrogen : 250 mM Tris-HCl pH 8.3 at room temperature, 375 mM KCl, 15 
mM MgCl2,), 5mM of DTT, 40U of RNaseOUT™ Recombinant RNase Inhibitor (Invitrogen, 
USA), and 200U of SuperScript™ III RT (Invitrogen, USA), was added to the mixture. The 
mixture was incubated at 25oC for 10 min followed by 50oC for 50 min. The reaction was 
terminated by heating at 85oC for 5 min and chilled at 4oC. The cDNA products were diluted 
into a concentration of 25-50 ng/µl and used them immediately or kept in aliquots at -80oC. 
2.2.10 Determination of DNMT gene expression 
DNMT gene expression was determined using semi-quantitative RT-PCR. Two µl of 
cDNA product (50 ng) were taken for PCR amplification. The reaction was in a total volume 
of 25 µl, which included TaqMan® Fast Universal PCR Master Mix 2X, No AmpErase UNG 
(Applied Biosystems, USA), 125 nM of probe, 300 nM of each forward primer, and 300 nM of 
each reverse primer. All Primers were purchased from Sigma (Balada et al., 2008). Taqman 
probes were used in all cases (Balada et al., 2008). All reactions were run in triplicate in Fast 
optical 96-well Reaction plates with Barcode sealed with optical adhesive covers (Applied 
Biosystems, USA) on a StepOnePlus™ Real-time PCR System (Applied Biosystems, USA). 
Taqman dual probes were labelled with a reporter dye [6-carboxy-fluorescein (6-FAM) or 
VIC® (Applied Biosystems, USA)] and a fluorescent quencher [6-carboxy-
tetramethylrhodamine (TAMRA)]. Forward primers, reverse primers and probe sequences 
were as follows.  
β-actin: 5’-TCACCCACACTGTGCCCATCTACGA-3’,  
5’-CAGCGGAACCGCTCATTGCCAATGG-3’, and  
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5’-VIC-ATGCCCTCCCCCATGCCATCCTGCGT-TAMRA-3’  
 
DNMT1: 5’-CGGTTCTTCCTCCTGGAGAATGTCA-3’,  
5’-CACTGATAGCCCATGCGGACCA-3’, and  
5’-6-FAM-AACTTTGTCTCCTTCAAGCGCTCCATGGTC-TAMRA-3’ 
 
DNMT3a: 5’-CAATGACCTCTCCATCGTCAAC-3’, 5’-CATGCAGGAGGCGGTAGAA-3’, and 
5’-6-FAM-AGCCGGCCAGTGCCCTCGTAG-TAMRA-3’;  
DNMT3b: 5’-CCATGAAGGTTGGCGACAA-3’, 5’-TGGCATCAATCATCACTGGATT-3’, and 
5’-6-FAM-CACTCCAGGAACCGTGAGATGTCCCT-TAMRA-3’.  
Thermocycling parameters were: 20 sec at 95oC and 40 cycles consisting of 1 sec at 95oC 
for denaturation and 20 sec at 60oC for annealing.  
 
2.2.11 Gene expression analysis by microarray 
A whole Microarray analysis was processed by Dr Paul R Heath, Department of 
Neuroscience, SiTRans, University of Sheffield. 
2.2.11.1 Sample preparation 
 RNA was extracted (see section 2.2.8) from  F+M+ and F-M- C4-II cells grown for 8 
days of three-independent experiments and determined the RNA purity and integrity by 
Agilent RNA 6000 Nano kit using Agilent 2100 bioanalyzer. The ratio of A260/A280 should 
be more than 1.8.  The ratio of 28S/18S RNA should be more than 1.0 and RNA integrity 
number (RIN) should be more than 5.0. The higher RIN the more intact the RNA (Schroeder 
et al., 2006). The RNA of each sample was used for gene microarray target preparation. 
2.2.11.2 Microarray target preparation 
 The target RNA was prepared by using the GeneChip® 3’ IVT Express Kit protocol in 
order to get linear RNA amplification and process T7 in vitro transcription. Briefly, the RNA 
was synthesised to first-strand cDNA containing T7 promoter and then converted into 
double-strand DNA by the Eberwine or reverse transcription-IVT (RT-IVT) reagents provided 
by the kit. The double-strand DNA was then transcribed and tagged with biotin-conjugated 
nucleotide to get cRNA or aRNA (amplified RNA).  The aRNA was further purified by 
magnetic-bead aRNA purification to clean from salts, enzyme, unincorporated NTP, and 
inorganic phosphate. The biotin-modified aRNA was fragmented into ~800 nucleotides and 
to be ready for hybridisation. 
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2.2.11.3 Hybridisation and probe array scan 
 The biotin-modified aRNA fragment was mixed with hybridisation cocktail followed 
the GeneChip® Hybridisation, Wash, and Stain Kit  protocol and loaded into GeneChip 
Human Genome U133 Plus 2.0 Array. Each array was comprised of more than 54,000 probe 
sets which can be used to analyze the human expression level of over 47,000 transcripts. 
The array was incubated in GeneChip® Hybridisation Oven 640 for 16 hours. After 
hybridisation, the array chip was washed and stained. The whole steps of washing and 
staining were all automatically processed by GeneChip® Fluidics Station 450. The array was 
scanned to define the probe signals and stored as a CEL image file by using GeneChip® 
Scanner 3000. 
2.2.12 Nuclear protein extraction 
Nuclear extracts were prepared by using NE-PER® Extraction Reagents. The 
cytoplasmic and nuclear protein extraction was processed using the reagent volumes 
indicated in the manufacturer’s protocol (Table 1) with the volume ratio of CER I: CER II: 
NER reagents at 200:11:100µl, respectively. The protease inhibitor cocktail solution was 
added to CER I and NER prior to use and all of the extraction processes were run at 40C. 
After trypsinization, the cells were washed twice with PBS and the cell pellets were collected 
by centrifugation and carefully remove supernatant. The ice-cold CER I reagent was added 
to the cell pellet and vortexed vigorously for 15 seconds.  The cell suspension tube was 
incubated on ice for 10 minutes. The ice-cold CER II was added to the cell suspension and 
vortexed on the highest setting for 5 seconds followed by incubation on ice for 1 minute. The 
cell suspension was vortexed for 5 second s and centrifuged at 16,000xg for 5 minutes. The 
supernatant (cytoplasmic extract) was transferred to a new pre-chilled tube and placed on 
ice or stored at -800C until use. The pellet fraction was suspended with ice-cold NER reagent 
and vortexed vigorously for 15 seconds every 10 minutes 4 times. The cell suspension was 
vortexed for 5 seconds and centrifuged at 16,000xg for 10 minutes. The supernatant 
(nuclear extract) was transferred immediately to a new pre-chilled tube and placed on ice or 
stored at -800C until use. 
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Table 1: Reagent volumes used for different packed cell volumes 
Packed Cell volume (µl) CER I* (µl) CER II* (µl) NER I* (µl) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
100 1000 55 500 
*CER I = cytoplasmic extraction reagent I, CER II= cytoplasmic extraction reagent II, NER = 
nuclear extraction reagent 
 
 
2.2.13 Protein quantification 
The BSA protein standard was made to 1.0, 0.75, 0.5, 0.25, 0.125, and 0.0625 mg/ml. 
The BSA standard series can be kept at 40C and used for several measurements. Protein 
quantification was determined by Bio-Rad Bradford assay. The Bio-Rad reagent was diluted 
in to the ratio of 1:5, and, the samples were diluted in to the ratio of 1:2, 1:4, and 1:8 in 
distilled water. 4 µl of water (blank), diluted standard, and, samples were pipetted in to a 96-
well plate in duplication for standard s and triplication for blank and samples. 200 µl of 
diluted Bio-Rad reagent were added into each well containing the standards, samples, and 
blank, mixed by pipetting. Absorbance at 595nm was measured by a microplate reader 
within 30 minutes. A standard curve of protein concentration was plotted and the protein in 
the samples quantified using the standard curve. 
2.2.14 Determination of DNMT activity 
Nuclear extracts were prepared by using NE-PER® Extraction Reagents following the 
manufacturer’s protocol (Thermo Scientific). Protein concentrations of the nuclear extracts 
were determined by using Bio-Rad protein assay before running the global DNA 
methyltransferase activity (EpiQuik™ DNA Methyltransferase Activity/Inhibition Assay Kit, 
Epigentek, USA). The activity assay followed the manufacturer’s protocol. Briefly, 3 µl 
nuclear extracts were incubated with methylation substrate at 37oC for 1.5 hours. The 
capture antibody was added and incubated at room temperature for 60 min on an orbital 
shaker. Then, the detection antibody was added and incubated for 30 min. The colour 
developing solution was added followed by the stop solution. The absorbance was 
determined by using a microplate reader at 450 nm. The global DNMT activity (O.D./h/mg)  
was calculated referring to the formula: (Sample OD – blank OD)/(sample protein amount 
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:µg × 1000), according to manufacturer's instructions. The results are given in activity units 
detected in treatments (F-M+ and F-M-) relative to the activity level detected in control 
(F+M+) at day 8. 
 
2.2.15 Determination of cell migration  
2.2.15.1 Cell proliferation assay (MTS assay) 
 Proliferation of C4-II cells cultured in a 96-well plate was determined for 6-technical 
replicates for each sample. The proliferation rate was investigated by measuring the number 
of living cells at given time points. The CellTiter 96® AQueous One Solution Reagent 
(Promega, USA) was used and the measurement was made followed the manufacturer’s 
protocol. The reagent stock was thawed and aliquoted into several 1-ml microcentrifuge 
tubes and stored at -200C in the dark. At three hours prior to each given time point, 20µl of 
reagent were added into each well of the 96-well plate containing the cells in 100μl of culture 
medium. The plate was incubated in the dark at 370C for 3 hours in a humidified, 5% CO2 
incubator. The absorbance at 490 nm was measured using a colorimetric microplate reader. 
A higher absorbance indicates a higher cell proliferation. The change in cell proliferation was 
compared with the control at 24-hours. 
2.2.15.2 Mitomycin C optimisation 
 After treatment for 8 days cells were trypsinised and re-plated into 96-well culture 
plates at a cell density anticipated to give 50-70% confluency after 24hours, Following 3 
hours of re-plating, cells were treated with mitomycin C in the range of 0.1-1.0µg/ml for 2 
hours. The cells were washed with PBS and then the 100µl of particular fresh medium was 
added. Cells were cultured in a humidified incubator at 37oC with 5% carbon dioxide. Prior to 
24, 48, and 72-hour culture period (at 21, 45, and 69 hour, respectively), the proliferation 
was determined (see section 2.2.15.1).  
2.2.15.3 Scratch assay 
 After 8-days treatment C4II cells were trypsinised and re-plated into 96-well culture 
plates at a cell density anticipated to give100% confluency by the next day (100,000 cells 
/well). After the cells reached 100% confluency, the cells were treated with 0.7µg/ml of 
mitomycin C for 2 hours. The cells were washed by PBS and the particular fresh medium 
was added. The cells were incubated at 37 0C for 1 hour and then a straight-line scratch was 
made for every cultured well by using p200-micropipette tips. The cells were washed twice 
by PBS to remove cell debris and the particular fresh medium was added.  A scratch at 0, 
24, and 48 hours was imaged under 4x objective microscope. The width of the scratch was 
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measured and analysed by using ImageJ program for 20 measurements in at least 6 areas 
(wells). The cell migration rate was expressed as a percentage of mean gap closure in 
comparison between control cells, mitomycin C-treated control cells, methyl-donor depleted 
cells, and mitomycin C-treated methyl-donor depleted cells. 
2.2.16 Statistic analysis 
Statistical analyses were carried out using SPSS statistics version 20 for Windows.  
Two-way ANOVA was used to compare treaments for experiments involving more than one 
time point. The results were considered significant if P-values were ≤ 0.05. Where a 
significant difference effect of time or treatment was indicated, one-way ANOVA and a 
Bonferroni or Dunnett T3 post-hoc test was carried out depending on the raw data 
homogeneity. 
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Chapter 3 Model development and validation 
3.1 Introduction 
Methyl donor metabolism plays an important role in both DNA synthesis and 
methylation. Deficiency in one carbon donors can induce DNA instability (Duthie et al., 2002) 
and alter methylation (Kim, 2004; Crider et al., 2012) which may in turn affect carcinogenesis 
(Kim, 2005). In order to study the effect of one carbon donor depletion on cervical cancer 
development and progression, a cervical cancer cell model of folate and methionine 
depletion was constructed. 
Many models of methyl-donor depletion have been generated both in different animal 
species and different cell types. These studies differ not only in terms of the model system 
itself but also the nature and severity of the depletion and the outcomes of interest. Several 
studies in in vitro models have been developed. Duthie et al. (2000a) investigated the effect 
of folate deficiency on uracil miscorporation and DNA methylation level in immortalized 
normal human colon epithelial cells. They reported a decrease in DNA stability was in cells 
at folate concentrations associated with folate concentrations found in human plasma (1-
10ng/ml), but DNA hypomethylation was not folate concentration dependent. In 2001, Chern 
et al. (2001) conducted a folate-depletion study in HepG2 cells and suggested that the 
accumulation of homocysteine in cells depleted of folate led to oxidative stress and 
apoptosis (Chern et al., 2001). Similarly, Novakovic et al. (2006) demonstrated that the 
expression of 5 and 12 genes involved in apoptosis were altered in folate-deficient human 
colon adenocarcinoma cell lines, HCT116 and Caco-2 cells, respectively.  However, there 
was only one gene, baculoviral IAP repeat-containing 3 (BIRC3; apoptosis inhibitor), which 
was altered in the same direction (up-regulation) in this study (Novakovic et al., 2006).  
The investigation of the one-carbon homeostasis resulting from folate deficiency is 
another focus of interest. A study in breast cancer cells, MCF-7/MR, of Ifergan et al. in both 
long-term (Ifergan et al., 2004) and short-term folate deficiency (Ifergan et al., 2005) 
demonstrated almost total loss of breast cancer resistance protein (BCRP/ABCG2) and only 
14% remaining in plasma membrane, respectively. BCRP is the transporter proteins, which 
exports folate mono-, di-, and triglutamate. Down-regulation of this protein was reported to 
increase [3H] folic acid accumulation in an experimental model and was associated with an 
increase in folylpoly-glutamate synthetase activity (FPGS: catalyses the conversion of folate 
to polyglutamate). This study suggested cell adaptation to manage the folate pool. An 
alteration of the transcript levels of genes related to folate metabolism was observed in folate 
deficient human colonic epithelial cell model was also determined by Hayashi et al. (2007). 
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They demonstrated the up-regulation of folate receptor (FR-α), FPGS, 
methylenetetrahydrofolate reductase (MTHFR) and DNMT1, and the down-regulation of 
reduced-folate carrier (RCF), thymidylate synthase (TS), methionine synthase reductase 
(MTRR), DHFR, serine hydroxymethyltransferase (SHMT), methionine synthase (MTR), and  
methyl DNA-binding domain protein 2 (MBD2) in HCT116, but these results different in some 
respects in Caco-2 cells. In Caco-2 cells, gene changes suggested that folate deficiency 
increased folate uptake and reduced folate hydrolysis. The authors also suggested that 
HCT116 adaptation indicated a preference of the shuttle of the flux of one-carbon units to 
the methionie cycle rather than nucleotide synthesis pathway (Hayashi et al., 2007). 
 
There have been a few studies of methionine-deficiency in in vitro models of the 
central nervous system  tumour cell lines which found an alteration of gene in  cell cycle 
checkpoints , proapoptotic pathways, and DNA repair (Kokkinakis et al., 2004; Najim et al., 
2009) and pancreatic tumour cell lines which found a disruption of mitosis and enhanced cell 
cycle arrest (Kokkinakis et al., 2005). Studies of combined methyl-donor depletion have 
been mostly conducted in animals and found an impact on liver such as an alteration of 
global DNA methylation and abnormal liver metabolism (Pogribny et al., 2004; Ghoshal et 
al., 2006; Romestaing et al., 2008).  
 
It is clear that there is a diversity of interest in terms of effects of moderate or severe 
methyl donor depletion on various functional outcomes and therefore the findings from these 
various model systems have only limited comparability. Our interest lies primarily in the 
importance of methyl donor status to cervical cancer risk and cancer progression. To our 
knowledge there have been no studies of methyl donor depletion in cervical cancer cells.   
In this study, folate and methionine were the focus of interest, partly because they 
have a very close relationship in their metabolism, also because we have previous 
experience of the effects on the methyl cycle of depletion of one or both these methyl donors 
(Nakano et al., 2005). Two cervical cancer cell lines were chosen, C4-II and SiHa cells.  
These two cervical cancer cell lines are derived from different sources and harbour different 
types of high risk HPV. The intention was to develop a model of moderate methyl donor 
depletion. 
 The proposal was to deplete cells of folate or folate and methionine, by culturing in 
media deficient in these substrates, to confirm a methyl donor-depleted state and to 
determine functional impact on the methyl cycle.   
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3.2 Aims 
To develop a cervical cancer cell model of folate and combined folate and methionine 
depletion, to determine effects on growth characteristics and to validate the model by 
examination of intracellular folate concentration, intracellular methionine concentration, and 
homocyteine export. 
3.3 Methods 
3.3.1 Determination of cell growth and cell characteristics 
C4-II and SiHa cells were thawed (see section 2.2.1.1) and a culture maintained 
through subculturing, as described (see section 2.2.1.2).  Cells were transferred to 
appropriate culture containers and medium for the determination of cell growth and cell 
characteristics (see section 2.2.2). Cell size was examined by measurement of cell diameter 
(in pixel scale) from cell images using ImageJ software. Twenty cells were randomly chosen 
and measured from one area and the mean cell diameter of ten areas was reported. 
3.3.2 Methyl-donor depletion  
3.3.2.1 Combined folate and methionine depletion 
In the first instance, a model of one-carbon donor depletion was established to 
maximize the likelihood of an effect on global DNA hypomethylation at a later date. C4-II and 
SiHa cells were cultured as 20,000 cell /cm2 for 12-20 days in two types of media in parallel: 
complete medium (F+M+) and folate and methionine-depleted medium (F-M-). Cell growth 
was observed every day and one flask of cultured flasks was chosen for cell counting every 
3-5th day for 12-20 days (see section 2.2.2).  
3.3.2.2 Differentiation of the effects of folate depletion alone from methionine 
depletion alone 
To differentiate the effects of folate depletion alone from methionine depletion alone, 
C4-II cells were cultured for 12-20 days in four types of media in parallel: complete medium 
(F+M+), folate and methionine-depleted medium (F-M-), folate and methionine-depleted 
medium to which folinic acid was added to a concentration of  900 nM (F+M-), and, folate 
and methionine-depleted medium to which L-methionine was added to a final concentration 
of 300 µM (F-M+). The growth rates were compared by cell counting (see section 2.2.2). 
3.3.2.3 Folate depletion, and, folate and methionine depletion 
C4-II and SiHa cells were cultured for 12-20 days in three types of media in parallel: 
complete medium (F+M+), folate and methionine-depleted medium (F-M-), and, folate and 
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methionine-free medium + 300 µM L-methionine (F-M+). The growth rates were compared 
by cell counting (see section 2.2.2). 
3.3.3 Measurement of intracellular folate 
More than 5 million cells were harvested on days 4, 8 and 12 of culture for C4-II cells, 
and at week 2, 4 and 6 for SiHa cells. Cells were prepared for the measurement of 
intracellular folate as described (see section 2.2.3), using an automated competitive folate 
protein binding assay (Beckman Access Kit). Intracellular folate concentration was 
expressed as pmol/106 cells. 
3.3.4 Measurement of intracellular methionine (C4-II only)  
More than 20 million cells were harvested on days 4, 8 and 12 of culture for C4-II 
cells only. Cells were prepared for the measurement of intracellular methionine and sent to 
the Department of Clinical Chemistry, Sheffield Children’s Hospital (see section 2.2.4). 
Intracellular methionine was measured using a Biochrom amino acid analyzer and 
expressed as pmol/106 cells. 
3.3.5 Measurement of homocysteine 
To determine intracellular homocysteine and extracellular homocysteine, cells were 
harvested and the culture medium was collected on days 0, 4, 8, and 12 of culture for C4-II 
cells or at 70-80% confluence of SiHa cells after 2, 4, and 6 passages (week 2, 4, and 6) in 
each treatment. Intracellular homocysteine and extracellular homocysteine were measured 
by HPLC (see section 2.2.5). 
3.3.6 Statistical analysis 
See section 2.2.16 and the Mann-Whitney U test was used for comparison between 
two samples. 
 
3.4 Results 
3.4.1 Cell characteristics  
Figure15 shows the mean C4II cell number over 20 days from three independent 
experiments. Results from three-independent experiments showed that the number of C4-II 
cells doubled every 3 or 4 days of culture. Growth was exponential from the fourth day of 
culture.  
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C4-II cells reached 100% confluence by day 10 of culture. Cells were observed to form 
diffuse monolayer colonies with domes and pile up in post-confluence from day 10 (figure 
16) 
SiHa cells were initially grown in DMEM to determine growth rate. The results are from 
one experiment using the same seeding density as for C4-II cells. Figure 17 shows SiHa cell 
growth and shows that SiHa cells double at approximately the same rate as C4-II. However, 
unlike C4-II cells, SiHa cells entered a plateau phase after day 10. Moreover, SiHa cells 
maintain a monolayer throughout the culture period, with few floating cells. Figure 18 shows 
images of SiHa cells at three time points. SiHa cells reached 100% confluence by day 8. 
3.4.2 Effect of methyl-donor depletion on cell growth 
3.4.2.1 Folate and methionine depletion 
Figure19 shows the growth of C4-II cells over 20 days, when grown in complete 
medium and folate and methionine-deplete medium. C4-II cells grown in complete medium 
reached 100% confluence by day 8-10, after which the cells started to pile up in multilayers. 
C4-II cells cultured in folate and methionine- depleted medium also reached 100% 
confluence by day 8-10, but after which the cells still appeared as a monolayer. There was a 
difference of 40 and 50 million cells between treatments by the end of day 15 and 20, 
respectively, and by day 20 the number of cells in the depleted medium was only 30% of that 
of cells grown in the complete medium. By day 12, folate and methionine-deplete cells were 
growing more slowly and this persisted to day 20 (P<0.05).  
Figure 20 shows the results from three growth experiments using SiHa cells. Cells 
grown in folate and methionine-deplete medium appeared to grow at the same rate as cells 
grown in complete medium, until day 12. From day 18, there was a fall in cell number in the 
depleted cells. By day 20, the cell number in folate and methionine-depleted medium was 
about 30% lower than for cells grown in complete medium (P<0.05). 
3.4.2.2 Differentiation of the effects of folate depletion alone from methionine 
depletion alone (C4-II only) 
In the first instance, C4-II cells were cultured in four different media; complete 
medium (F+M+), folate-depleted medium (F-M+), methionine-depleted medium (F+M-), and 
folate and methionine-depleted medium (F-M-). Figure 21 shows growth rate during 20 days 
of culture.  
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Figure 15: Growth of C4II cells cultured in complete medium for 20 days 
Each value shows mean of three-independent experiments and error bars show 
SEM.   
 
 
Figure 16: Characteristics of C4-II cells after 4, 11 and 18 days of culture 
All of the images were taken under10x objective lens.   
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Figure 17: Growth of SiHa cells cultured for 15 days in complete medium 
 
 
 
Figure 18: Characteristics of SiHa cells after 4, 8 and 12 days of growth in complete 
medium 
All of the images were taken under10x objective lens.   
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Figure 19: The growth curves of C4-II cells grown in folate and methionine-depleted 
medium compared with controls 
Each value shows mean of three-independent experiments and error bars show SEM.  
*Cell number significantly different between treatments, P < 0.05 (Mann-Whitney U test). 
 
Figure 20: The growth curves of SiHa cells growing in folate and methionine- 
depleted medium compared with controls 
Each value shows mean of three-independent experiments and error bars show SEM.   
*Cell number significantly different between treatments, P < 0.05 (Mann-Whitney U test). 
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Figure 21: Effects of methyl donor depletion on growth of C4-II cells 
Each value shows mean of three-independent experiments and error bars show SEM.   
* Cell number significantly different from control, P < 0.05 (one-way ANOVA, post hoc test).  
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Growth was significantly influenced by time (P<0.001) and treatment (P< 0.001), and a 
significant interaction occurred between these factors (P<0.001). Cells appeared to grow at 
a similar rate under each of the four conditions, up to day 4, from which time cells grown in 
the complete medium appeared to grow faster than cells grown in either of the deplete 
media (figure 21). At day 12, there was a greater number of cells when grown in complete 
medium than under any other condition (P<0.01) but the number of cells grown in the three 
depleted conditions did not differ from each other. This effect of treatment was also seen at 
day 20; there was a greater number of cells when grown in complete medium than all other 
conditions (P<0.05) but the number of cells grown in those three depleted conditions did not 
differ from each other.  
From three independent experiments, it was observed that a combined folate and 
methionine depletion was associated with a lower mean growth rate than for folate or 
methionine alone, even though this did not reach statistical significance. It was decided that 
further experiments would focus on folate depletion alone, and combined folate and 
methionine depletion.  
3.4.2.3 Determination of effects on growth of folate depletion alone, and combined 
folate and methionine depletion 
The effect of folate depletion alone on growth rate was determined in three 
independent experiments for C4-II and SiHa cells. Because of the tendency of C4-II cells to 
grow in a multilayer after 12 days all further experiments using these cells were carried out 
up to day 12 only.  C4-II cells were grown in T75  flasks while SiHa cells were grown in 24-
well plates, but in the same seeding ratio-20,000 cell/cm2. Figure 22A) and 22B) show the 
results for C4-II and SiHa cells, respectively. C4-II cells grown in complete medium gave the 
highest growth rate. By day 12, cell mean number was lowest for cells grown in folate and 
methionine-depleted medium, intermediate for cells grown in folate-deplete medium and 
highest for cells grown in complete medium. 
In C4-II cells cell growth was significantly influenced by time (P<0.001) and treatment 
(P< 0.001), and a significant interaction occurred between these factors (P<0.001). C4-II 
cells appeared to grow at a similar rate under each of the three conditions, up to day 4, from 
which time cells grown in the complete medium appeared to grow faster than cells grown in 
either of the deplete media (figure 22A). One-way ANOVA and post hoc analysis with 
treatment as factor on day 8 showed a significantly greater number of cells grown in 
complete medium than that in folate and methionine-deplete medium (P<0.001), and the cell 
number for cells grown in folate deplete medium was greater than that in folate and 
methionine deplete medium (P=0.017). At day 12, the growth rate was significantly different 
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for all three treatments (P<0.001). The doubling time (DB) of cells grown in combined folate 
and methionine depleted medium was 5.08 days compared with 2.77 days for control cells 
and 3.62 day for folate-depleted medium.  
Growth of SiHa cells was influenced by time (P<0.001), treatment (P< 0.001), and a 
significant interaction occurred between these factors (P<0.001). SiHa cells appeared to 
grow at a similar rate under each of the three conditions, up to day 12, from which time cells 
grown in the folate and methionine-depleted medium grew more slowly, and by day 20, there 
was a lower cell number than for other treatments (P<0.001) (figure 22B). The doubling time 
(DB) of SiHa cells grown in complete, folate-depleted, and, folate and methionine-depleted 
medium were 2.46 days, 2.52 days, and 2.57 days, respectively.  
The cell size of C4-II cells grown in folate and methionine deplete medium was greater 
than the complete medium and folate deplete medium after 8 days of culture (figure 23). 
Two-way ANOVA showed effects of time and treatment (P<0.001) and a significant 
interaction between the two factors (P<0.001). From day 4 until day 12 there was a 
significant decrease in cell size for cells grown in either the complete medium or the folate 
deplete medium. In contrast, cells grown in the folate and methionine deplete medium 
increased in size from day 4 until day 8. As a result, by day 8, cells grown in the folate and 
methionine depleted medium were larger than those grown in complete medium or folate 
deplete medium, and this was also evident at day 12 (figure 24). The cell size and 
morphology of SiHa cells grown in all three media were similar throughout culture period 
(figure 25).  
Growth of SiHa cells seemed resistant to growth in folate and methionine-depleted 
medium and therefore, in order to determine long-term effects, SiHa cells were exposed to 
long-term depletion for 6 weeks with subculture at 70-80% cell confluence every week.   
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Figure 22: Growth of C4-II cells (A), and SiHa cells (B) in complete medium, folate-
deplete and combined folate and methionine-deplete medium 
Each value shows mean of three-independent experiments and error bars show SEM.  
*Significantly different from control, P<0.05, § significantly different from F-M+, P<0.05 (one-
way ANOVA, post hoc test) 
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Figure 23: Characteristics of C4-II cells grown in (A) F+M+ (B) F-M+, and (C) F-M-
after 4, 8 and 12 days of culture 
All of the images were taken under10x objective lens.   
 
Figure 24: Cell size of C4-II cells grown in F+M+, F-M+, and F-M- after 4, 8 and 12 
days of culture 
Each value shows mean cell diameter from ten measurements and error bars show SEM.  
*significantly different from control and F-M+, P<0.05 (one-way ANOVA, post hoc test) 
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Figure 25: Characteristics of SiHa cells grown in (A) F+M+ (B) F-M+, and (C) F-M-
after 4, 8 and 12 days of culture 
All of the images were taken under10x objective lens.   
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3.4.3 Effect of methyl donor depletion on intracellular folate concentration 
For the cell lysate preparation, it was anticipated from experience with other cultured 
cells that a large number of cells would have to be available for the measurement of 
intracellular folate (more than 5x106 cells). To make the data comparable, intracellular folate 
concentration was corrected for cell number and calculated as nmol/106cell or pmol/106cell.   
Intracellular folate fell by by 90% within 4 days of culture of C4-II cells in folate –deplete 
or folate and methionine-deplete medium. C4-II cells grown in either folate-deplete or folate 
and methionine-deplete medium for only 4 days had an intracellular folate concentration of 
0.1-0.3 pmol/106 cells compared with 2 pmol/106 cells in cells grown in complete medium 
(figure 26). Two-way ANOVA showed a significant effect of time and treatment on 
intracellular folate concentration (P<0.001) and a significant interaction between these 
factors (P<0.001). On day 4, 8, and 12 cells grown in folate deplete or folate and methionine 
deplete medium had significantly lower intracellular folate concentration than control cells 
(P<0.001), but were not different from one another.  
Intracellular folate concentration was lower at day 12 than day 4 for cells grown in folate 
and methionine deplete medium (P=0.036), and lower at day 12 from that at day 8 for cells 
grown in folate deplete medium (P=0.05). There was an unexpectedly higher folate 
concentration at day 8 compared with day 4 and day 12 in cells grown in complete medium 
(P=0.001).  
Since the preliminary experiments had indicated that growth of SiHa cells was relatively 
resistant to methyl donor depletion, effects of long term growth in folate-depleted medium 
were determined .The folate concentration in SiHa cells grown in complete, folate-deplete, 
and folate and methionine deplete medium was measured for one experiment after 6 
passages (42 days), in cells at 70-80% confluence. Figure 27 shows that intracellular folate 
in cells grown in both folate-deplete, and folate and methionine-deplete medium decreased 
to only about 2% of that in control cells. Further work was then carried out to determine how 
quickly SiHa cells become folate-deplete in order to establish the model. 
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Figure 26: Intracellular folate concentration of C4-II cells grown in folate and 
methionine-depleted medium and complete medium 
Each value shows mean values from three-independent experiments and error bars show 
SEM.  
* Intracellular folate concentration was significantly different from control, P<0.05 (one-way 
ANOVA, post hoc test) 
 
 
Figure 27: Intracellular folate concentration of SiHa cells grown in complete, folate-
deplete, and, folate and methionine-depleted medium after 6 passages (42 days) 
 Each value shows mean values for two technical replicates from one experiment and error 
bars show SD. 
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A lower intracellular folate concentration was observed in SiHa cells after 6 passages 
of growth in folate and methionine-deplete medium, an experiment was set up to determine 
how quickly SiHa cells became folate-depleted. Cells were grown for 6-weeks and harvested 
every 2 weeks for the measurement of intracellular folate. Figure 28 compares intracellular 
folate concentration of SiHa cells grown in three different conditions for a long term 
depletion. There was a significant effect of treatment on intracellular folate concentration 
(P<0.001). At weeks 2, 4 and 6, cells grown in folate deplete and folate and methionine 
deplete medium had significantly lower intracellular folate concentration than control cells 
(P<0.001), but were not different from one another. Folate concentrations were not different 
between weeks 2, 4 and 6. 
3.4.4 Effect of methyl donor depletion on Intracellular methionine concentration 
The intracellular methionine concentration was measured in only the C4-II cells 
because, at the time SiHa cells were still under study the measurement was not available. 
By the time the measurement was available, the SiHa cells were no longer under study. 
Time (P = 0.05) and treatment (P = 0.001) influenced the intracellular concentration of 
methionine. In C4-II cells grown in folate and methionine depleted medium showed a 
reduction in intracellular methionine from about 300 pmol/106 cells in control cells to 100 
pmol/106 cells at day 4 (figure 29) and a further decrease to about 30 pmol/106 cells at day 
8. Intracellular methionine was lower in folate and methionine-depleted cells than that in 
control (P<0.002) and in folate-depleted cells (P<0.001) on day 4 and day 8 (P=0.026).   
However, unexpectedly, at day 12 there was no significant difference in intracellular 
methionine concentration between treament. One-way ANOVA with time as factor and post 
hoc analysis showed that intracellular methionine concentration was higher at day 12 than 
day 8 for cells grown in folate and methionine deplete medium (P=0.05). However, 
unexpectedly, there was an increase in methionine between day 8 and 12 in cells grown in 
methionine-depleted. 
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Figure 28: Intracellular folate concentration of SiHa cells grown in folate-deplete, 
folate and methionine depleted medium and complete medium 
Each value shows the mean value from three-independent experiments and error bars show 
SEM.  
* Intracellular folate concentration was significantly different from control, P<0.05 (one-way 
ANOVA, post hoc test) 
 
 
Figure 29: Intracellular methionine concentration of C4-II cells grown in folate and 
methionine depleted medium, folate-depleted medium, and, complete medium 
Each value shows mean of three-independent experiments and error bars show SEM.   
*Intracellular methionine concentration was significantly different from control, P<0.05 (one-
way ANOVA, post hoc test). 
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3.4.5 Effect of methyl donor depletion on intracellular and extracellular homocysteine
  
Intracellular homocysteine in C4-II cells 
Elevated homocysteine concentration in the medium of cultured cells is an indicator 
of functional folate deficiency (Ueland et al., 1993; Zittoun & Zittoun, 1999). This reflects 
accumulation of homocysteine intracellularly, due to a failure to remethylate homocysteine to 
methionine.  
 
Table 2 shows the intracellular homocysteine concentration of C4-II cells expressed 
as µmol/L. There was an effect of time (P<0.001) on homocysteine concentration, but no 
discernible trend. Unexpectedly, mean homocysteine concentration was lower at day 8 than 
at other time points (P<0.01). The intracellular homocysteine of C4-II cells was not 
significantly different across the three treatments at any time point.  
Table 3 shows intracellular homocysteine concentration of C4-II cells expressed as 
pmol/106 cells. Expressed in this way the mean homocysteine concentration was lower at 
day 8 than at other time points (as shown when expressed as µmol/L) but there was no 
significant difference across the three treatments at any time point. However, the 
concentration of intracellular homocysteine was extremely low, close to the lowest limitation 
of this method (1.0-200 µmol/L). Therefore, results need to be interpreted cautiously.  
Table 2: Intracellular homocysteine concentration (µmol/L) of C4-II cells grown in complete, 
folate-deplete, and folate and methionine-deplete medium 
Day of culture 
Intracellular homocysteine (µmol/L) 
F+M+ medium 
(mean ± SEM) 
F-M+ medium 
(mean ± SEM) 
F-M- medium  
(mean ± SEM) 
0 4.78 ± 0.076 4.78 ± 0.076 4.78 ± 0.076 
4 5.76 ± 0.57 5.53 ± 0.62 6.08 ± 0.53 
8 1.48 ± 0.68* 3.18 ± 0.48* 1.56 ± 0.33* 
12 7.74 ± 0.54 8.49 ± 0.64 6.70 ± 0.64 
Values are mean values from three experiments. *significantly lower than other time points, 
P<0.01 (one-way ANOVA, post hoc test). 
 
 
 
78 
 
Table 3: Intracellular homocysteine concentration (pmol/106 cell) of C4-II cells in complete, 
folate-deplete, and, folate and methionine-deplete medium 
Day of culture 
Intracellular homocysteine (pmol/106 cells) 
F+M+ medium 
(mean ± SEM) 
F-M+ medium 
(mean ± SEM) 
F-M- medium  
(mean ± SEM) 
0 35.9 ± 0.58 35.9 ± 0.58 35.9 ± 0.58 
4 47.6 ± 3.29 43.3 ± 3.75 42.4 ± 3.92 
8 5.6 ± 0.42* 35.8 ± 1.34 1.6 ± 0.29* 
12 31.4 ± 6.35 39.6 ± 1.62 51.9 ± 2.94 
Values are mean values from three experiments. *significantly lower than other time points, 
P<0.01 (one-way ANOVA, post hoc test). 
 
Extracellular homocysteine C4-II cells 
Figure 30 shows the homocysteine concentration in the medium when C4-II cells 
were grown under different conditions. Two-way ANOVA showed a significant effect of time 
and treatment on extracellular homocysteine concentration (P<0.001) and a significant 
interaction between these factors (P<0.001). At day 8 the concentration of homocysteine in 
the medium was greater for cells grown in folate-deplete medium than for cells grown in 
complete medium (P=0.001), and greater than for cells grown in folate and methionine 
depleted medium (P=0.004). At day 12, the concentration of homocysteine in culture 
medium of folate and methionine depletion was greater than of that in control (P=0.011). The 
mean homocysteine concentration in the medium increased from day 4 to day 12 for cells 
grown in folate depleted medium (P<0.001). The homocysteine concentration in the medium 
of cells grown in complete (P=0.001) and folate and methionine depleted medium (P=0.002) 
increased from day 4 to day 8, but showed no further increase thereafter.  
Intracellular homocysteine SiHa cells 
When considering the experiment for SiHa cells it was anticipated from experience 
with C4-II cells that a very large number of cells would have to be available for the 
measurement of intracellular homocysteine (more than 20x106 cells). For this reason, one 
single experiment was carried out in which intracellular homocysteine concentration was 
measured in cells at 70-80% cell confluence after 6 passages (42 days) when grown in 
complete, folate-deplete and folate and methionine-deplete medium. Homocysteine 
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concentration was measured in technical triplicates and shown in figure 31. Concentrations 
were similar to those observed for C4-II cells.  
Mean concentrations of intracellular homocysteine, for both C4II cells and SiHa cells, 
were extremely low, close to the lower limit of this assay (range 1.0-200 µmol/L), and 
therefore the results need to be interpreted cautiously. 
Extracellular homocysteine SiHa cells 
Figure 32 shows extracellular homocysteine following growth of SiHa cells in 
different media over long-term culture. Two-way ANOVA showed a significant effect of 
treatment on extracellular homocysteine concentration (P<0.001). The concentration of 
homocysteine in the medium was greater for cells grown in folate-depleted medium and 
folate and methionine depleted medium than for cells grown in complete medium (P<0.05) at 
weeks 2 to week 6, but were not different from one another.  
 
 
Figure 30: Extracellular homocysteine concentration of C4-II cells cultured in 
complete, folate-deplete, and, folate and methionine-deplete medium 
Each value shows mean of three-independent experiments and error bars show SEM.  
* Significantly different from control, P<0.05. §significantly different from F-M+, P<0.05 (one-
way ANOVA, post hoc test) 
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Figure 31: Intracellular homocysteine of SiHa cells grown in complete, folate-
deplete, and, folate and methionine-deplete medium for 6 passages (42 days) 
The values are expressed as pmol/106 cells.  
Each value shows mean values for technical replicates from one experiment and error bars 
show SD. 
 
 
Figure 32: Extracellular homocysteine for SiHa cells cultured in complete, folate-
deplete, and, folate and methionine-deplete medium 
Each value shows mean of three-independent experiments and error bars show SEM.   
* Significantly different from control, P < 0.05 (one-way ANOVA, post hoc test). 
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3.5 Discussion 
In order to develop a model of one-carbon donor depletion, customized media was 
obtained representing two states of depletion; F-M+ (folate-depletion alone) and F-M- (folate 
and methionine-depletion). The folate and methionine concentrations in the F-M- medium 
were estimated to be 12-30 nM and 20 µM, respectively, compared with 900 nM and 300 
µM, respectively in the complete medium. In comparison to the human physiological system, 
the normal folate concentration in human plasma is about 7-28 nM  (Ruston et al., 2004) and 
the methionine concentration is about 10-40µM (Garlick, 2006) so the model represents a 
moderate deficiency state, rather than an acute deficiency state.  
3.5.1 Cell culture 
C4-II is the most similar cell to cervical cancer cells in gene expression profile when 
compared with other cervical cancer cell lines (Carlson et al., 2007). Therefore, C4-II was 
chosen for this research. C4-II is an epithelial cervical cancer cell line with hemicysts 
(domes) which are characteristic of transporting epithelia and respond to crowding by 
separation and shedding. A study showed that C4-II cell growth patterns in host tissue had 
characteristics of ectocervical basal cells and/or endocervical epithelium (Auersperg et al., 
1989).Our studies show that C4-II cells complete the first cell cycle within 2-3 days of culture 
(lag phase), after which C4-II cells were observed to  divide faster and grow in a log phase 
for more than 20 days without entering a plateau phase. With 20,000 cell /cm2 in the initial 
seeding, C4-II cells reach 100% confluence by 8-10 days. After C4-II cells reached 100% 
confluence they started to make domes and pile up in multilayers. To examine cell 
characteristics during culture, these early experiments involved examining cells in three 
phases of cell growth: pre-confluence, confluence, and post-confluence. 
SiHa is another cervical cancer cell which shows genetic characteristics similar to 
human primary cervical cancer cells, although SiHa and C4-II cells have different cell 
characteristics. SiHa cells complete the first cell cycle within 2-3 days of culture (lag phase), 
after which SiHa cells were observed to divide faster and entered a plateau phase around 
day 16 of culture period. With 20,000 cell /cm2 in the initial seeding, SiHa cells reach 100% 
confluence by 8-10 days. While C4-II cells showed a tendency to form multilayers, SiHa cells 
did not. Clearly a protocol which works well with one cell line may not be appropriate for 
another cell line.  
3.5.2 Effect on growth rate 
Growing C4-II cells in folate and methionine depletion retarded cell growth to a 
greater extent than folate or methionine depletion alone. Folate plays an important role in 
DNA synthesis by supplying tetrahydrofolate derivatives for construction of thymine. A 
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reduction in the availability of thymine leads to a decrease in the rate of cell proliferation and 
cells are arrested at S-phase of cell cycle (Jackson et al., 1997). The methionine depletion 
together with folate deficiency resulted in enhanced growth retardation because methionine 
is an essential amino acid which is required not only for protein synthesis but also the 
methylation process. In our study, the effect on growth rate was profound and was evident 
from about 8 days of culture in depleted medium. The tendency of C4-II cells to multilayer 
after about day 12 of culture was unexpected. We reduced the seeding density in order to 
prevent C4-II cells reaching confluence before 8-10 days of culture, but this impaired early 
growth. Nevertheless, a comparison of effects of one-carbon donor depletion up to the point 
from which multilayering was evident, providing some useful information.  
Interestingly, on days 8 and 12, the C4-II cells grown in folate and methionine-
deplete medium were bigger than those grown in the complete and folate depleted state. 
Despite the hyperconfluence of cells grown in the complete and folate depleted medium at 
day 12, the confluence at day 4 and day 8 was the same. Therefore, a difference in available 
space did not obviously explain the difference in cell size. The loss of contact inhibition is 
one of the characteristics of cancer cells (Lipkin & Knecht, 1974; Abercrombie, 1979). The 
higher proliferation rate and the greater loss of cell contact inhibition for cells grown in 
complete and folate depleted medium may explain the difference in cell size. This suggests 
that sensitivity to contact inhibition is influenced by folate and methionine depletion. 
Unlike C4-II cells, folate and/or folate and methionine depletion did not influence the 
growth rate of SiHa cells until cells were post-confluence. Growth curves of both complete 
and depleted cells started to diverge from about day 16 compared with day 8 for C4-II cells, 
and even dropped further at day 20. This may be because the SiHa cells started their 
apoptosis process. 
For both cell models of methyl donor depletion, there is a small contribution to the folate 
and methionine pool from fetal calf serum, which is replenished at each point of medium 
replacement, thereby maintaining some growth in the depleted cells.  
There have been numerous reports of folate-depletion studies in various kinds of cell 
lines and tissue types. The effect of folate deficiency seems to depends very strongly on the 
individual cell and the extent of folate depletion (Kim, 2005). Severe folate deficiency in 
untransformed NIH/3T3 and CHO-K1 cells, and human HCT116 and Caco-2 colon cancer 
cells led to a significant and progressive retarded growth by day 12 in untransformed cell 
lines and by day 20 in human colon cancer cell lines (Stempak et al., 2005). Crott et al 
(2008) studied the effect of folate depletion in three normal human colonic cell lines (HCEC, 
NCM460, and NCM356). Those cells were cultured for 30-32 days in various concentrations 
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of folic acid (25, 50, 75, and 150 nM). Cell growth of HCEC and NCM356 showed 
incremental growth retardation with decreasing folate concentration, whereas NCM460 
growth was retarded only at the lowest concentration of folate, which was comparable to the 
concentration of folate in our depleted media. On the other hand, the growth of three clonal 
cell lines generated from prostate cell lines derived from the transgenic adenoma of the 
mouse prostate (TRAMP) was not affected by culture in what the authors described as 
folate-restricted (100 nM)  medium even after 20 population doublings (Bistulfi et al., 2010). 
It should be noted that folate concentration used by this group was about five-fold higher 
than the concentration used in our study. 
There has been no previous study of methionine depletion of cervical cancer cells, 
although other cells have been studied. Hu & Cheung investigated effects of methionine 
depletion by methioninase in neuroblastoma and found that cell proliferation was inhibited 
and the cells were arrested at G2 phase (Hu & Cheung, 2009).  Graziosi et al generated a 
methionine depletion of peritoneal carcinomatosis and xenograft model in gastric cancer 
cells. They showed evidence for increased apoptosis and decreased cellular adhesion and 
migration associated with reduction of the promoter methylation of E-cadherin gene 
(Graziosi et al., 2013). Although the authors did not report methionine concentration, the 
gastric cancer cells in this study were grown in methionine-free RPMI supplemented with 
dialyzed serum, therefore, the final concentration might have been lower in methionine 
concentration than our methionine-depleted model. 
3.5.3 Effect on intracellular folate concentration 
Growth of C4-II cells in folate and methionine-depleted medium led to a decrease in 
the intracellular folate concentration compared with control cells, evident by day 4 of culture. 
C4-II cells grown in complete medium showed a fall in intracellular folate over 20 days of 
culture, presumably because of a competition for folate and methionine in the face of very 
rapid growth, eventually leading to multilayering. The decrease in intracellular folate 
concentration occurred before the decline in growth rate in the depleted cells, supporting a 
cause-effect relationship.  
Effects of methyl donor depletion on intracellular folate at day 8 and 12 corrected for 
cell number may actually underestimate the effect, given that cell size increased in response 
to depletion. However, intracellular folate expressed in this way fell significantly by day 4 at 
which point cell diameter was unchanged. Also, the effect on cell diameter was only 
observed in the double depleted state, whilst intracellular folate was significantly lower in the 
folate-depleted state as well as the double-depleted state. It is therefore reasonable to 
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conclude that cells were profoundly folate deplete from day 4 of growth in folate depleted 
and folate and methionine depleted medium. 
SiHa cells also showed a substantial decrease in intracellular folate concentration 
after 6 passages in folate and methionine-depleted medium. The intracellular folate in 
complete cells of SiHa was higher than of that C4-II more than 5 times, but the intracellular 
folate concentration of depleted cells in both cell lines was the same. Folate depletion in 
SiHa cells seemed to affect intracellular folate more than in C4-II. However, folate depletion 
in SiHa cells did not produce as great an effect on growth rate as for C4-II cells.  
The response to folate depletion evidently depends on cell type. Effects on 
intracellular folate concentration of growth under folate-deplete conditions is reported from 
many studies and in various models. Growth of untransformed CHO-K1 Chinese hamster 
ovary cells and NIH/3T3 mouse fibroblasts and human colon adenocarcinoma cells-HCT116 
and Caco-2 showed a significant  decrease (~90%) in intracellular folate after 12-20 days of 
culture in folate-depleted medium (Stempak et al., 2005). Depletion had a similar effect as in 
our study, in which the intracellular folate concentration dropped to 10% within 4 days and 
was sustained until day 12. Bistulfi et al. (2010) conducted a study of prostate cancer cells 
lines, which were generated from a primary prostate tumour in a TRAMP mouse, and 
demonstrated that folate-depleted medium also led to a significant depletion of intracellular 
folate. After culture in restricted folate medium (100nM) for 20 population doublings, 
intracellular folate concentration of prostate cancer cells in depleted medium was decreased 
to 10ng/5 million cells compared with 20-70 ng/5 million cells in control cells (Bistulfi et al., 
2010). The intracellular folate concentration in the depleted cells from our study was about 
20-fold lower than this study. This may be because our study used a medium with a lower 
folate concentration. Therefore, our model seemed to be more folate deplete than this 
research group. 
Although a reduction in extracellular folate can lead to cellular folate depletion cells 
do adapt to this folate restriction. A folate receptor gene may be up regulated by folate 
depletion (Kelemen, 2006). In cell culture studies, human KB (nasopharyngeal carcinoma) 
cells increased the uptake of folate by increasing the expression of the membrane folate 
receptor to maintain folate concentration of cells (Kane et al., 1988; Chung-Tsen & Dolnick, 
1993; Kelemen, 2006). Cells may extract enough nutrients from folate-depleted medium to 
survive, but at a slower proliferation rate (Antony, 1996). In our study, C4-II cells showed 
greater sensitivity to folate depletion than SiHa cells. This may suggest that SiHa cells might 
adapt themselves to folate depletion by upregulation of their folate receptor.  
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3.5.4 Effect on intracellular methionine concentration 
 Intracellular methionine of C4-II cells grown in folate and methionine-deplete medium 
dropped significantly by 4 days and fell further over the subsequent 4 days, confirming the 
combined depletion. Unlike the intracellular folate concentration which fell progressively over 
12 days of culture in the double-depleted state, the intracellular methionine concentration 
increased from day 8 to day 12, suggesting that the cells can adapt to growth in methionine-
deplete medium. A study in a rat model of sulphur amino acid deficiency demonstrated an 
up-regulation of activating transcription factor (ATF) and also an up-regulation of other genes 
involved in the solute carrier (SLC) family amino acid transporter (Sikalidis & Stipanuk, 
2010). Therefore, cells grown for a prolonged period in methionine deplete medium may 
express more methionine transporter, and consequently, increase uptake of methionine and 
increase intracellular methionine concentration to support cell function. 
3.5.5 Effect of growth in a folate-depleted medium on methyl cycling: measurement of 
intracellular homocysteine and homocysteine export 
Intracellular homocysteine concentration depends on the activity of the methyl cycle, 
which is in turn dependent on the availability of enzyme co-factors and enzyme regulation. 
Accumulation of intracellular homocysteine leads to export from the cell (Svardal et al., 1986; 
Nakano et al., 2005). To determine whether folate depletion affects the methyl cycle, in 
cervical cancer cells both intracellular and extracellular homocysteine concentrations were 
examined in this study. From three-independent experiments in C4-II cells, it was concluded 
that the results of intracellular homocysteine concentration could not be relied on because of 
the very low concentrations observed. Homocysteine is rapidly exported from cells once they 
are no longer adherent, during cell harvesting (Antony et al., 2004). We generated a very 
large number of cells for the measurement of intracellular homocysteine but we could not 
generate an intracellular homocysteine in the range that could be reliably detected. On the 
other hand, the results from the studies of extracellular homocysteine were consistent, and 
compatible with a functional folate depletion. Results indicated a higher homocysteine export 
from folate-depleted cells than folate-replete cells and this was greatest for cells depleted 
only of folate. Methionine will act as a methyl donor in the methyl cycle and drive the 
synthesis of homocysteine, therefore enhancing effects of folate depletion. The methionine 
cycle was evidently disturbed by folate depletion, so that homocysteine could not be 
efficiently remethylated to methionine, resulting in accumulation of homocysteine. Results 
are compatible with previous findings from this laboratory, in which the presence of 
methionine enhanced homocysteine export from folate-deficient human umbilical vein 
endothelial cells (HUVECs) (Nakano et al., 2005).  
86 
 
In SiHa cells, also we found that homocysteine concentration (both intracellular and 
extracellular concentration) of methyl donor depleted cells was consistently higher than of 
the complete cells, reflecting the fact that impairment of the methionine cycle leads to 
intracellular homocysteine accumulation and enhanced export.  
Few studies of methyl-donor depleted cells in culture have examined effects on 
homocysteine remethylation or on the effects of methionine in particular.  Nakano and 
colleagues established a model using human umbilical vein endothelial cells (HUVECs) to 
determine the role of homocysteine in atherosclerosis. They showed that folate depletion of 
these cells led to enhanced homocysteine export, and that addition of folinic acid back into 
the medium mitigated this effect. Furthermore, they showed that the availability of 
methionine enhanced the effects of folate depletion on homocysteine export. Buemi et al 
(2001)  showed that adding folic acid to human vascular monocytes in culture decreased 
homocysteine concentration in the medium (Buemi et al., 2001). However, Brown et al 
(2006) investigated the effect of folate status on EA.hy926 endothelial cell line grown in two 
types of medium containing 23nM (LO) or 9µM folic acid (HI) with 10% FCS supplement for 
13 weeks. They found no difference in either intracellular homocysteine concentration, SAM, 
SAH, SAM/SAH ratio or global DNA methylation of cells grown in these media. They also 
reported that the secreted homocysteine showed no consistent difference (Brown et al., 
2006). This study suggested that mild folate deficiency did not disturb methylation potential 
of the cells. However, they did report difference in cell size, morphology, and folate 
metabolites. They reported that cells grown in the lower folate concentration were larger, 
more elongated, more permeable, and formed a disordered monolayer. Also the intracellular 
THF, 5-methyl THF, and formylated THF of the LO cells were significant lower than the HI 
cells. It should be noted that the high folate concentration used in this study was much 
higher than in human plasma, and also, 10 fold higher than our study. And even though the 
low folate concentration used in this study was classified as a mild deficiency, the final 
concentration, including 10% FCS supplement in the medium, may be pronounced as 
normal.  
 Our results show clearly that growing cervical cancer cells in folate-deplete medium, 
and, folate and methionine-deplete medium has an adverse effect on the methyl cycle.  
3.6 Summary 
Growth of C4-II cells in both folate depleted medium, and folate and methionine-
depleted medium led to growth retardation. A further reduction of growth rate was achieved 
by depleting the medium of methionine too. There was a profound decrease in the 
concentrations of intracellular folate and methionine, and as these effects occurred before 
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the decline in growth rate this supports a cause-effect relationship. Moreover, results from 
our study of extracellular homocysteine were consistent and compatible with a functional 
methyl-donor depletion. The increase in homocysteine export occurred after the decrease in 
intracellular folate and methionine, and occurred at the same time as the decline in growth 
rate in the depleted cells, again supporting a cause-effect relationship. Thus, a protocol was 
established to generate a model of methyl-donor deficiency using C4-II cells (figure 33). 
On the other hand, SiHa cells were relatively resistant to methyl-donor depletion and 
these cells required long-term growth in depleted medium in order to a lower intracellular 
folate concentration and increase homocysteine export. Therefore, the depletion model of 
SiHa will be conducted using a long-term depletion protocol (figure 34). 
 
 
 
 
Figure 33: Methyl donor depletion protocol for C4-II 
 
C4-II cells were cultured in particular medium up to 12 days and changed medium every 4 
days to maintain cell growth. At day 4, 8, and 12, cells were harvested for further analysis. 
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Figure 34: Methyl donor depletion protocol for SiHa 
SiHa cells were cultured in particular medium and subcultured once a week up to 6 weeks. 
At week 2, 4, and 6, cells were harvested for further analysis. 
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Chapter 4 Effects of methyl donor depletion on DNMTs expression 
and DNA Hypomethylation  
4.1 Introduction  
DNA methylation is known to be a crucial process in the regulation of parental 
imprinting (Li et al., 1993), X chromosome inactivation (Panning & Jaenisch, 1998), and the 
protection of genomic integrity by recruitment of retroviruses and transposons (Walsh et al., 
1998). In addition, the DNA methylation profile can affect gene expression (Lande-Diner et 
al., 2007; Miranda & Jones, 2007), and thereby influence cancer risk and cancer progression 
(Jones & Baylin, 2007). 
DNA methylation is catalysed by DNA methyltransferases (DNMT).  DNMTs catalyse 
the donation of a methyl group from S-adenosylmethionine (SAM) to the C5 of the cytosine 
nucleotide. Some publications suggest strongly that aberrant DNMT expression influences 
the DNA methylation profile (Mizuno et al., 2001; Biniszkiewicz et al., 2002; Yin et al., 2012), 
but there is a great deal of uncertainty in this area (Eads et al., 1999; Oue et al., 2001; Saito 
et al., 2001; Oh et al., 2007). 
Several studies report the over expression of one or more DNMTs in cancer tissue 
such as gastric cancer (Etoh et al., 2004), liver cancer (Choi et al., 2003), ovarian cancer 
(Ahluwalia et al., 2001), uterine cervix squamous cell carcinoma (Sawada et al., 2007) 
cervical cancer (Piyathilake et al., 2008) and breast cancer (Roll et al., 2008). On the other 
hand, down-regulation of DNMTs has been linked with cancer progression (Yaqinuddin et 
al., 2008; Gao et al., 2011; Su et al., 2013). The implications of altered DNMT expression or 
activity to carcinogenesis and progression are far from clear. 
Despite the evident relevance of DNA global methylation and DNMT expression to 
cancer risk and expression the role of methyl donor status to these processes is still poorly 
understood. We have carried out a study to specifically investigate the effects of folate and 
methionine depletion in cervical cancer cells on DNMT expression and DNA global 
methylation.  
4.2 Aims 
To examine how methyl-donor status influences DNA methylation profile and DNA 
methyltransferase (DNMT) gene expression in cervical cancer cells, and to determine 
whether any such effects are reversible. 
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4.3 Methods 
4.3.1 Cell sample preparation 
 A detailed description of cell culture is given for individual experiments. Generally, 
the C4-II cells were seeded at a density of 1.5 million cells / T75 flask and grown for 12 days, 
with a change of medium every 4 days. The cells were harvested at day 4, 8, and 12 for 
further analysis. The SiHa cells were seeded at a density of 0.8 million cells / T75 flask and 
grown for 6 weeks, with a passage every week. The cells were harvested at weeks 2, 4, and 
6 for further analyses. 
4.3.2 Development of the global DNA methylation assay 
4.3.2.1 DNA Methyl Acceptor Assay  
Cells were harvested on days 4, 12, and 20 of culture for C4-II cells, or at 70-80% 
confluence for SiHa cells after six passages in each treatment. Genomic DNA was extracted 
(see section 2.2.6) and DNA yield quantified by nanodrop spectrophotometric analysis.  0.5 
µg DNA samples were taken for the determination of global DNA methylation status using 
the [3H]-SAM donor assay (see section 2.2.7.1). For a positive control, 0.5 µg of 5-
azadeoxycytidine-treated Jurkat genomic DNA (5-azadeoxycytidine treatment demethylates 
DNA) was used instead of the cell DNA. For a negative control, 0.5 µg of CpG methylated 
Jurkat genomic DNA was used. The DPM result reflected the [3H]-methyl incorporation into 
DNA. To calculate sample DNA hypomethylation, blank DPM (the mixture lacking CpG 
methyltransferase) was subtracted from sample DPM and reported as DPM/1 µg of DNA. 
4.3.2.2 Immunocytochemistry of 5-methylcytosine (C4-II cells only) 
Cells were grown in T25 or T75 flasks, were trypsinised and then were seeded onto 
4-well slide chambers and incubated at 370C/ 5%CO2 for 24 hours, 8 days and 15 days. On 
the indicated day, 5-methylcytosine was measured using immunocytochemistry (see section 
2.2.7.2). Cells were visualized using a Nikon ECLIPSE e400 microscope and images were 
taken with an objective lens setting of X20. NIH 3T3 cells with and without primary antibody 
were used as a positive and negative control, respectively. Cells positive for 5-
methylcytosine had DAB brown stained nuclei, negative cells were haematoxylin blue 
counterstained. 
4.3.2.3 Flow cytometric analysis of DNA hypomethylation 
The immunocytochemistry method modified from Habib et al (1999) and Mcmanus et al 
(2006) together with flow cytometry detection was used as the basis for the development 
and optimisation of this approach for 5-methylcytosine assessment in our system.  
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Initially, a protocol similar to the one used for immunohistochemistry was followed for 
staining of cells for flow cytometry, the difference being the cells were in suspension in tubes 
rather than being fixed to slides. In addition, the secondary antibody used was conjugated to 
a fluorochrome. However, initial experiments failed to show any positive staining for 5- 
methylcytosine and also many cells were lost during the microwaving stage of the 
procedure. 
As the lack of positive staining may have been due to insufficient permeabilization of the 
cells, an incubation step with Triton X-100 was added to the staining procedure, and the 
fixation method was expanded to include an incubation with methanol at -200C; however 
results still proved unsatisfactory. 
Further modification of the protocol included antigen retrieval, where cells were 
incubated with 2N HCl at 370C followed by neutralisation with sodium borate pH8.5 Tween-
20 and BSA were added into the washing solution to prevent cell clumping. The 
concentrations of primary and secondary antibody and also number of cells required were 
optimized. Problems of non-specific background staining were solved by including donkey 
serum in the blocking buffer. The combined modifications gave a consistent and 
reproducible result. 
Cells were harvested on days 4, 8, and 12 of culture for C4-II cell, or at 70-80% 
confluence for SiHa cells after 2, 4, and 6 passages in each treatment, and 5-methylcytosine 
was quantified using flow cytometric detection method (see section 2.2.7.3). Cells were 
analysed by BD FACSCalibur™. Appropriate controls were utilized and included unstained 
cells, secondary antibody alone and 5-azadeoxycytidine treated cells for a negative control. 
Non-specific antibody binding was monitored with a mouse IgG1 isotype. Data analysis was 
run by BD CELLQuest software. 
4.3.3 RNA extraction and cDNA synthesis (C4-II cells only) 
Total RNA was extracted by RNeasy® Mini kit (see section 2.2.8) and quantified by 
nanodrop spectrophotometry. Each first-strand cDNA synthesis was carried out using the 
SuperScript™ III Reverse Transcriptase (see section 2.2.9). The cDNA was diluted to a 
concentration of 25-50 ng/µl and kept in aliquots. 
4.3.4 Determination of DNMTs expression (C4-II cells only) 
DNMT gene expression was determined using semi-quantitative RT-PCR (see 
section 2.2.10). Negative controls (in which water instead of cDNA was added) were also run 
in each plate. Contamination of genomic DNA in the RNA samples was excluded by an 
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analysis with the cDNA synthesis products in the system without reverse transcriptase. 
Reactions for determining the expression of the gene of interest and the reference gene (β-
actin) were carried out as separate PCR reactions. Normalization of RNA amounts was 
performed using β-actin expression analysed with the same procedure. Finally, expression 
ratios between the DNMTs from F+M+ (control), F-M+, and F-M- were calculated. The gene 
expression was analyzed and expressed as a relative gene expression by using the 2-∆∆CT 
Method (Livak & Schmittgen, 2001). 
4.3.5 Determination of DNMT activity (C4-II cells only) 
Nuclear extracts were prepared by using NE-PER® Extraction Reagents (see section 
2.2.12). Protein concentrations of the nuclear extracts were determined by using the Bio-Rad 
protein assay (see section 2.2.13). The global DNA methyltransferase activity was measured 
by EpiQuik™ DNA Methyltransferase Activity/Inhibition Assay Kit (see section 2.2.14). The 
global DNMT activity (OD/h/mg protein) was calculated referring to the formula: (sample OD 
– blank OD)/(sample protein amount :µg × 1000), according to manufacturer's instructions. 
The results are given in activity units in treatments (F-M+ and F-M-) relative to the activity 
level in control (F+M+) on day 8. 
4.3.6 Repletion study (C4-II cells only) 
Cells were seeded at a density of 1.5 million cells / T75 flask and grown for 12 days, 
with a change of medium every 4 days. For methyl-donor repletion experiments, cells were 
grown for 8 days in folate-depleted medium (F-M+), and, combined folate and methionine-
depleted medium (F-M-). Both depleted medium containing less than 30 nmol/L of folate. At 
day 8, the complete medium (F+M+) were transferred to the cultured cells for a further 4 
days. Cells were processed for growth rate determination by cell counting (see section 2.2.2) 
and DNMT gene expression (see section 2.2.10) at days 4, 8, and 12. 
4.3.7 Statistical analysis 
 See section 2.2.16 
 
4.4 Results 
4.4.1 Development of the global DNA methylation assay 
4.4.1.1 DNA methyl acceptor assay 
The DPM value represents the extent of incorporation of [3H]-methyl groups into 
DNA, therefore, the higher the DPM value, the lower the global DNA methylation. Figure 35 
shows the average DPM value for three independent experiments over 25 days. Two-way 
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ANOVA was run to determine the effect of culture time and/or treatment on hypomethylation 
level.  Hypomethylation level increased significantly with time (P=0.006), but there was no 
significant effect of folate-depletion (P=0.982).   
Post-hoc test (one-way ANOVA), revealed that global DNA hypomethylation for C4-II 
cells grown in folate depleted medium was significantly higher at day 24 than at days 4, 12, 
and 20 (P=0.003). In complete medium, the hypomethylation level was significantly greater 
at day 24 than day 4 (P< 0.05).  
Figure 36 shows the average DPM value, from one experiment at day 8 (80% 
confluence) after 6th subculture in each treatment, for SiHa cells. At this time point, the 
incorporation of [3H]-methyl group into the DNA of SiHa cells was not significantly different 
between cells grown in F+M+, F-M+, and F-M- media. However, when the DPM value of the 
unmethylated DNA control and the DNA of all three treatments were compared, SiHa 
cervical cells grown in complete medium were found to have a high level of DNA 
hypomethylation.  
4.4.1.2 Immunocytochemistry of 5-methylcytosine (C4-II only) 
An immunocytochemical method was used to determine the 5-methylcytosine load of 
cells grown under different conditions. Anti 5-methylcytosine was used to detect 5-
methylcytosine and results examined microscopically. Cells grown in folate and methionine-
replete and folate and methionine-depleted media were compared at three time points. Cells 
grown for 24 hours, 8 days, and 15 days were chosen to represent sub-confluence, 
confluence, and post-confluence, respectively. Cells staining positively for methyl cytosine 
stained brown, cells staining negatively for methylcytosine stained blue. Figure 37(A) shows 
positive staining and negative staining. At 24 hours (figure 37(B)) there was no difference in 
the ratio of brown: blue staining between treatments. The second time point was 8-days, by 
which time cells under both treatments had increased in cell density, but the ratio of brown: 
blue staining was similar in the two treatments. By day 15 cells cultured in folate and 
methionine-replete condition (figure 37(C), left) had reached post-confluence, were 
multilayered and appeared to show more blue-stained cells than brown-stained cells. On the 
other hand, cells cultured in folate and methionine-depleted medium, which were still 
growing in a monolayer and had a lower cell density (figure 37(D), right), seemed to have 
more brown-stained cells than blue-stained cells. 
It was difficult to obtain an accurate value for cell staining for cells growing at high density 
and for this reason this particular approach was considered unsuitable for our needs and no 
further experiments were performed using this technique. 
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Figure 35: Global DNA methylation of C4-II cells grown in complete and folate and 
methionine-depleted medium, using the methyl acceptor assay 
Each value shows mean of three-independent experiments and error bars show SEM.  
* Hypomethylation increased significantly with time, P=0.003 (one-way ANOVA) 
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Figure 36: Global DNA methylation of SiHa cell DNA determined using the DNA 
methyl acceptor assay 
The global DNA methylation was compared between the cells grown in complete, folate-
depleted, and folate and methionine depleted medium using CpG methylated Jurkat 
genomic DNA as a negative control and using 5-azadeoxycytidine-treated Jurkat genomic 
DNA as a positive control. The more incorporation of [3H]-methyl group, the more 
hypomethylation of the DNA. 
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Figure 37: Detection of 5-methylcytosine of C4-II DNA by immunocytochemistry 
NIH 3T3 fibroblast cells as control (A). C4-II cells grown in folate and methionine-depleted 
medium were compared with cells grown in complete medium at three different time points 
of culture: (B) 24 hrs 
 
 
 
NIH 3T3 cells: positive control NIH 3T3 cells: negative control 
C4-II 24hrs: complete cells C4-II 24hrs: folate and 
methionine-depleted cells 
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Figure 37: Detection of 5-methylcytosine of C4-II DNA by immunocytochemistry 
(continued) 
C4-II cells grown in folate and methionine-depleted medium were compared with cells grown 
in complete medium at three different time points of culture: (C) 8 days, and (D) 15 days.  
 
 
C4-II 8days: complete cells C4-II 8days: folate and 
methionine-depleted cells 
C4-II 15days: complete cells C4-II 15days: folate and 
methionine-depleted cells 
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4.4.1.3 Flow cytometric analysis of DNA methylation 
 Cells were stained for flow cytometry using a mouse monoclonal anti-5-
methylcytosine antibody and a fluorescent donkey anti-mouse secondary antibody. Cell-
staining controls included unstained, IgG1 isotype and secondary antibody only and also on 
one occasion, the primary antibodies alone were assessed. Graphs show cell count (Y-axis) 
versus fluorescence intensity, on a logarithmic scale (X-axis) (figure 38). 
 Figure 38 shows a negative result for controls (A-E) and a positive result in (F-H) 
from anti-5-methylcytosine antibody staining of C4-II cells. The right-shift in F indicates a 
greater concentration of 5-methylcytosine. Staining in graph B indicated a degree of 
positivity when compared with the unstained cells which suggested possible non-specific 
binding, which needed further consideration.  
In order to compare the intensity of staining between growth conditions we looked at 
mean fluorescence. The higher the mean value the higher the average fluorescence and 
therefore cellular 5-methylcytosine content. The 5-azadeoxycytidine-treated cells were used 
as negative control and gave a lower mean fluorescence value, suggesting a demethylation 
effect and confirming the specificity of our primary antibody (figure 38(F) and (G)). 
To assess the effect of folate depletion on 5-methylcytosine, C4-II cells were cultured 
in three conditions.  At 3 time points (days 4, 8, and 12) cells were stained with anti-5-
methylcytosine for flow cytometric analysis and this was done on three separate occasions.  
Figure 39 shows the raw data from one experiment. A left shift in the mean channel of 
fluorescence in F-M- at day 8 and an even greater left shift at day 12 when compared with 
F+M+ and F-M+, indicating relative DNA hypomethylation. This was evident as a 
progressive decrease in the mean fluorescence of the cells depleted of both folate and 
methionine. 
Figure 40 shows raw data for the flow cytometry for SiHa cells.  Results are shown 
for unstained cells, three treatments (F+M+, F-M+, and F-M-), and from a negative control. 
On the basis of reproducibility of findings for both the C4-II cells and SiHa cells, the flow 
cytometry method was used to determine global DNA methylation status in our study. 
 However, frequency plots in figures 40 and for figure 41D, show a split peak, 
suggestive of two populations of cells. It was not possible to re-analyse the data. The 
software for the flow cytometry estimates the mean fluorescence for each treatment. The 
effects on mean fluorescence of what appears to be two populations of cells for some of the 
conditions is not known, but there may be implications for the calculated effects of methyl 
donor depletion. Further work would have to be carried out to explore this possibility further. 
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Figure 38: Pattern of 5-methylcytosine detection of C4-II cells by flow cytometry 
Unstained (A), IgG1 isotype+2o antibody (B), anti 5-methylcytosine (1o) antibody alone (C), 
2o antibody alone (D), IgG1 isotype alone (E), 20µM 5-aza-2-deoxycytidine-treated cells (F), 
10µM 5-aza-2-deoxycytidine-treated cells (G), and non 5-aza-2-deoxycytidine-treated cell 
(H), respectively. 
The graphs show cell count (Y-axis) versus fluorescence intensity, on a logarithmic scale (X-
axis). Graph in A to E shows an example of negative result for controls and F to H shows an 
example of positive result from anti-5-methylcytosine antibody staining. The right-shift in H 
indicates a greater concentration of 5-methylcytosine 
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M1     1,    21 9996 99.96 99.96 1.96 1.78 54.29 1.67 1
M2    21,  9910 4 0.04 0.04 40.11 38.98 26.60 40.68 27
File: Data.009 Log Data Units: Linear Values
Sample ID: C4 II - Auto Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 7.96 6.79 65.26 6.61 1
M1     1,    21 9683 96.83 96.83 7.31 6.49 49.30 6.49 1
M2    21,  9910 320 3.20 3.20 27.75 27.04 24.97 25.48 25
File: Data.010 Log Data Units: Linear Values
Sample ID: C4 II - Isotype Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 50.48 42.32 66.95 40.32 35
M1     1,    21 517 5.17 5.17 12.01 8.34 56.74 13.82 1
M2    21,  9910 9498 94.98 94.98 52.52 46.18 63.62 41.42 35
File: Data.011 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.93 1.74 75.61 1.63 1
M1     1,    21 9991 99.91 99.91 1.90 1.73 52.86 1.63 1
M2    21,  9910 9 0.09 0.09 35.45 33.58 32.65 38.54 20
File: Data.012 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc prim only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 2.65 2.38 56.81 2.21 2
M1     1,    21 9998 99.98 99.98 2.65 2.38 54.99 2.21 2
M2    21,  9910 2 0.02 0.02 30.23 30.23 1.27 30.23 29
File: Data.013 Log Data Units: Linear Values
Sample ID: C4 II - secondary only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.94 1.75 61.44 1.63 1
M1     1,    21 9997 99.97 99.97 1.94 1.75 55.64 1.63 1
M2    21,  9910 3 0.03 0.03 31.21 30.60 23.37 33.38 23
File: Data.014 Log Data Units: Linear Values
Sample ID: C4 II - isotype only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
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Data.014
100 101 102 103 104
FL1-H
M1 M2
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.97 1.78 66.96 1.67 1
M1     1,    21 9996 99.96 99.96 1.96 1.78 54.29 1.67 1
M2    21,  9910 4 0.04 0.04 40.11 38.98 26.60 40.68 27
File: Data.009 Log Data Units: Linear Values
Sample ID: C4 II - Auto Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 7.96 6.79 65.26 6.61 1
M1     1,    21 9683 96.83 96.83 7.31 6.49 49.30 6.49 1
M2    21,  9910 320 3.20 3.20 27.75 27.04 24.97 25.48 25
File: Data.010 Log Data Units: Linear Values
Sample ID: C4 II - Isotype Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 50.48 42.32 66.95 40.32 35
M1     1,    21 517 5.17 5.17 12.01 8.34 56.74 13.82 1
M2    21,  9910 9498 94.98 94.98 52.52 46.18 63.62 41.42 35
File: Data.011 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.93 1.74 75.61 1.63 1
M1     1,    21 9991 99.91 99.91 1.90 1.73 52.86 1.63 1
M2    21,  9910 9 0.09 0.09 35.45 33.58 32.65 38.54 20
File: Data.012 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc prim only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 2.65 2.38 56.81 2.21 2
M1     1,    21 9998 99.98 99.98 2.65 2.38 54.99 2.21 2
M2    21,  9910 2 0.02 0.02 30.23 30.23 1.27 30.23 29
File: Data.013 Log Data Units: Linear Values
Sample ID: C4 II - secondary only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.94 1.75 61.44 1.63 1
M1     1,    21 9997 99.97 99.97 1.94 1.75 55.64 1.63 1
M2    21,  9910 3 0.03 0.03 31.21 30.60 23.37 33.38 23
File: Data.014 Log Data Units: Linear Values
Sample ID: C4 II - isotype only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Data.011
100 101 102 103 104
FL1-H
M1 M2
Data.009
0 200 400 600 800 1000
FSC-H
Data.009
100 101 102 103 104
FL1-H
M1 M2
Data.010
100 101 102 103 104
FL1-H
M1 M2
Data.012
100 101 102 103 104
FL1-H
M1 M2
Data.013
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Data.014
100 101 102 103 104
FL1-H
M1 M2
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.97 1.78 66.96 1.67 1
M1     1,    21 9996 99.96 99.96 1.96 1.78 54.29 1.67 1
M2    21,  9910 4 0.04 0.04 40.11 38.98 26.60 40.68 27
File: Data.009 Log Data Units: Linear Values
Sample ID: C4 II - Auto Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 7.96 6.79 65.26 6.61 1
M1     1,    21 9683 96.83 96.83 7.31 6.49 49.30 6.49 1
M2    21,  9910 320 3.20 3.20 27.75 27.04 24.97 25.48 25
File: Data.010 Log Data Units: Linear Values
Sample ID: C4 II - Isotype Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 50.48 42.32 66.95 40.32 35
M1     1,    21 517 5.17 5.17 12.01 8.34 56.74 13.82 1
M2    21,  9910 9498 94.98 94.98 52.52 46.18 63.62 41.42 35
File: D ta.011 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.93 1.74 75.61 1.63 1
M1     1,    21 9991 99.91 99.91 1.90 1.73 52.86 1.63 1
M2    21,  9910 9 0.09 0.09 35.45 33.58 32.65 38.54 20
File: Data.012 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc prim only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 2.65 2.38 56.81 2.21 2
M1     1,    21 9998 99.98 99.98 2.65 2.38 54.99 2.21 2
M2    21,  9910 2 0.02 0.02 30.23 30.23 1.27 30.23 29
File: Data.013 Log Data Units: Linear Values
Sample ID: C4 II - secondary only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.94 1.75 61.44 1.63 1
M1     1,    21 9997 99.97 99.97 1.94 1.75 55.64 1.63 1
M2    21,  9910 3 0.03 0.03 31.21 30.60 23.37 33.38 23
File: Data.014 Log Data Units: Linear Values
Sample ID: C4 II - isotype only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
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Data.014
100 101 102 103 104
FL1-H
M1 M2
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.97 1.78 66.96 1.67 1
M1     1,    21 9996 99.96 99.96 1.96 1.78 54.29 1.67 1
M2    21,  9910 4 0.04 0.04 40.11 38.98 26.60 40.68 27
File: Data.009 Log Data Units: Linear Values
Sample ID: C4 II - Auto Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 7.96 6.79 65.26 6.61 1
M1     1,    21 9683 96.83 96.83 7.31 6.49 49.30 6.49 1
M2    21,  9910 320 3.20 3.20 27.75 27.04 24.97 25.48 25
File: Data.010 Log Data Units: Linear Values
Sample ID: C4 II - Isotype Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 50.48 42.32 66.95 40.32 35
M1     1,    21 517 5.17 5.17 12.01 8.34 56.74 13.82 1
M2    21,  9910 9498 94.98 94.98 52.52 46.18 63.62 41.42 35
File: Data.011 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.93 1.74 75.61 1.63 1
M1     1,    21 9991 99.91 99.91 1.90 1.73 52.86 1.63 1
M2    21,  9910 9 0.09 0.09 35.45 33.58 32.65 38.54 20
File: Data.012 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc prim only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 2.65 2.38 56.81 2.21 2
M1     1,    21 9998 99.98 99.98 2.65 2.38 54.99 2.21 2
M2    21,  9910 2 0.02 0.02 30.23 30.23 1.27 30.23 29
File: Data.013 Log Data Units: Linear Values
Sample ID: C4 II - secondary only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10 00 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.94 1.75 61.44 1.63 1
M1     1,    21 9997 99.97 99.97 1.94 1.75 55.64 1.63 1
M2    21,  9910 3 0.03 0.03 31.21 30.60 23.37 33.38 23
File: Data.014 Log Data Units: Linear Values
Sample ID: C4 II - isotype only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
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Data.014
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Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.97 1.78 66.96 1.67 1
M1     1,    21 9996 99.96 99.96 1.96 1.78 54.29 1.67 1
M2    21,  9910 4 0.04 0.04 40.11 38.98 26.60 40.68 27
File: Data.009 Log Data Units: Linear Values
Sample ID: C4 II - Auto Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 7.96 6.79 65.26 6.61 1
M1     1,    21 9683 96.83 96.83 7.31 6.49 49.30 6.49 1
M2    21,  9910 320 3.20 3.20 27.75 27.04 24.97 25.48 25
File: Data.010 Log Data Units: Linear Values
Sample ID: C4 II - Isotype Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10 00 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 50.48 42.32 66.95 40.32 35
M1     1,    21 517 5.17 5.17 12.01 8.34 56.74 13.82 1
M2    21,  9910 9498 94.98 94.98 52.52 46.18 63.62 41.42 35
File: Data.011 Log Data Units: Line r Values
Sample ID: C4 II -anti 5-mc Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.93 1.74 75.61 1.63 1
M1     1,    21 9991 99.91 99.91 .90 1.73 52.86 1.63 1
M2    21,  9910 9 0.09 0.09 35.45 33.58 32.65 38.54 20
File: Data.012 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc prim only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 00.00 2.65 2.38 56.81 2.21 2
M1     1,    21 9998 99.98 99.98 2.65 2.38 54.99 2.21 2
M2    21,  9910 2 0.02 0.02 30.23 30.23 1.27 30.23 29
File: Data.013 Log Data Units: Linear Values
Sample ID: C4 II - secondary only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.94 1.75 61.44 1.63 1
M1     1,    21 9997 99.97 99.97 1.94 1.75 55.64 1.63 1
M2    21,  9910 3 0.03 0.03 31.21 30.60 23.37 33.38 23
File: D ta.014 Log Data Units: Linear Values
Sample ID: C4 II - isotype only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 1 0 X Parameter: FL1-H (Log)
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Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.97 1.78 66.96 1.67 1
M1     1,    21 9996 99.96 99.96 1.96 1.78 54.29 1.67 1
M2    21,  9910 4 0.04 0.04 40.11 38.98 26.60 40.68 27
File: Data.009 Log Data Units: Linear Values
Sample ID: C4 II - Auto Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 7.96 6.79 65.26 6.61 1
M1     1,    21 9683 96.83 96.83 7.31 6.49 49.30 6.49 1
M2    21,  9910 320 3.20 3.20 27.75 27.04 24.97 25.48 25
File: Data.010 Log Dat  Units: Line r Values
Sample ID: C4 II - Isotype Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 50.48 42.32 66.95 40.32 35
M1     1,    21 517 5.17 5.17 12.01 8.34 56.74 13.82 1
M2    21,  9910 9498 94.98 94.98 52.52 46.18 63.62 41.42 35
File: Data.011 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.93 1.74 75.61 1.63 1
M1     1,    21 9991 99.91 99.91 1.90 1.73 52.86 1.63 1
M2    21,  9910 9 0.09 0.09 35.45 33.58 32.65 38.54 20
File: Data.012 Log Data Units: Linear Values
Sample ID: C4 II -anti 5-mc prim only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 0000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % To al Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 2.65 2.38 56.81 2.21 2
M1     1,    21 9998 99.98 99.98 2.65 .38 54.99 2.21 2
M2    21,  9910 2 0.02 0.02 30.23 30.23 1.27 30.23 29
Fil : Data.013 Log Data Units: Linear Values
Sample ID: C4 II - secondary only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median Peak Ch
All     1,  9910 10000 100.00 100.00 1.94 1.75 61.44 1.63 1
M1     1,    21 9997 99.97 99.97 1.94 1.75 55.64 1.63 1
M2    21,  9910 3 0.03 0.03 31.21 30.60 23.37 33.38 23
File: Data.014 Log Data Units: Linear Values
Sample ID: C4 II - isotype only Acquisition Date: 07-Oct-10
Gate: No Gate Gated Events: 10000
Total Events: 10000 X Parameter: FL1-H (Log)
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Histogram Statistics
Marker Left, Right Events % Gated % Total Mean
All     1,  9910 10000 100.00 100.00 1.03
M1     1,    16 9999 99.99 99.99 1.03
M2    16,  9910 1 0.01 0.01 35.87
File: Data.007 Log Data Units: Linear Values
Sample ID: 20uM Patient ID: 1 in 250P, 1 in 50 S
Acquisi ion Date: 02-Dec-10 Gate: No Gate
Gated Events: 10000 Total Events: 1000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean
All     1,  9910 10000 100.00 100.00 4.22
M1     1,    16 9950 99.50 99.50 4.11
M2    16,  9910 51 0.51 0.51 25.58
File: Data.008 Log Data Units: Linear Values
Sample ID: 20uM  IgG Neg Patient ID: 
Acquisition Date: 02-Dec-10 Gate: No Gate
Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean
All     1,  9910 10000 100.00 100.00 60.14
M1     1,    16 198 1.98 1.98 5.04
M2    16,  9910 9803 98.03 98.03 61.24
File: Data.009 Log Data Units: Linear Values
Sample ID: 20uM  Patient ID: 1 in 250 p, 1 in 50 S
Acquisition Date: 02-Dec-10 Gate: No Gate
Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
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Histogram Statistics
Marker Left, Right Events % Gated % Total Mea
All     1,  9910 10000 100.00 100.00 1.01
M1    1,    16 9999 99.99 99.99 1.01
M2    16,  9910 1 0.01 0.01 38.54
File: Data.004 Log Data Units: Linear Values
Sample ID: 10uM Auto Patient ID: 
Acquisition Date: 02-Dec-10 Gate: No Gate
Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram St tistics
Marker Left, Right Events % Gated % Total Mean
All     1,  9910 10000 100.00 100.00 3.14
M1     1,    16 997 99.73 99.73 3.08
M2    16,  9910 28 0.28 0.28 25.39
File: Data.005 Log Data Units: Linear Values
Sample ID: 10uM IgG Neg Patient ID: 
Acquisition Date: 02-Dec-10 Gate: No Gate
Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean
All     1,  9910 10000 100.00 100.00 41.88
M1     1,    16 293 2.93 2.93 9.98
M2    16,  9910 9713 97.13 97.13 42.82
File: D ta.006 Log Data Units: Linear Values
Sample ID: 10uM Patient ID: 1 in 250P, 1 in 50 S
Acquisition Date: 02-Dec-10 Gate: No Gate
Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
10uM Auto
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***
***
10uM 
1 in 250P, 1 in 50 S
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Figure 39: Detection of 5-methylcytosine of C4-II DNA by flow cytometry 
The graphs show 5-methylcytosine stained cells from three time points  (day 4,8, and 12) 
and three different conditions (from left F+M+, F-M+, and F-M-, respectively) 
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File: Data.013 Log Data Units: Linear Values
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Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
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File: Data.019 Log Data Units: Linear Values
Sample ID: Au o  F-M+ Patient ID: Day 12
Acquisition Date: 14-Dec-10 Gate: No Gate
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X Parameter: FL1-H (Log)
Histogram Statistics
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File: Data.021 Log Data Units: Linear Values
Sample ID: 1 in 250 P,1 in 50 S,  F-M+ Patient ID: Day 12
Acquisition Date: 14-Dec-10 Gate: No Gate
Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Peak Ch
All     1,  9910 10000 100.00 100.00 1.61 1
M1     1,    12 9984 99.84 99.84 1.22 1
M2    12,  9910 16 0.16 0.16 248.41 16
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Histogram Statistics
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M2    12,  9910 1520 15.20 15.20 27.38 12
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Histogram Statistics
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X Parameter: FL1-H (Log)
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M1     1,    12 146 1.46 1.46 2.37 1
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Figure 40: Detection of 5-methylcytosine of SiHa DNA by flow cytometry 
 Unstained (A), IgG1 isotype+2o antibody (B), 2o antibody alone (C), 5-aza-2-deoxycytidine-
treated cell (D), anti 5-methylcytosine+2o antibody of F+M+ cells (E), anti 5-
methylcytosine+2o antibody of F-M+ cells (F), and anti 5-methylcytosine+2o antibody of F-M- 
cells (G), respectively. 
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Histogram Statistics
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File: Data.001 Log Data Units: Linear Values
Sample ID: Auto SiHa F+M+ Patient ID: P17
Acquisition Date: 16-Feb-11 Gate: No Gate
Gated Events: 10000 Total Events: 10000
X Parameter: FL1-H (Log)
Histogram Statistics
Marker Left, Right Events % Gated % Total Mean Geo Mean CV Median
All     1,  9910 10000 100.00 100.00 55.95 48.96 75.52 46.14
M2    12,  9910 9977 99.77 99.77 56.07 49.26 75.33 46.14
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4.4.2 Determination of Global DNA methylation 
In C4-II cells, there was evidence of a decrease in 5-methylcytosine in folate and 
methionine depleted cells in comparison with cells grown in complete medium, as seen in 
the data shown in table 4. 
Results were expressed as a percentage reduction of global DNA methylation in 
treated cells compared with controls. There was a significant effect of time on global DNA 
methylation status from day 4 to day 8 (P=0.016). There was a progressive reduction in 
global DNA methylation in folate and methionine depleted cells compared with control cells. 
At day 4 there was a 2.03% reduction, at day 8 there was a 13.6% reduction, and by day 12 
this had reached a 17.5% reduction, but the effect of time was not statistically significant 
(P=0.08). The mean percentage reduction in DNA methylation level was higher at all time 
points for cells grown in folate and methionine depleted medium compared with cells grown 
in complete medium and this reached statistical significance on day 8 (P=0.024). Effects of 
folate depletion alone on 5-methyl cytosine were more modest, resulting in a mean fall of 4-
9% over 12 days of depletion, not significantly different from control cells. 
 
Table 4: The percentage reduction in global DNA methylation in C4-II cells depleted of 
methyl donors, compared with control cells 
Day of culture 
Percentage reduction in global DNA methylation 
F-M+ medium 
(mean ± SEM) 
F-M- medium 
(mean ± SEM) 
4 4.39±4.93 2.03±11.85 
8 8.99±4.35 13.61±1.46* 
12 6.94±9.66 17.46±2.78 
Values are mean values from three-independent experiments 
*significantly different from control, P<0.05 (one-way ANOVA, post hoc test) 
 
In SiHa cells, the mean percentage reduction in global DNA methylation was greater 
in cells depleted of both folate and methionine than control cells at weeks 4 and 6 but the 
effect just failed to reach statistical significance (P=0.052) (table 5). 
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Table 5: The percentage reduction of global DNA methylation in SiHa cells depleted of 
methyl-donors, compared with control 
Week of culture 
Percentage reduction in global DNA methylation 
F-M+ medium 
(mean ± SEM) 
F-M- medium   
(mean ± SEM) 
2 2.51±1.04 2.39±0.65 
4 1.17±1.63 10.17±3.75 
6 1.28±8.23 8.40±4.12 
Values are mean values from three-independent experiments 
 
4.4.3 DNMT expression (C4-II cells only) 
As an effect of methyl donor depletion on global DNA methylation was only observed 
to be significant in C4-II cells, the relative quantification (RQ) real-time PCR of DNMT 
expression was examined in C4-II cells only  
There was a downregulation in expression of DNMT3a and 3b, in response to 
methyldonor depletion, in contrast with DNMT1 which was not significantly influenced by 
methyl donor depletion (Figure 41). Although the mean expression of DNMT1 was lower in 
folate and methionine-depleted cells than control cells or folate-depleted cells at day 8, the 
difference was not statistically significant (figure 41A). DNMT3a expression was significantly 
influenced by treatment (P=0.001) (figure 41B). At day 4 the expression was significantly 
lower in folate depleted (P=0.02) and folate and methionine depleted cells (P=0.001) than in 
the control.  At day 8, the difference was only significant between the folate and methionine 
depleted cells and the controls (P=0.024). There was 2.62-fold lower expression of DNMT3a 
on this day compared with control cells. The folate depleted and folate and methionine 
depleted cells were not different from one another on either day. DNMT3a gene expression 
decreased from day 4 to day 8, in cells depleted of both folate and methionine (P=0.03).  
DNMT3b expression was also significantly influenced by time (P=0.004) and by 
treatment (P<0.001), and a significant interaction was observed between these factors 
(P=0.038) (figure 41C).  On day 4, there was a significantly lower expression of DNMT3b in 
folate deplete (P=0.032) and folate and methionine depleted cells (P=0.006) than control, 
and this difference was also evident on day 8 (P<0.05). On this day, DNMT3b expression 
was 3.60-fold lower in folate and methionine depleted cells compared with control. Folate 
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depleted cells were not different from folate and methionine depleted cells on either day. 
There was a significant fall in DNMT3b gene expression in folate and methionine depleted 
cells from day 4 to day 8 (P=0.008).  
4.4.4 Total DNMT activity  
As global DNA methylation was lower in folate and methionine depleted cells than 
cells grown in complete medium and expression of both DNMT3a and 3b was 
downregulated in response to methyl donor depletion, it was anticipated that methyl donor 
depletion would lead to a fall in the activity of DNMTs. Thus total nuclear DNMT activity was 
measured in cells grown under different methyl donor conditions.  
Unexpectedly, cells depleted of folate and methionine showed a 2.5 fold increase in 
total DNMT activity at day 8 compared with cells grown in complete medium and this 
difference was highly significant (P=0.001). Folate depletion alone did not influence total 
DNMT activity (Figure 42). 
 
4.4.5  Folate and methionine repletion (only C4-II cells) 
4.4.5.1 Effect on cell growth   
After growth of cells in folate and methionine-deplete medium for 8 days, cells were 
grown in complete medium for a further 4 days. On day 12 cell number was still significantly 
greater in control cells than cells grown initially in either deficient media (P<0.02), and there 
were more cells for the folate-replete treatment than for the folate and methionine-replete 
treatment (P=0.022) (Figure 43). Cells transferred from a folate and methionine-deplete 
medium to a complete medium at day 8 showed a significant increase in cell number by day 
12 (P<0.001). The growth rate of folate depleted cells after repletion also increased 
significantly between day 8 and 12 (P<0.001). 
4.4.5.2 Effect on DNMT gene expression 
In this depletion/repletion experiment, combined depletion of folate and methionine 
led to a significant loss of expression of DNMT1, 3a and 3b, which was recovered following 
transfer of depleted cells to a complete medium for 4 days (Figure 44).  
 
Folate and methionine-depletion led to a downregulation in expression of DNMT1, 
such that by day 8 DNMT1 expression was lower in depleted cells than controls (P=0.045) 
(figure 44A). Following transfer to complete medium, there was an increase in expression of 
DNMT1 from day 8 to day 12 (P<0.05) and there was no longer any significant difference in 
DNMT1 expression between treatments.  
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 Figure 41: DNMT expression of C4-II cells grown in folat depleted medium, folate 
and methionine-depleted medium and complete medium 
DNMT1, 3a, and 3b expression (A-C) respectively. 
 
 Each value shows the mean of four-independent experiments and error bars show SEM. 
 * Significantly different from control, P<0.05 (one-way ANOVA, post hoc test) 
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Figure 42: Total DNMT activity of methyl-donor depleted cells in comparison with 
control 
Each value shows mean of four-independent experiments and error bars show SEM. 
* Significantly different from control and F-M+, P< 0.05 (one-way ANOVA, post hoc test) 
 
 
Figure 43: Growth of cells depleted of methyl donors for 8 days and then grown in 
complete medium for a further 4 days 
The dotted lines refer to the growth rate of the 12-day depletion model and the solid 
lines refer to the growth rate of the repletion model. 
Each value shows mean of five -independent experiments and error bars show SEM.  
** Significantly different from value after 8 days of depletion, P<0.05 (one-way ANOVA, post 
hoc test) 
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There was a significant fall in DNMT3a gene expression from days 4 to 8 in folate and 
methionine-depleted cells (P=0.002) such that after 8 days of depletion DNMT3a expression 
was significantly lower in folate deplete (P=0.016) and folate and methionine depleted cells 
(P<0.001) than in the control cells. It was also lower in folate and methionine-depleted cells 
than in folate deplete cells (P = 0.014) (figure 44B). Repletion led to a significant increase in 
DNMT3a gene expression (P<0.001) so that by day 12 there was no significant difference in 
DNMT3a expression between treatments.  
DNMT3b expression behaved in a similar fashion. DNMT3b expression fell in 
response to 8 days of growth in folate and methionine depleted medium (P=0.008); following 
4 days of repletion DNMT3b gene expression increased (P=0.038) (figure 44C). After 8 
days of depletion, expression of DNMT3b was lower in folate and methionine depleted cells 
than control cells and cells depleted of folate alone (P<0.01). This difference was reversed 
by 4 days of repletion.  
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Figure 44: Effects of methyl donor repletion on DNMTs expression in C4-II cells 
Cells were grown in folate or folate and methionine-depleted medium for 8 days, 
after which they were transferred to complete medium and grown for a further 4 
days.(A) DNMT1 (B) DNMT3a (C) DNMT3b 
 
Each value shows mean of five to seven-independent experiments and error bars show 
SEM.  
*Significantly different from control, P<0.05 (one-way ANOVA, post hoc test) 
§ Significantly different from F-M+, P<0.05 (one-way ANOVA, post hoc test) 
** Significantly different by time, P<0.05 (one-way ANOVA, post hoc test) 
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4.5 Discussion 
4.5.1 Effect of methyl donor depletion on global DNA methylation 
4.5.1.1 DNA methyl acceptor assay 
In our study, this particular method for determining DNA methylation showed poor 
precision, despite intensive efforts to improve reproducibility. The coefficient of variation of 
this method was quite high (11.62%). Dahl & Guldberg (2003) suggested in their review 
paper that this may be partly due to instability of SAM and SssI methyltransferase. They also 
mentioned that although the DNA methyl acceptor assay appears to be relatively 
straightforward, others have reported many technical problems.  
The [3H]-SAM donor assay for global DNA methylation did not reveal any effects of 
folate and methionine depletion, in either C4-II or SiHa cells, although with increased 
number of cell passages there was an increase in DNA hypomethylation. Whilst there are no 
explicit reports of an increase in hypomethylation of cells during successive passages there 
are reports describing a correlation between ageing and increasing hypomethylation, such 
as in reports of Catania et al. (Catania & Fairweather, 1991) and Kim et al. (Kim et al., 2009). 
They concluded that 5-methylcytosine loss occurred during cell culture and appeared to be 
related to cell division. The rate of 5-methylcytosine loss was related to in vitro lifespan.  
 
4.5.1.2 Immunocytochemistry for the detection of 5-methylcytosine 
Piyathilake et al. (2000) used an immunohistochemistry method for the detection of 
5-methylcytosine in squamous cell lung cancer specimens, in order to investigate the level of 
global DNA methylation (Piyathilake et al., 2000). We examined the potential of this method 
for the quantification of 5-methylcytosine in C4-II cells. However, because of the high density 
of cells it was very difficult to reliably assess and score the intensity of staining after several 
days of culture. This problem was compounded by the appearance of multilayers after longer 
periods of growth in complete medium. The binding of primary antibody appeared 
problematic too, leading to probable false negative results. Therefore, it was concluded that 
determination of global DNA methylation using this method was not appropriate for C4-II 
cells. 
4.5.1.3 Flow cytometric analysis of 5-methylcytosine 
Although flow cytometry has been widely used in methylation studies of cells in 
culture we are not aware of its application to studies of effects of folate depletion in cell 
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culture. Flow cytometry was performed in order to detect 5-methylcytosine at a cellular level 
because it had been difficult to quantify the degree of staining in our immunocytochemistry 
owing to factors such as hyperconfluence over many days of cell growth, as well as operator 
subjectivity (Habib et al., 1999; McManus et al., 2006). 
A protocol for the flow cytometric determination of 5-methylcytosine in cultured cells 
was developed and optimised. Using the optimised method it was possible to demonstrate 
an effect of methyl donor depletion on global DNA methylation in C4-II cells in culture. 
Staining for flow cytometry was also carried out on SiHa cells for three experiments. 
However, no difference was seen in the mean fluorescence intensities between the different 
growth conditions. One possible explanation for this is that the DNA methylation process in 
these cells may be preserved to some extent at the expense of other methyl acceptors. 
The flow cytometric analysis of C4-II cells and SiHa cells was suggestive of two sub-
populations of cells, for some conditions at certain time-points. It is not immediately apparent 
why this should be the case. However, differences in cell size, shape and internal complexity 
such as stage of life-cycle, might influence the results of flow cytometry (Shapiro, 2003). 
Since flow cytometry detects light scattering and fluorescence properties in order to sort cells 
and discriminate cell groups. The split peaks in some of the plots, which suggest sub-
populations of cells, might reflect differences between cells in stages of the cell cycle and in 
cell size. Different stages of the cell cycle stage are associated with a distinct DNA content 
(Darzynkiewicz et al., 2010) and differences between cells might lead to a non-homogeneity 
of 5-methylcytosine detection. Moreover, any hyperconfluency of C4-II cells at the later time 
point might have resulted in apoptosis or in limited access of the 5-aza-deoxycytidine to 
some cells; either possibility could have contributed to sub-populations of fluorescing cells. It 
is not possible to re-analysis the data because the original file has been removed from the 
database of our facility. 
Results from other studies, using various methods, have been inconsistent and there 
are various reasons why this might be so, including differential responses of different cell 
lines to methyl donor depletion. The study by Stempak et al. (2005) suggested that effects 
might be cell-specific. Using the SAM donor assay they showed a lower global DNA 
methylation in folate-deficient untransformed cells (NIH/3T3 and CHO-K1), but not in folate-
deficient transformed cells (HTC116 and Caco-2). Folate depletion in normal human colonic 
epithelial cell lines, HCEC, NCM356 and NCM460 using LC-MS (high-performance liquid 
chromatography/ electrospray ionization mass spectrometry), did not influence global DNA 
methylation (Crott et al., 2008). A study of moderately folate-depleted rats showed no 
significant change in DNA methylation of liver or colonic mucosa, using the SAM donor 
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assay (Kim et al., 1995). Moreover, using liquid chromatography-mass spectrometry, feeding 
a folate-deficient diet to mice for 8 months found only a 9% fall in global DNA methylation in 
splenocytes, a decrease of 4% in small intestinal epithelial cells and a 7.2% reduction in 
colon epithelial cells, only the latter reaching statistical significance (P < 0.05) (Heinz et al., 
2009). 
 Other studies, in various systems and using various methods, have reported effects 
of folate depletion on global DNA methylation. For example, folate depletion of immortalized 
colonic epithelial cells resulted in an increase in global DNA hypomethylation (Duthie et al., 
2000a). There have been few studies in humans, but Rampersaud et al. (2000) reported a 
fall in global DNA methylation in leukocytes in response to a moderate  folate-depletion (118 
µg folate/day) of elderly women (age 60-85) for 7 weeks, which was not reversed over a 7 
week repletion period (200 or 415 µg folate/day).  
S-adenosylmethionine is the methyl donor for very many methylation reactions, 
possibly more than 50, and DNA is only one substrate for methylation. Other substrates for 
methylation include guanidinoacetate (forming creatine), and phosphatidylethanolamine 
(forming phosphatidylcholine). To maintain other methylation activities, the DNA methylation 
profile may be preserved to some extent at the expense of other methyl acceptors. The 
effect of one-carbon depletion may be evident in changes in other methylated substrates 
before effects on DNA methylation are noted (Brosnan et al., 2004). Furthermore, others 
have shown interactions between the activities of dietary methyl donors (Niculescu & Zeisel 
2002); notably, choline may mitigate effects of folate depletion (Craciunescu et al., 2010). 
Their study was conducted to investigate the effect of folate-deficiency (FD) and folate-
deficiency with choline-supplementation (FDCS) on the neurogenesis and apoptosis of 
regions of fetal mouse brain. While folate deficiency led to a reduction in the mitosis rate and 
an increase in apoptosis of neural progenitor cells in different regions of the brain, choline 
supplementation mitigated some of these effects. 
Serum choline concentration depends on the intake of choline in the diet and 
fluctuates during meals (Bligh, 1952; Zeisel, 1981).  While the normal human plasma choline 
concentration is about 10µM (Savendahl et al., 1997), the choline concentration in the 
medium used to grow the C4-II cells is about 1.8mM (0.454g/L of choline bitartrate), 
compared with a choline concentration of 0.2-0.3 µM (0.003-0.004 g/L of choline chloride) in 
RPMI-1640 and DMEM media, which are commonly used to culture cells in vitro. As the 
medium used to grow the C4-II cells was particularly rich in choline, this may have 
compensated for the depletion of folate and methionine and maintained methionine 
synthesis and therefore SAM synthesis, through the betaine pathway. 
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The accumulation of homocysteine produced in our folate and methionine-depleted 
system may be another influence on DNA methylation. Jiang et al. (2007) investigated the 
effect of induced hyperhomocysteinemia in rats fed various concentrations of methionine. 
They demonstrated that a high plasma homocysteine concentration was associated with an 
increase in genome hypomethylation of B1 repetitive element (B1 is SINE: Short 
Interspersed Element in mouse which shares 70-80% sequence homology of Alu in human). 
However, there is no certainty that the effects were due to elevated homocysteine or 
decreased methionine.They also suggested that the different concentrations of 
homocysteine impacted on methyl metabolism (Jiang et al., 2007a). It is known that SAH is a 
DNA methyltransferase inhibitor, the reversible reaction from accumulated homocysteine to 
SAH could increase the inhibition of DNA methyltransferase and thereby influence DNA 
methylation (James et al., 2002).  
Effects of methyl-donor depletion on global DNA methylation seem very dependent 
on the model system, the protocol for depletion, and the method of analysis.  
4.5.2 Effect on DNMTs expression 
To determine whether effects of methyl donor depletion on global DNA 
hypomethylation in C4-II cells could be explained by altered expression of DNMTs, mRNA 
was determined for DNMT1, 3a and 3b. A combined methionine and folate depletion 
resulted in a progressive reduction in the mean expression of all DNMTs with time, and this 
was especially so for DNMT3b. Folate depletion alone had less marked effects than the 
double-depletion, but did lead to a loss of DNMT3a and 3b expression. DNMT1 expression 
was more resistant to effects of methyl donor depletion than DNMT 3a and 3b, but did also 
show a reduced expression in reponse to a combined depletion of folate and methionine. 
Repletion of cells with folate or folate and methionine reversed effects on growth and DNMT 
expression.  
Others have studied effects of methyl donor depletion on the expression of DNMTs 
but the direction of any effects observed are not consistent between studies, or between 
DNMTs. Hayashi et al (2007) observed a down regulation of DNMT3a and 3b in folate-
depleted human colon adenocarcinoma cells but DNMT1 was upregulated in this system. 
They did not propose a mechanism for the effect. Stempak et al (2005) reported a decrease 
in DNMT1 and DNMT3a protein expression in folate-depleted untransformed NIH/3T3 
mouse fibroblast cells, which was reported global DNA hypomethylation, but also in human 
HCT116 and Caco-2 colon cancer cells in which they did not observe DNA hypomethylation. 
Moreover, a rat model of multi methyl-donor deficiency (methionine, folate, and choline) 
showed an increase in the protein and mRNA of DNMT1 and DNMT3a in liver, but no 
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change in DNMT3b expression (Ghoshal et al., 2006). Importantly, in our studies the 
additional depletion of methionine generated more pronounced effects than folate depletion 
alone, and the effects were reversible. This suggests a mechanism that is not specific to 
either folate or methionine but is rather underpinned by methyl group deficiency. 
Several factors are thought to influence the expression of DNMTs, such as the 
expression level of microRNAs (miRNAs) and non-coding RNAs (ncRNAs), and chromatin 
conformation. The effect of methyl-donor deficiency on DNMTs expression might be 
explained in the context of a change in chromatin structure. A change in methyl-donor status 
may lead to aberrant DNA methylation and subsequent histone acetylation, leading to a 
reduced accessibility of transcription factors to the binding site of chromatin (Jones et al., 
1998; James et al., 2003; Pogribny et al., 2007; Delage & Dashwood, 2008). Kovacheva et 
al. (2007) were able to show that DNMT1 expression was influenced by methylation; 
specifically, hypomethylation at a key regulatory CpG within the DNMT1 locus led to 
upregulation of this gene. In contrast, in our study of C4-II cells, we did not observe the up-
regulation of DNMTs, even though global DNA hypomethylation was observed. The 
explaination in this case may be that the gene-specific hypomethylation did not function 
directly at DNMTs themselves. In contrast, the expression of other regulators, such as 
repressor proteins, involved in DNMTs transcription may be up-regulated by gene-specific 
hypomethylation mediated by methyl-donor depletion, resulting in the decrease in DNMTs 
expression. 
The functional significance to cancer progression of altered expression of DNMTs in 
response to methyl donor depletion is unclear. DNMTs have been found to be 
overexpressed in some human cancers (De Marzo et al., 1999; Mizuno et al., 2001; Etoh et 
al., 2004; Su et al., 2013). On the other hand, Choi et al demonstrated a loss of cytoplasmic 
expression of DNMT3a in hepatic carcinogenesis and suggested that dysregulation of 
DNMT3a expression might be involved in cancer progression (Choi et al., 2003). There is 
also limited evidence that silencing of DNMT1 may be associated with demethylation and 
reactivation of some tumour suppressor genes, in various cancer cell lines, although effects 
were not wholly consistent (Zhang et al., 2011). Two potentially important studies suggest an 
inverse relationship between DNMT3a and 3b expression and carcinogenesis; Hlady 
conducted a study in which he inactivated DNMT3b in a mouse model of lymphomagenesis 
and observed an accelerated lymphomagenesis. He showed a gradual demethylation of a 
tumour modifier gene MENT (methylated in normal thymocytes) and overexpressed in the 
DNMT3b knockout model. MENT expression was up-regulated over 60% of human 
lymphomas. His findings suggested that DNMT3b has a role in maintaining tumour modifier 
gene methylation in cancer and he proposed DNMT3b as a tumour suppressor (Hlady et al., 
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2012) . Similarly, Gao showed that deletion of DNMT3a in a mouse model of lung cancer led 
to an enhanced tumour progression associated with increased expression of genes 
important to the cancer phenotype (Gao et al., 2011).  He proposed DNMT3a as a tumour-
suppressor-like gene. Taken together these findings suggest that a down regulation of 
DNMT3a and 3b in response to methyl donor depletion may have cancer- promoting effects. 
Time constraints meant that we were unable to progress these observations to a 
validation of DNMTs gene expression by investigating the protein expression. Preliminary 
studies showed non-specific bands, which precluded an accurate interpretation. Further 
investigation of a more suitable primary antibody could have been conducted to improve the 
quality of the result, but this was not possible within our time-frame. 
4.5.3 Effect of methyl donor repletion on cell growth and DNMT expression 
The diminished growth rate of both folate depleted cells and the folate and 
methionine depleted cells was corrected after 4 days repletion.  
The effect of folate and methionine depletion on DNMT1 expression was equivocal, 
as our depletion/repletion experiment did suggest a down-regulation following folate and 
methionine depletion, and reversibility of this effect, but the effect seen in the earlier 
depletion experiment did not reach statistical significance. This may simply be a reflection of 
the greater number of independent experiments conducted for the depletion/repletion study. 
A repletion of methyl donor status from a combined-depletion state led to a significant 
recovery in the expression of all DNMTs. The effect of folate repletion alone was to improve 
expression of all DNMTs but to a more modest extent. Our result confirmed that DNA 
methyltransferase gene expression can be altered by the methyl donor depletion and 
reversed after repletion. 
Relatively few studies have reported effects of methyl donor repletion. Wasson et al. 
conducted an experiment in human colonic adenocarcinoma cell lines (SW620). They grew 
the cells in folate depleted medium for 7 days and then transferred to a complete medium 
(3µmol/L folic acid) for further 7 days and found that folate deprivation led to DNA 
hypomethylation, and that this was reversed on folate repletion (Wasson et al., 2006). 
Williams & Jacobson (2010) observed the growth rate of immortalized human epidermal 
keratinocytes (HaCaT cells) after 10-day folate depletion and then 10-day repletion and 
found that cell proliferation, which was decreased by depletion, was recovered after 
repletion. They reported an  increase in the S- and G2-phase cells, during depletion and a 
reverse this trend on repletion (Williams & Jacobson, 2010). Results of the two studies are 
likely compatible to our results in which the growth rate and DNMTs expression were 
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resumed after repletion. Folate and methionine repletion initiated cell cycle and cell 
proliferation again by restoring DNA synthesis. The methyl cycle was also normalized 
resulting in the recovery of DNA methylation level and a rescue of gene expression of all 
relevant genes in DNMTs transcription.  
Our results demonstrated that DNA methyltransferase gene expression can be 
reduced by methyl donor depletion and reversed by repletion, which may have implications 
for the effects of dietary restriction and supplementation on DNMT expression in vivo. 
4.5.4 Effect on DNMT activity 
Using a method for the measurement of total DNMT activity, rather than the activity 
of individual DNMTs, combined folate and methionine depletion led to an apparent increase 
in activity. This seemed counter-intuitive given the loss of expression of DNMT1, 3a and 3b 
by the same depletion regimen. Furthermore, it was surprising that there was no 
intermediate effect of folate depletion alone, which we had seen for all other outcomes. 
Unfortunately, we cannot differentiate between the individuals DNMTs because of the 
limitations of the activity assay and therefore we do not know whether any particular DNMT 
is driving this apparent effect. The DNMT activity assay kit used in our research is an ELISA-
based protocol in which the methylated DNA products can be detected with a 5-
methylcytosine antibody. A discussion of the limitations of the kit used to measure total 
DNMT activity is warranted here. The percentage of coefficient of variation (%CV) of this 
protocol was very high (>20%). From 4-independent experiments, there was one experiment 
in which folate-depleted cells gave a 1.8 fold higher activity than complete cells while the 
other three experiments resulted in a modest lowering of activity. In addition, the activity 
detected was different from lot to lot of the kit. The actual activity value could not be 
obtained, even for the positive control enzyme provided from the manufacturer. The 
sensitivity of the assay is also a potential limitation because this kit requires a high protein 
concentration of nuclear extract in a tiny microlitre volume. Moreover, the protein 
concentration of the nuclear extract did not relate directly to the amount of DNMT, rather to 
the total protein concentration of the extract. There was also uncertainty about those factors 
which influenced enzyme stability, which depended on pH, temperature, amount of 
substrates and cofactors. Therefore, the interpretation of total DNMT activity should be 
considered cautiously. The lack of effect of folate depletion alone was in accordance with 
findings of Uthus et al (2006) in their study of 70-day folate deficiency in rats; using the SAM 
donor based assay, they found no change in total DNMT activity in the liver or colon of the 
rats (Uthus et al., 2006). 
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Total DNMT activity was also studied in folate-deficient cells using the SAM-donor 
assay based protocol. They found a lower total DNMT activity in folate-deficient non-
transformed cells HIH/3T3 but not in CHO-K1 cells. They also reported a lower DNMT 
activity in folate-deficient Caco-2, but not in HCT116 colon cancer cells (Stempak et al., 
2005), indicating a cell-specificity. According to the DNA methylation and DNMTs results of 
Stempak et al, folate depletion has more influence on non-transformed cells than 
transformed cells. The depleted non-transformed NIH/3T3 cells have an increased DNA 
hypomethylation, despite increased DNMTs activity and DNMT1 and DNMT3a protein. Jiang 
et al. (2007) found an increased activity of DNMT3a and DNMT3b in vascular smooth 
muscle cells exposed to high homocysteine concentrations, which is usually interpreted as 
reflecting disturbance to the methylation cycle and is associated with folate deprivation as in 
our study (Jiang et al., 2007b). However, they also found an increase in s-
adenosylhomocysteine, which is understood to inhibit DNMT activity (Saavedra et al., 2009) 
and therefore their results are difficult to interpret.  
Most cancer cells have a genome-wide hypomethylation and Belinsky et al. (1996) 
suggested that an increase in total DNMT activity is a sign of neoplastic development and 
carcinogenesis (Belinsky et al., 1996). Jiang et al. (2007) suggested that an increase in 
DNMT activity could be seen as a compensatory mechanism in order to maintain a DNA 
methylation profile (Jiang et al., 2007a).  
The anti-correlation between DNMTs expression and activity in the methyl donor 
depletion was unexpected. The underlying mechanism of this mismatch may be explained in 
the context of post-translational modification. For DNMT1, there are some documented 
examples of post-translational modifications which influence its stability/activity. For 
example, Goyal et al. removed the phosphorylated serine 515 from DNMT1 and found a 
severe loss of DNMT1 activity (Goyal et al., 2007). Estève et al. showed that lysine 
methylation of DNMT1 mediated by SET7 (histone methyltransferase) influenced 
proteasome-mediated degradation of DNMT1 (Estève et al., 2009). In the DNMT3 family, a 
study of sumoylation of DNMT3a at the N-terminal regulatory region, showed a disruption of 
interaction with HDAC interaction, leading to impaired stability and activity of DNMT3a (Ling 
et al., 2004). 
The existence of DNMT isoforms, especially splice variants of DNMT3b, could also 
explain the mismatch between expression and activity of DNMTs. Depending on the specific 
splice variant, there may be different effects on the function of a particular DNMT (Choi et 
al., 2011).  There are more than 30 isoforms of DNMT3b and several of them are inactive 
because the catalytic C-terminal domain is missing. Moreover, there is evidence that inactive 
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isoforms of DNMT3b could influence overall activity and lead to a difference in DNA 
methylation patterns. Godon et al. proposed that DNMT3b3 isoform binds to the regulatory 
site of DNMT3a and modestly increases DNMT3a activity. In contrast, DNMT3b4 isoform 
inhibits the DNMT3 family enzyme activity by competitive binding to DNA substrate (Gordon 
et al., 2013). 
 
4.6 Summary 
Our results show for the first time that a combined folate and methionine deficiency in 
a cervical cancer cell line induces global DNA hypomethylation and this may be caused by 
the observed down regulation of the de novo DNA methyltransferases. There was a 
concordance between DNMT expression and global DNA methylation, but a lack of 
concordance between DNMT expression and activity.  Loss of DNMT expression has been 
associated with enhanced cancer progression in some studies, which suggests that methyl 
donor depletion in people with an existing cancer might have adverse effects. However, 
there is also evidence that down-regulation of DNMT expression may lead to a re-activation 
of tumour suppressor genes which would have a beneficial effect. It is therefore difficult to be 
certain of the overall effect on cancer progression of a down-regulation of DNMTs.  
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Chapter 5 Gene expression 
5.1 Introduction 
 Diets supplemented with methyl donors have been reported to influence gene 
expression, via the alteration of DNA methylation. Our research has demonstrated that 
methyl donor depletion can result in modest DNA hypomethylation which is linked to the 
down-regulation of de novo DNA methyltrasferases. Changes in the gene expression profile 
of cancer cells are likely to lead to changes in cell behaviour; some changes may be relevant 
to cancer progression.  Therefore, it was considered that an investigation of the role of 
methyl donors in determining the gene expression profile of cervical cancer cells may bring 
some benefits to understanding cancer prognosis. 
 Other studies have reported gene expression in cervical cancer. In the review of 
Dueñas-González et al. (Dueñas-González et al., 2005), several genes were proposed as 
being causally linked with cervical carcinogenesis, through epigenetic mechanisms. Those 
altered genes involved several which are known to be involved in many important processes 
such as apoptosis, the cell cycle, Wnt signalling pathway, and DNA repair. In their study of 
cervical cancer progression, Hagemann et al. (2007) compared the molecular profile of 
lymph node micrometastases with primary tumours using Taqman Low-Density Arrays. They 
reported that AKT, BCL2, CSFR1, EGFR1, FGF1, MMP3, MMP9 and TGF-b were 
upregulated by more than 2-fold (Hagemann et al., 2007). Recently Rajkumar et al. (2011) 
carried out an oligo-microarray study in samples from various stages of cervical cancer. 
They identified seven genes which they proposed were involved in tumourigenesis, which 
were UBE2C, CCNB1, CCNB2, PLOD2, NUP210, MELK, and CDC20. In addition they 
demonstrated an upregulation of IL8, INDO, ISG15, ISG20, AGRN, DTXL, MMP1, MMP3, 
CCL18, TOP2A , and STAT1 in cancers compared to normal, CIN1/2 or CIN3/CIS stages of 
cell abnormality (Rajkumar et al., 2011). Those genes are likely to be important in cervical 
cancer progression. 
In terms of methyl-donor depletion, some studies, in various cell types, have 
investigated the effecs of folate depletion on gene expression. For example, Jhaveri et al. 
(2001) conducted a gene microarray of folate-depleted human nasopharyngeal epidermoid 
carcinoma KB. Surprisingly, they found only three genes showing up-regulation (Brain-
expressed HHCPA78 homolog, Calmegin, and Insulin-induced protein 1) and five genes 
showing down-regulation (Keratin type 1 cytoskeleton 14, Cyclin D3, H-cadherin, Gravin, 
and Interferon-inducible protein 1-8U) (Jhaveri et al., 2001). This result pointed that there 
seemed to be cell communication leading to cell proliferation and transformation genes 
affected by folate deficiency. In the study conducted by Katula et al. (Katula et al., 2007) to 
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investigate global gene expression in folate-deficient normal human fibroblast cells 
(GM03349), effects were observed in the Wnt pathway, cell signalling, and the cytoskeleton 
and extracellular matrix. In the above depletion studies, the proteomic and pathway analysis 
was also investigated in folate-deficient NCM460 human colon epithelial cells by Duthie et al. 
(2008). They reported a significantly altered protein expression in proteins important to cell 
proliferation,DNA repair, apoptosis, cytoskeleton organization, and malignant transformation. 
They also suggested that folate status most associated with the regulation of actin 
cytoskeleton, which significantly affects cell motility and locomotion (Duthie et al., 2008). All 
of the above studies showed that no matter what cell types are, folate deficiency seems to 
affect signalling pathways and cytoskeleton organization. 
The gene expression in methyl-donor depleted cervical cancer cells has not been 
investigated so far. In order to determine the effects of folate and methionine depletion on 
global gene expression of cervical cancer cells, a gene microarray analysis was conducted. 
5.2 Aims 
 To investigate the effects of methyl-donor depletion of C4-II cervical cancer cells on 
gene expression profile by gene microarray, in order to gain insight into possible implications 
for cancer progression. 
 
5.3 Methods 
5.3.1 Microarray 
A genome-widemicroarray analysis was processed by Dr Paul R Heath, Department 
of Neuroscience, SiTRans, University of Sheffield. Briefly, the C4-II RNA of F+M+ and F-M- 
cells was extracted as described (see section 2.2.8). The purity and integrity of C4-II RNA 
was determined by Agilent 2100 bioanalyzer and Agilent RNA 6000 Nano Kit before further 
processing (see section 2.2.11.1). The RNA was used for the microarray target preparation 
(see section 2.2.11.2) and hybridisation (see section 2.2.11.3).  
5.3.2 Data analysis 
 The F+M+ and F-M- samples probe array images were merged for probe intensities 
and normalised by GeneChip® Command Console® Software (Affymetrix, UK). The data 
from each sample were analysed and compared by using GeneSpring Software version11 
(Agilent Technologies, Germany). The probe signals were filtered based on fold change and 
statistical significance (t-test). Genes were selected if there was a statistically significant 
difference (P<0.05) in gene expression between F+M+ and F-M-. DAVID (The Database for 
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Annotation, Visualization and Integrated Discovery) Bioinformatics Resource 6.7 software  
was used to identify effects on specific gene clusters, according to biological function, as 
described by Huang et al. (Huang et al., 2009) . 
5.4 Results and discussion 
 From more than 54,000 probes detected in the microarray, there were about 10,000 
probes which appeared to show a significant difference (P<0.05, t-test) in gene expression 
between methyl-donor depleted cells and complete cells. The analysis did not take account 
of multiple testing because the use of the Bonferroni method to make such a correction led 
to an almost complete loss of differentiating genes. Therefore, results will be discussed 
primarily on the analysis of uncorrected data. However, some attempt has been made to use 
the Benjamini-Hochberg’s method for correction of multiple testing, and results have been 
included as a brief summary at the end of this chapter.  
Those 10,000 probes IDs were further clustered according to biological function. The 
expressed transcripts were clustered using the DAVID software (David Bioinformatics 
Resource 6.7). In order to maximize the possible benefit from the microarray, three thousand 
probe IDs, which was the maximum size of data for analysis with DAVID, were uploaded to 
DAVID software. The first 3000 probe IDs from up- and down-regulation in methyl donor 
depleted cells were analysed.  All of the significant probes gave the difference in gene 
expression more than 1.5-fold change. Functional annotation clustering according to 
biological function revealed 464 clusters of up-regulated genes and 476 clusters of down-
regulated genes (figure 45-46).  
Each cluster was given an enrichment score which indicated the functional 
importance of the gene group. The clusters which have an enrichment score of more than 
1.3 (Huang et al., 2009), were considered further. There were 64 clusters of up-regulated 
genes and 51 clusters of down-regulated genes, for which the enrichment score was more 
than 1.3. Of these clusters seven were selected on the basis of a high enrichment score and 
the biological grouping. These are presented in table 6 
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Figure 45: Example of functional annotation clustering using DAVID Bioinformatics. This 
screen shot shows a few clusters from the up-regulated gene list 
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Figure 46: Example of functional annotation clustering using DAVID Bioinformatics. This 
screen shot shows a few clusters from the down-regulated gene list 
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Table 6: Summary of selected gene clusters from both up- and down-regulated genes of 
methyl-donor depleted cells 
Up-regulation Enrichment score Down-regulation Enrichment score 
Cell death 7.13 Cell cycle 23.85 
Cell motion 4.05 
Condensed 
chromosome 
11.1 
Protein kinase 
cascade 
3.21 
Cytoskeleton 
organization 
9.6 
Signal 
transduction 
3.21 
DNA metabolic 
process 
5.43 
Cell 
communication 
3.21 Transferase 3.77 
Blood vessel 
development 
3.21 
Lipid 
biosynthesis 
process 
2.6 
Focal adhesion 2.16 
Chromosome 
organization 
1.8 
 
 From the results of the DAVID resource, the gene list of each cluster could be 
examined. An example of a gene list from DAVID analysis is presented in figure 47 and 48 
Gene lists were examined and a small number of genes on the basis of either having a high 
fold change for that cluster or appearing in more than one cluster were identified and 
considered more closely. Table 7 and 8 show such genes and the fold change and direction 
of change, for the methyl donor depleted cells relative to the controls. In the arm of up-
regulation, interesting genes were selected from each cluster and are considered further 
here. Transforming growth factor beta 2 (TGFB2), which is a secreted cytokine protein, was 
upregulated 3.76 fold in folate and methionine depleted cells compared with complete cells 
and this plays an important role in 6 of the 7 clusters considered in our study. TGFB2 
functions as a signal to regulate the expression of the extracellular matrix and is linked to 
several biological processes important to cancer cell activity such as cell adhesion, 
migration, differentiation, and proliferation. Thrombospondin1 (THBS1) appeared in 4 of the 
7 selected clusters. THBS1 expression of folate and methionine depleted cells was 2.2 fold 
greater than complete cells. This gene encodes the adhesive glycoprotein which is involved 
in the interaction between cells and cell-matrix. The key roles of THBS1 are in cell migration 
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and angiogenesis, both of which are important to cancer progression. Another gene which 
was regulated in folate and methionine depleted cells was transglutaminase 2 (TGM2). Its 
expression was 29 fold higher than in the complete cells and this gene was involved in 4 of 
the 7 selected clusters. TGM2 is the gene for a calcium-dependent enzyme which catalyses 
the transamidation of protein leading to altered protein conformation conferring resistance to 
proteolytic degradation. TGM2 function can be linked to various cell processes such as 
extracellular matrix stabilization, cell adhesion, wound healing, cell signalling, and cell 
motility (Griffin et al., 2002). Tumour protein p63 (TP63) works as a transcription factor and 
in this way regulates several cell processes such as cell proliferation, cell adhesion, and 
apoptosis. TP63 expression was 14.18 fold higher in folate and methionine depleted cells 
compared with complete cells and appeared in 3 of the 7 clusters shown here. 
 According to the arm of down-regulation, interesting genes were selected from each 
cluster and some are described here. Breast cancer 1, early onset (BRCA1) which appeared 
in 5 of the 7 clusters, was down-regulated in folate and methionine depleted cells by 1.74 
fold compared to complete cells.  BRCA1 is known as a tumour suppressor gene. Aurora 
kinase B (AURKB) which is the gene for an enzyme involved in cell cycle check point, was 
down-regulated 3.36 fold and appeared in 3 of the 7 clusters. E1A binding protein p300 
(EP300) was down-regulated 3.59 fold and appeared in 3 of the 7 clusters. This gene works 
as a histone acetyltransferase and is involved in chromosome remodelling. The last example 
is DNMT3b which we have already shown to be down regulated in folate and methionine 
depleted cells compared with complete cells, as described in chapter 4. From the microarray 
result, we also found a down regulation of this gene, the expression of which was 3.03 fold 
lower in the methyl donor depleted cells, and appeared in 2 of the 7 clusters.  
Regarding cancer cell characteristics, Hanahan and Weinberg (2000) proposed six 
major characteristics of cancer cells which distinguish cancer cells from normal cells. Firstly, 
cancer cells have their own growth signals. The cells achieve an active proliferative state 
without relying on stimulatory signals. Secondly, cancer cells are insensitive to antigrowth 
signals. Thirdly, cancer cells are resistant toward apoptosis. Fourthly, cancer cells have a 
infinite replicative potential. Fifthly, to maintain their viability, cancer cells require 
angiogenesis. And finally, cancer cells can move and travel to their surrounding tissue, 
resulting in tissue invasion and metastasis (Hanahan & Weinberg, 2000). Moreover, in 2011, 
Hanahan and Weinberg (2011) suggested two more hallmarks of cancer cell potential which 
are (1) reprogramming of energy metabolism, and (2) evading immune destruction. In 
addition, they proposed four main intracellular signalling networks which support cancer cell 
activity. These are motility circuits, proliferation circuits, viability circuits, and cytostasis and 
differentiation circuits. To understand cervical cancer behaviour in methyl-donor depletion, 
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we need to look closely at all of those circuits. Unfortunately, within the time constraints of 
this study it was not possible for us to carry out such an exhaustive analysis. 
As far as we know, there has been no other study conducted to examine the effects 
of folate and methionine deficiency on gene expression profile in cervical cancer cells. 
However, there have been studies focussing on aspects of gene expression profiles of 
cervical cancer cells and on methyl donor-depleted cells of various types. Perez-Plasencia et 
al. (2007) conducted a study to investigate the alteration of metabolic pathways in invasive 
squamous cervical cancer stage IIB of human biopsies harbouring HPV16 compared to 
normal cervical tissues. They demonstrated an upregulation of the Wnt signalling pathway, 
calcium signalling pathway, and MAPK signalling pathway in invasive cervical cancer and a 
down regulation of focal adhesion and TGF-β signalling pathways (Perez-Plasencia et al., 
2007). In addition, Liu et al. (2007) showed that a combined folate and multiple B vitamin 
(B2, B6, and B12) depletion in a mouse model led to an alteration of Wnt pathway 
metabolites in mouse colon cells (Liu et al., 2007).  
The alteration of Wnt signalling pathway is the most frequently cited in cancer 
development (Giles et al., 2003) and the altered expression of genes involved in this 
pathway have been reported in cervical cancer (Dueñas-González et al., 2005). For 
example, Chen et al. (2003) investigated methylation level at the promoter of E-cadherin 
gene in 5 cervical cancer cell lines and 20 cervical cancer samples. They found that all five 
cell lines and 8/20 of cervical cancer samples have hypermethylation. Protein expression of 
E-cadherin was absent in 3/5 of cell lines and 6/8 of cervical cancer sample. They also 
reported an increase of DNMT1 expression. However, E-cadherin expression was recovered 
when DNMT1 was interrupted. This cervical cancer study suggested a positive relation 
between promoter DNA methylation level and DNMT1 expression (Chen et al., 2003). 
Another study, conducted by Cheung et al. (2004), was focused on PTEN (phosphatase and 
tensin homolog). They determined methylation level at promoter of PTEN in 10 samples of 
high-grade cervical intraepithelial neoplasia (CIN-H) and in 62 squamous cell carcinoma 
(SCC) tissues. Hypermethylation was found in 40% of CIN-H and 58% of SCC (Cheung et 
al., 2004).Taken together, these findings encouraged us to focus primarily on the effects of 
methyl-donor depletion on the Wnt signalling pathway. 
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The Wnt signalling pathway involves the control of several cell functions. Figure 49 
shows the Wnt signalling pathway from KEGG (Kyoto Encyclopedia of Genes and 
Genomes) database. There are three major pathways activated downstream from the Wnt 
reaction.  
(1) The canonical pathways which is β-catenin dependent. This pathway affects gene 
transcription. Some important genes in this pathway are Wnt, Frizzled, Dvl, GSK-3β, 
APC, and β-catenin. 
(2) The planar cell polarity pathway, which is important in cell polarization and plays a 
key role during nueral tube closure. Some important genes in this pathway are 
Wnt11, Frizzled, Dvl, RhoA, ROCK, and genes in focal adhesion 
(3) The Wnt/Ca2+pathway (non-canonical pathway) which mediates cell adhesion and 
cell motility. Some important genes in this pathway are Wnt5, Frizzled, PLC, and 
CaMKII. 
 
Within the whole picture of the Wnt signalling pathway there are several other 
pathways which work harmoniously to regulate cell behaviour. In order to select a part of the 
Wnt signalling pathway for further consideration, we found that several genes were 
significantly up-regulated in the cluster of cell motion, cell communication, and focal 
adhesion, which may be particularly related the planar cell polarilty pathway and the 
Wnt/Ca2+pathway. Those two arms of the Wnt signalling pathway may direct us to 
understand the effect of methyl-donor depletion on cervical cancer motility. Therefore, the 
focal adhesion pathway is considered more closely. 
Focal adhesion is the process whereby the integrins and glycoprotein receptors on 
the cell membrane interact with the extracellular matrix (e.g. collagen, laminin, and 
fibronectin) (Abercrombie et al., 1971; Burridge et al., 1988). Once focal adhesion has 
occurred, the consequent signals are transmitted to several parts of the cells. Two major 
participants are (1) the connection of membrane receptors and bundles of actin filaments, 
and (2) signalling molecules such as protein kinase and phosphatase which can transmit 
signals through several substrates and adaptor proteins (Petit & Thiery, 2000). The 
downstream signals can lead to cytoskeleton rearrangements which are involved in an 
alteration of cell shape and cell motility, and in changes in gene expression which lead to an 
alteration of cell proliferation and cell survival (Lo, 2006). 
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Table 7: Example of genes which were up-regulated in methyl-donor depleted cells and their relevance to biological function 
Gene lists were chosen on the basis of either having a high fold change for that cluster or appearing in more than one cluster  
 
Gene name 
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change 
Cluster 
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SMAD family member3 (SMAD3) 3.63 √ √           
adenomatous polyposis coli (APC) 1.68 √ √ √ √       
cyclin-dependent kinase inhibitor 1A (p21, Cip1, CDKN1A)  2.39 √     √       
insulin-like growth factor binding protein3 (IGFBP-3) 3.56 √ √           
transforming growth factor beta2 (TGFB2) 3.76 √ √ √ √ √ √   
transglutaminase2 (TGM2, protein-glutamine-gamma-
glutamyl transferase)  
29 √   √   √ √   
caspase1  3.03 √   √ √ √     
son of sevenless homolog1 (SOS1) 1.57 √     √       
tumor necrosis factor member2 (TNF2) 3.82 √   √         
tumor protein p63 (TP63) 14.18 √     √ √     
adrenergic, beta2 receptor (ADRB2) 3.06 √   √ √ √     
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Table 7: Example of genes which were up-regulated in methyl-donor depleted cells and their relevance to biological function (continued). 
 Gene lists were chosen on the basis of either having a high fold change for that cluster or appearing in more than one cluster  
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tensin 4 (TNS4) 2.14 √           √ 
nexilin (F actin binding protein) (NEXN) 2.65   √           
endothelin1 (ET-1) 4   √ √     √   
fibroblast growth factor 2 basic (FGF2) 2.16   √       √   
histone deacetylase 9 (HDAC9) 2.03   √           
interleukin 6 (IL-6) 2.06   √ √ √ √     
thrombospondin1 (THBS1) 2.22   √   √ √ √   
vascular endothelial growth factor C (VEGF-C) 1.74   √       √   
integrin alpha2 (ITGA2) 1.69   √     √   √ 
apolipoprotein L3 (APOL3) 2.3     √ √ √     
leptin receptor (LEPR) 2.29     √ √ √     
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Table 7: Example of genes which were up-regulated in methyl-donor depleted cells and their relevance to biological function (continued) 
Gene lists were chosen on the basis of either having a high fold change for that cluster or appearing in more than one cluster  
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TNF receptor associate factor6 (TRAF6) 2.32     √ √ √     
protein phosphatase1A (PPM1A) 1.76     √ √       
epiregulin (EREG) 2.67       √ √ √   
cyclin-dependent kinase inhibitor 2B (CDKN2B, p15, 
inhibits CDK4) 
3.37       √ √     
collagen, type I, alpha 1 (COL1A1) 2.4           √   
Rho GTPase activating protein 24 (ARHGAP24) 2.22           √ √ 
cadherin 1, type 1, E-cadherin (epithelial) (CDH1) 1.62             √ 
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Table 8: Example of genes which were down-regulated in methyl-donor depleted cells and their relevance to biological function 
Gene lists were chosen on the basis of either having a high fold change for that cluster or appearing in more than one cluster  
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H2A histone family, member X (H2AFX) 2.38 √     √     √ 
Cullin 4A (CUL4A) 1.79 √     √       
E1A binding protein p300 (EP300) 3.59 √       √   √ 
anillin, actin binding protein (ANLN) 2.44 √   √         
aurora kinase B (AURKB) 3.36 √ √     √     
cyclin-dependent kinase 2 (CDK2) 1.78 √     √ √     
aurora kinase A (AURKA) 2.56 √   √         
breast cancer 1, early onset (BRCA1) 1.74 √ √ √ √   √   
retinoblastoma 1 (RB1) 2.13 √           √ 
Erbb2 interacting protein (ERBB2IP) 1.75 √   √         
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Table 8: Example of genes which were down-regulated in methyl-donor depleted cells and their relevance to biological function (continued). 
Gene lists were chosen on the basis of either having a high fold change for that cluster or appearing in more than one cluster  
Gene name 
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epidermal growth factor receptor (EGFR) 2.23 √       √     
calcium/calmodulin-dependent protein kinase II gamma 
(CAMK2G) 
2.16 √       √     
Holliday junction recognition protein (HJURP) 2.81 √ √         √ 
tubulin, beta (TUBB) 3.6 √   √         
stathmin 1 (STMN1) 3.25 √   √         
ras homolog gene family, member U (RHOU) 4.86 √   √         
O-6-methylguanine-DNA methyltransferase  (MGMT) 5.32       √ √     
DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) 3.02         √   √ 
NIMA (never in mitosis gene a)-related kinase 2 (NEK2) 2.41   √ √       √ 
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Figure 47: Example of genes from the cell death cluster which were up-regulated in 
methyl-donor depleted cells 
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Figure 48: Example of genes from the cell cycle cluster which were down-regulated 
in methyl-donor depleted cells 
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Figure 49: The Wnt signalling pathway from KEGG database 
 
Wnt signalling pathway can be divided into 3 paths; (1) the canonical pathway which affects 
the stabilization of β-catenin in order to activate Wnt regulated gene through its interaction 
with TCF (2) the planar cell polarity pathway which leads to remodelling of cytoskeleton, cell 
adhesion and cell motility (3) the Wnt/Ca2+ pathway which leads to an increase in free 
calcium to activate kinase and phosphatase 
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The KEGG database was interrogated, in order to identify genes involved in focal 
adhesion (figure 50). Among more than 200 genes involved in the focal adhesion pathway, 
we found 29 genes were up-regulated and 26 genes were down-regulated in our methyl-
donor depleted cells (table 9 and 10). In addition to the genes shown in the KEGG focal 
adhesion pathway, there numerous genes identified from other sources, which are not 
shown in the KEGG figure. Some of those genes are also included in the table. 
Our analysis and data interrogation show that folate and methionine depletion of C4-
II cells leads to both an up- and down-regulation of genes in the integrin family. Some 
studies have suggested that the alteration of integrin expression or its activation results in 
more dense focal adhesion (Keely et al., 1995; Palecek et al., 1997).The cell region 
exhibiting stronger adhesion migh trestrict the protrusion of the membrane and lead to a 
decrease in cell migration. We also found an increase in the expression of RAC1 (1.98 fold, 
P<0.05), slightly increased RhoA (1.15 fold, P<0.01), and slightly decreased CDC42 (1.17 
fold, P<0.01) in our depletion model. RhoA, RAC1, and CDC42 are a gene group belonging 
to the Rho family of GTPases which functions as a transducer to convey the extracellular 
signal into cells. These genes contribute to cell motility by stimulating the re-organization of 
the actin cytoskeleton. RAC1 and CDC42 serve to stimulate cell protusion while RhoA 
serves as a focal adhesion stimulator (Nobes & Hall, 1995). Even though up-regulation of 
RhoA and down-regulation of CDC42 may lead to a decrease in cell migration, RAC1 was 
up-regulated and would lead to increased cell motility. It should be noted that the fold 
change of RhoA and CDC42 were not high and may not be sufficient to influence cell 
migration compared with replete cells. In contrast, the upregulation of RAC1 was somewhat 
greater and may have the dominant effect.  
To be more certain of the likely functional effects of methyl donor depletion on gene 
expression, on cell migration in particular, results from this microarray study need to be 
validated by other methods such as qRT-PCR and western blot.   
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Figure 50: The focal adhesion pathway from KEGG database 
Focal adhesion is the contact point in which ECM-integrin receptor and growth factor-
receptor interaction take place. Downstream targets include actin skeleton and signalling 
molecule such as kinase and phosphatase which control cell motility, cell proliferation, and 
cell survival.  
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Table 9: The list of up-regulated genes of focal adhesion pathway in F-M- cells compared 
with in F+M+ cells 
Gene name Fold change 
Up-regulation   
Integrin, alpha 2 (ITGA2) 1.7 
Rho GTPase activating protein 5 (RhoGAP5) 2.28 
Rho GTPase activating protein 24(RhoGAP24) 2.22 
Rho GTPase activating protein 26(RhoGAP26) 2.29 
Src homolog 2 domain containing transforming protein (SHC1) 1.65 
Filamin B, beta (FLNB) 1.51 
Calpain 2(CAPN2) 1.65 
Phosphoinositde-3-kinase, regulatory subunit 1 alpha (PIK3R1) 1.7 
Son of sevenless homolog 1 (SOS1) 1.57 
v-crk sarcoma virus CT10 oncogene homolog (avain) (CRK) 1.76 
vav 1 guanine nucleotide exchange factor (VAV1) 1.94 
Ras-related C3 botulinum toxin substrate 1 (RAC1) 1.98 
Dedicator of cytokinesis 1 (DOCK1) 2.13 
     Additional genes not appearing in the KEGG figure 
v-erb-b2 erythroblastic leukemia viral (ERBB2) 1.53 
Baculoviral IAP repeat  containing 3 (BIRC3) 4.73 
Laminin, beta 3 (LAMB3) 5.03 
Thrombospondin 1 (THBS1) 2.2 
Tenascin R (TNR) 2.6 
Vascular endothelial growth factor C (VEGFC) 1.75 
Breast cancer anti-estrogen resisteance 1 (BCAR1) 1.79 
Insulin-like growth factor 1 receptor (IGF1R) 1.58 
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Table 10: The list of down-regulated genes of focal adhesion pathway in F-M- cells 
compared with in F+M+ cells 
Gene name Fold change 
Down-regulation   
Integrin, beta 4 (ITGB4) 2.37 
Integrin, beta 6 (ITGB6) 1.92 
Integrin, beta 8 (ITGB8) 1.51 
FYN oncogene (FYN) 1.83 
Guanine nucleotide exchange factors for Rho/Rac/Cdc42-like 
GTPase (RhoGEF) 
4.5 
Actinin, alpha 2 (ACTN2) 13.57 
Talin 1(TLN1) 1.55 
Calpain 3(CAPN3) 1.74 
Calpain 6(CAPN6) 1.52 
Calpain 8(CAPN8) 2.61 
Phosphatise and tensin homolog (PTEN) 1.92 
Phosphoinositol-4,5-bisphosphate -3-kinase, catalytic subunit 
delta (PIK3CD) 
2.36 
Parvin, beta (PARVB) 1.98 
Integrin-linked kinase (ILK) 1.53 
Myosin light chain kinase (MLCK) 2.35 
Ras-related C3 botulinum toxin substrate 3 (RAC3) 2.2 
p21 protein (Cdc42/Rac) –activated kinase 4 (PAK4) 1.68 
Additional genes not appearing in the KEGG figure   
Collagen, type I, alpha 1 (COL1A1) 3.54 
Collagen, type IV, alpha 2 (COL4A2) 3.51 
Collagen, type IV, alpha 3 (COL4A3) 2.22 
Collagen, type V, alpha 1 (COL5A1) 2.52 
Fibronectin 1(FN1) 1.62 
Myosin light chain kinase (MYLK) 2.35 
Thrombospondin 3 (THBS3) 3.98 
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Addendum: 
The gene microarray data were re-analysed using Benjamini Hochberg’s method to correct 
for multiple testing. The number of genes for which a significant effect on expression was 
observed, following methyl donor depletion reduced to about 4,700 probe genes (P<0.05, t-
test). The number of probe genes for which the differences according to treatment were 
more than a 1.5-fold change was about 3,900, of which 2,193 were down-regulated and 
1,749 up-regulated. The identities of those 3,900 probes were further clustered according to 
biological function using the DAVID software (David Bioinformatics Resource 6.7) again. 
Functional annotation clustering according to biological function revealed 348 clusters of up-
regulated genes and 374 clusters of down-regulated genes (figure 51-52.  
There were 48 clusters of up-regulated genes and 47 clusters of down-regulated 
genes, for which the enrichment score was more than 1.3. Of these clusters seven were 
selected on the basis of a high enrichment score and the biological grouping. These are 
presented in table 11. 
 
Table 11: Summary of selected gene clusters from both up- and down-regulated genes of 
methyl-donor depleted cells (re-analysis with multiple corrections) 
Up-regulation Enrichment score Down-regulation Enrichment score 
Cell death 5.73 Cell cycle 18.4 
Defense response 3.92 
Condensed 
chromosome 
12.75 
Chromosome 
organisation 
3.06 
Cytoskeleton 
organization 
5.97 
Proteolysis 2.96 
DNA metabolic 
process 
5.24 
Epithelial cell 
differentiation 
2.89 
Lipid biosynthesis 
process 
2.92 
Focal adhesion 2.76 Transferase 1.92 
DNA damage 
response, signal 
transduction 
2.17 
Chromosome 
organization 
1.8 
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Figure 51: Example of functional annotation clustering using DAVID Bioinformatics. This 
screen shot shows some clusters from the up-regulated gene list (re-analysis) 
141 
 
 
Figure 52: Example of functional annotation clustering using DAVID Bioinformatics. This 
screen shot shows some clusters from the down-regulated gene list (re-analysis) 
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The result taking account of multiple corrections in re-analysis gave a similar 
outcome to the previous analysis, especially for those gene clusters which were down 
regulated. A few differences in up-regulated gene clusters were observed compared with the 
previous analysis, but the general effect profile was very similar. Moreover, in the new 
analysis gene clusters for epithelial cell differentiation, focal adhesion, blood vessel 
development and regulation of cell migration appeared again in those 48 clusters for which 
the enrichment score was more than 1.3, as was found in the uncorrected data analysis.  
Interestingly, the gene cluster for chromosome organisation appeared to be both up- 
and down-regulated. This suggests chromatin remodelling may be central to effects of 
methyl donor depletion on gene expression, leading to phenotypic changes relevant to 
cancer progression. 
 
5.5 Summary 
 Folate and methionine depletion led to an up-regulation of several genes involved in 
cell death, chromosome organisation, and cell signalling, but a down-regulation of genes 
important for the cell cycle, condensed chromosome, and cytoskeleton organization. The 
results from gene clustering directed us to an interest in signalling pathways leading to cell 
motility, which were the Wnt signalling pathway and focal adhesion. The focal adhesion 
pathway itself also has various signalling complexes. A single specific signal has to work in 
concert with others in order to drive specific cell behaviour and our results have identified a 
focus for further research of the effects of methyl donor depletion on cancer cell behaviour. It 
will be important to validate of the genes of interest to clearly indicate the mechanisms 
driving the specific behaviour of folate and methionine-depleted cancer cells.  
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Chapter 6 Cell Migration 
6.1 Introduction 
 Cell migration and invasion are hallmarks of cancer progression (Hanahan & 
Weinberg, 2011).Cell migration is also a feature of non-pathological states and homeostasis, 
skin renewal, and wound healing (Webb et al., 2005)  
In our study methyl-donor depletion of cervical cancer cells gave rise to an altered 
expression of many genes in the ‘cell motion’ cluster, as defined by DAVID software (see 
chapter 5).  Other studies have also indicated a possible link between methyl donor status 
and the expression of several genes involved in cell migration and invasion. Novakovic et al. 
(2006) reported that folate deficiency in human colon adenocarcinoma cell lines (HCT116) 
induced the up-regulation of integrin beta 1 and integrin alpha 6, but a down-regulation of 
vascular endothelial growth factor (VEGF). VEGF is known to be important in angiogenesis 
by primarily stimulating cell proliferation and cell migration. It is expressed and secreted from 
several tumours during their expansion. Crott et al. (2004) also found a decrease in the 
expression of VEGF in the colonic mucosa of rats fed a folate-deficient diet. This group also 
reported an elevation of E-cadherin (cell adhesion protein) and SMAD-4 (a protein which 
conveys the TGF-β signal from cell surface to nucleus) (Crott et al., 2004). In normal human 
colon cells, NCM356, both these proteins are involved in cell migration, cell invasion, and 
cell adhesion (Crott et al., 2008). In addition, the gene expression profile of lymph node 
micrometastases of invasive cervical cancer cells confirmed the up-regulation of fibroblast 
growth factor and transforming growth factor compared to the primary tumour (Hagemann et 
al., 2007). Although limited, these gene expression studies suggest that cell migration and/or 
invasion might be influenced by methyl donor depletion. 
There is a modest literature describing migration or invasion studies in cells deprived 
of one or more methyl donors. In their study of folate-deficient hepatocellular carcinoma cells 
(SK-Hep-1), WenChun & Huang (2009) demonstrated an approximate 25% inhibition of 
migration which was reversed when the cells were supplied by 100 µM folate, when the 
migration rate increased 1.21-fold (WenChun & Huang, 2009). Cell migration rate was also 
investigated in a methionine-deficient model of gastric tumor cells. Graziosi et al. suggested 
that a decrease of migration was modulated by a methionine-deficient diet (Graziosi et al., 
2013). To my knowledge there have been no studies of cell migration in response to a 
combined folate and methionine-depletion. 
 Migration studies have been carried out in several cervical cancer cell lines. For 
example, SiHa cells were used to investigate effects on the migration rate of silencing MTA1 
(metastasis-associated gene 1), using a wound-healing assay (Rao et al., 2011). After 
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disruption of the gene expression of MTA1, cell adhesion, cell migration and cell invasion 
were decreased. The expression of E-cadherin and p53 were up-regulated by MTA1 
silencing indicating a role for these genes in SiHa cell motility. Sun et al (2011) used the 
cervical cancer cells, CaSki, in order to investigate the effect of overexpressed autophagy-
related gene Beclin1 on cell migration. Using the trans-well migration assay they found that 
VEGF and MMP9 (matrix metalloproteinase-9) expression were down-regulated and that this 
was associated with inhibition of metastasis. This demonstrates the importance of 
angiogenesis and extracellular matrix degradation to cell migration (Sun et al., 2011). Su et 
al. (2013) carried out a study in cervical cells to determine the consequence of knock down 
of DNMT3b in cell migration of HeLa3rd and CaSki by using an Oris Cell Migration Assay 
(Su et al., 2013).They demonstrated that disrupted DNMT3b led to a re-expression of 
PTPRR (protein tyrosine phosphatase receptor type R), which was followed by the inhibition 
of downstream signalling of cell migration. This can be related to our research in which 
DNMT3b was down-regulated in methyl donor depletion. Therefore, the migration rate of 
methyl-donor deficient cervical cells in our model may be altered. However, no study has 
been conducted in C4-II cervical cancer cells.  
 Several different methods have been used to estimate cell migration rate. The basic 
method is a wound healing assay or a scratch assay. This method can be easily set up in 
cell culture ware and therefore, the first choice for our study was the scratch assay. 
  
6.2 Aims 
 To determine whether methyl donor depletion influences cell migration, estimated 
using the scratch assay.  
6.3 Methods 
6.3.1 Cell culture 
 After culturing cells in complete and folate and methionine-depleted media for 
8 days in T75 flasks, C4-II cells were transferred for growth in 96-well plates. Cells were 
plated at various seeding densities ranging from 10,000-500,000 cells/cm2 in order to set up 
the mitomycin C opimisation assay and the scratch assay. We needed 50-70% confluence 
by 24 hours for the mitomycin C optimisation and 100% confluence by 24 hours for the 
scratch assay. In the first place, three-independent experiments were carried out and 
confluence observed to determine the appropriate seeding density. The suitable seeding 
density for mitomycin C optimisation was 50,000 cells/cm2 (~50,000cells/well) and for the 
scratch assay was 100,000 cells/cm2 (~100,000 cells/well). The experiment was set up using 
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100µl culture medium/well for at least 6 replicates for each sample (at least 6 wells). The 
culture period was up to 72 hours after setting up the plate for mitomycin C optimisation. The 
culture period for the scratch assay was 48-72 hours after confluence. 
6.3.2 Mitomycin C optimisation 
 To determine cell migration, in order to avoid confounding from cell proliferation, the 
cells must be treated with mitomycin C (MMC), which is used to stop DNA synthesis. 
However, mitomycin C is very toxic against cell viability, and therefore an optimum 
concentration must be identified to ensure that cells can survive throughout the assay 
period.  The mitomycin C optimisation method was used as described (see section 2.2.15.2). 
Cell proliferation was determined by using the method described (see section 2.2.15.1) at 
24, 48, and 72 hours. The absorbance at 490nm was measured and set the A490 of control 
as 100% cell proliferation. Cell proliferation was determined for mitomycin-treated and 
untreated cells following growth in complete or methyl-donor deplete media. Figure 53 
shows the flow chart of mitomycin C optimisation protocol. 
 
 
 
Figure 53: The flow chart of mitomycin C optimisation protocol 
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6.3.3 Scratch assay 
 The protocol for the scratch assay was followed as described (see section 2.2.15.3). 
Each scratch was visualised under a 4x objective microscope at 0, 24, and 48-hour time 
points. The migration rate was determined by measuring the width of a scratch for 20 areas 
of each scratch by using ImageJ tool and at least 6 technical replicates were determined for 
each sample. The experiment was conducted for at least three-independent cell culture 
batches. The migration rate was calculated as a mean percentage of gap closure of treated 
cells compared with the mean gap width of control (non-mitomycin C-treated F+M+ cells) at 
0 hour. Figure 54 shows the flow chart of scratch assay protocol. 
 
 
 
Figure 54: The flow chart of the scratch assay protocol 
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6.4 Results 
6.4.1 Mitomycin C optimisation 
 Since we are not aware of any publication describing migration of C4-II cervical 
cancer cells, the optimal range of mitomycin C concentration had to be determined in the 
first instance. A broad range of concentrations (0-20 µg/ml) was set up as a single 
experiment to estimate the optimum concentration of mitomycin C and cell proliferation was 
measured after 24 and 48 hours. 
 Figure 55 shows the cell proliferation at 48 hours for cells grown in various 
concentrations of mitomycin C for cells grown in both complete medium, and folate and 
methionine-depleted medium. Results suggested that a concentration of mitomycin C 
greater than 1 µg/ml was toxic to C4-II cells grown in complete medium, therefore, the 
optimum concentration range was thought likely to be 0-1 µg/ml. Cells depleted of folate and 
methionine showed evidence of toxic effects at only 0.5µg/ml of mitomycin C, therefore, the 
optimum concentration range of mitomycin C for these cells was thought to be 0-0.5µg/ml. 
Mitomycin C concentrations of 0, 0.1, 0.3, 0.5, 0.7, and 1.0µg/ml were used for cells grown 
in complete medium. For cells depleted of folate and methionine mitomycin C was used at 
concentrations of 0, 0.1, 0.2, 0.3, 0.4, and 0.5µg/ml. 
 From 3 independent experiments, cells treated with 0.1, 0.3, and 0.5µg/ml of 
mitomycin C continued to proliferate over 72 hours of culture. However, cells grown in 
complete medium appeared to stop proliferation after 48 hours (this was evident at 72hours 
too) when treated with 0.7 or 1.0µg/ml (figure 56). Therefore, a mitomycin C concentration 
of 0.7µg/ml was chosen for the scratch assay experiment. In contrast, cells grown in methyl-
donor depleted medium and exposed to 0.5µg/ml of mitomycin C continued to proliferate 
until 48hours. Because of uncertainty remaining about the optimum concentration to prevent 
proliferation, 3 further replicate experiments were carried out at mitomycin C concentration of 
0.7, 1.0, and 2.0µg/ml for methyl-donor depleted cells. 
After 24 hours, the results showed that no matter which concentration of mitomycin C 
was used proliferation fell by about 20% (figure 57). The cells grown in methyl-donor 
deplete medium appeared to stop proliferating after 48 hours (this was evident at 72 hours 
too) when treated with 0.7 or 1.0µg/ml. At the concentration of 2.0µg/ml, cells also appeared 
to stop proliferating after 48 hours, but started to show signs of cell death before 72 hours. 
Thus, we decided to use 0.7µg/ml, the same concentration used in cells grown in complete 
medium. 
 
148 
 
 
 
Figure 55: The effect of mitomycin C on cell proliferation 
Cells grown in a) methyl-donor replete and b) methyl-donor depleted medium. 
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Figure 56: Mitomycin C optimisation considering the effect on cell proliferation 
a) methyl-donor replete and b) methyl-donor depleted cells over 72 hours 
Each value shows mean of four-independent experiments and error bars show SEM. 
 
0
20
40
60
80
100
120
140
control  0.1  0.3  0.5  0.7  1.0ce
ll 
p
ro
lif
e
ra
ti
o
n
 a
s 
 a
 %
 o
f 
co
n
tr
o
l a
t 
2
4
h
r 
Mitomycin C concentration (µg/ml) 
24hr
48hr
72hr
a) 
0
20
40
60
80
100
120
140
160
control  0.1  0.2  0.3  0.4  0.5
C
e
ll
 p
ro
li
fe
ra
ti
o
n
 a
s
 a
 %
 o
f 
c
o
n
tr
o
l 
a
t 
2
4
h
r 
Mitomycin C concentration (µg/ml) 
24hr
48hr
72hr
b) 
150 
 
 
Figure 57: The effect of mitomycin C on F-M- cell proliferation (repeat) 
The repeat experiment with increase mitomycin C concentration shows the effect of 
treatment on folate and methionine-depleted cells at the concentration of 0.7, 1.0, 
and 2.0 µg/ml 
 
Each value shows mean of three-independent experiments and error bars show SEM. 
  
   
 
 
Figure 58: Scratch wound model 
The pictures show C4-II cells that have been (A) freshly wounded (B) 24 hours after 
wounding, and (C) 48 hours after wounding at which time point cells can be clearly 
seen to have migrated to fill the wound. Dotted lines indicate the edge of the wound 
at 0-hour time point. The migration rate is evaluated at 24- and 48-hour time points 
by determining the reduction of mean gap width. 
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6.4.2 Scratch assay 
 As the scratches were made with a p200 pipette tip, the gap between cells was wide 
enough to investigate gap closure by cell migration over 48-72 hours.  Figure 58 illustrates 
that cell movement was sufficient to close the gap before 72hours, and so an image at the 
72-hour time point was not taken. From the gap width at 0, 24, and 48-hour time point, the 
gap closure was determined as a percentage of the gap width at 0 hours. One-way ANOVA 
with time as factor showed a significant increase in % gap closure with time under all 
conditions (P < 0.003) as expected. One-way ANOVA and post hoc analysis with treatment 
as factor showed no significant effect of methyl donor depletion at either the 24-hour or 48-
hour time points (figure 59).  The methyl donor depleted cells showed no significant 
difference in cell migration rate in comparison with complete cells, also the migration rate of 
the mitomycin C-treated F-M- cells and the mitomycin C-treated F+M+ cells were not 
different. 
Regarding the migration rate, the mitomycin C optimisation was carried out at 50-
70% cell confluence but the scratch assay was carried out at 100% cell confluence. So, we 
were curious to know whether cell proliferation had contributed to gap closure. A further 
experiment was carried out to examine mitomycin C efficiency but this time using cells at 
100% cell confluence.  
Cell proliferation was examined over 72 hours for cells grown in complete or methyl 
donor-deplete medium and exposed to mitomycin C or not. Cell proliferation rate seemed 
unaffected by methyl donor depletion or mitomycin C exposure (figure 60). Cells grown to 
100% confluence showed no further proliferation. Therefore, we were absolutely sure that 
the cell movement to fill the gap resulted only from cell migration. Furthermore, time-lapse 
microscopy was carried out to investigate cell movement in real time and also confirmed 
these findings. 
Time-lapse microscopy was set up with 5x objective bright phase microscopy. The 
cell images were captured every 20 minutes for 48 hours (figure 61). This experiment was 
set up for the observation of cell movement and cell morphology in real time in order to 
confirm that cell migration was occurring. From the observation, the cell movement was 
caused by only cell migration, not cell proliferation, since no cell division was detected. The 
figure 61 shows the images from time-lapse microscopy for cells grown under methyl donor-
replete and methyl donor deplete medium, in the presence or absence of mitomycin C. No 
difference in cell migration rate could be detected between these treatments. 
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Figure 59: The percentage of gap closure of the C4-II cells grown under four 
different conditions 
F+M+, mitomycin C-treated F+M+, F-M-, and mitomycin C-treated F-M-. 
Each value shows mean of five-independent experiments and error bars show SEM. 
 
Figure 60: The effect of mitomycin C treatment on cell proliferation 
 
Measurements were made at 100% confluence of both methyl-donor replete and 
methyl-donor depleted cells. 
 
Each value shows mean of three-independent experiments and error bars show SEM. 
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Figure 61: Scratch wound model from time-lapse microscopy 
The pictures show the frame sequence recorded for C4-II cell migration at 0-, 24-, 
and 48-hr time points (left to right of each row) for (A) F+M+ cells (B) mitomycin C-
treated F+M+ cells (C) F-M- cells, and (D) mitomycin C-treated F-M- cells. Dotted 
lines indicate the edge of the wound at 0-hour time point.  
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6.5 Discussion 
 In order to investigate a functional outcome from alterations in the expression of 
genes involved in cell motion, which we found in the gene microarray study, the scratch 
assay was carried out. The objective was to compare migration rates between methyl donor 
replete and folate and methionine-deplete cells.  
 The scratch assay is a two-dimensional (2D) investigation of cell migration. This 
assay determines the directed movement of the cell on a planar surface (in this case a 
plastic culture plate) without the barrier of fibre network in 3D migration. The whole protocol 
was modified from the wound-healing assay protocol of Rodriguez et al (Rodriguez et al., 
2004) and of Dr Carolyn Staton, Department of Oncology, University of Sheffield (personal 
contact). Since, to our knowledge, this is the first time cell migration has been investigated in 
C4-II cells, the appropriate seeding density for the assay had to be determined at the outset. 
The confluency of the cells is important for mitomycin C optimisation because, at 
hypoconfluency, the usage of mitomycin C becomes limiting at a lower concentration and at 
higher confluency mitomycin C efficiency falls. Furthermore, the scratch assay needs to be 
conducted at 100% confluency to avoid cell movement into the unoccupied space between 
cells rather than filling the gap made from a scratch. 
 Cell proliferation can confound results of the migration assay. Some protocols solve 
this problem by culturing the cells in serum-free medium to arrest or slow proliferation, but 
treatment with an anti-proliferation drug can also be used. Mitomycin C is an antineoplastic 
antibiotic used to stop DNA synthesis in cells by nucleotide alkylation; treated cells will not 
be able to proliferate and may die. An appropriate concentration needs to be selected so as 
to prevent cell proliferation but not cause cell death. The mitomycin C optimisation was set 
up for a broad range of concentrations in the first instance, and a more appropriate narrower 
range for the final experiment. The MTS assay used for the determination of cell proliferation 
in this study is widely accepted. MTS is a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] in a solution with an electron 
coupling reagent-phenazine ethosulfate.This assay is used to determine the number of living 
cells in culture by measuring the quantity of formazan product using absorbance at 490nm, 
which results from cell bioreduction by NADPH or NADH (Berridge & Tan, 1993). The MTS 
assay is an improved version of the MTTassay. 
From a single observation, we have seen that, to maintain healthy cells the 
mitomycin C concentration should not exceed 1.0 µg/ml for F+M+ and not exceed 0.5µg/ml 
for F-M-. However, after setting up the mitomycin C optimisation experiment 0.5 µg/ml 
seemed too low to stop cell proliferation and therefore, a concentration of 0.7 µg/ml of 
mitomycin C concentration was chosen for the scratch assay, for both F+M+ and F-M- cells. 
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Further experiments using cells at 100%confluence also confirmed the absence of cell 
proliferation and therefore it was concluded that gap closure would be due solely to cell 
migration.  
We did not observe any effect of methyl donor status on migration rate. Since the 
protocol resulted in a large variance around a mean for gap closure, regardless of the 
treatment results should be interpreted cautiously. The scratch assay has many advantages 
as reviewed in Hulkower & Herber (2011) such as (1) the assay can be performed using any 
normal laboratory materials, (2) cell movement is in a defined direction which is easy to 
track, (3) the assay can be modified to investigate the cell migration on different extracellular 
matrices (ECMs), and (4) the cell movement and morphology can be observed under the 
microscope at any time point together with the capability of image capturing all through the 
assay period (Vogt, 2010). 
However, the scratch assay also has some disadvantages. The size and shape of 
the assay scratches are difficult to reproduce perfectly from well to well, even in the same 
assay plate. In addition, it is not easy to reproduce equivalent characteristics of cells at the 
edge of the wound because monolayer cell confluence is difficult to standardise (Staton et 
al., 2009), and the area of the wound may be imprecise. This means that cell damage occurs 
unequally between scratches, resulting in imprecision in the damage to the underlying ECM 
(Kam et al., 2008; Staton et al., 2009; Hulkower & Herber, 2011). Figure 58 shows that the 
cells on the left-hand side move faster than cells on the other side. This suggested that even 
in the same well, the cell characteristics around the wound would be different.  
Although we were not able to demonstrate an effect of methyl donor depletion on 
migration of cervical cancer cells others have investigated the role of DNA methylation in 
cervical cell metastasis. Su et al. (2013) found that DNMT3b was overexpressed in the 
highly invasive HeLa3rd and Caski cervical cancer cell lines. They knocked down DNMT3b 
and found that this led to a disruption of cell migration in both cell lines (Su et al., 2013). It is 
important to note that they used the Oris cell migration assay rather than the scratch assay, 
and this is considered to have better reproducibility. They suggested that down-regulation of 
DNMT3b resulted in the demethylation of PTPRR (protein tyrosine phosphatase receptor 
type R) promoter and led to its re-expression. The PTPRR inhibited the MAPK (mitogen-
activated protein kinase) signalling and EMT (epithelial-mesenchymal transition), thus 
disrupting cell migration. A study in DNMT3b-depleted prostate-derived PC3 cells also 
demonstrated a reduction in cell migration, this time using scratch assay (Yaqinuddin et al., 
2008).  
Although we were able to demonstrate a down-regulation of DNMT3b in methyl-
donor depleted C4-II cells this was not associated with altered cell migration characteristics, 
as determined using the scratch assay. 
156 
 
Effects of methyl donor depletion on cell migration may be cell-specific. The 
migration of human umbilical venous endothelial cells (HUVEC) was inhibited by treatment 
with a high concentration of folic acid (10µM)  (Hou et al., 2013). On the other hand, folate-
depleted epithelial colon carcinoma cells (HCT116) showed enhanced cell migration (Wang 
et al., 2012). These two studies suggest that high folate concentration decreases cell 
migration and that migration rate increases in response to folate depletion. Methionine 
deprivation in vascular smooth muscle cells was shown to increase cell migration, both in 
vitro and in vivo (Luo et al., 2012).  In contrast to vascular smooth muscle cells, Graziosi et 
al. (2013) found that methionine-depleted gastric cancer cells showed a decrease in cell 
migration, both in vitro and in vivo (Graziosi et al., 2013).  
It is not suprising that there is some inconsistency in the cell migration literature, 
given the complexity of the process being observed. Cell migration requires the concerted 
action of many molecules important to cell communication and cell adhesion and matrix 
degradation (Friedl & Wolf, 2003). The migration mechanism has been described in detail by 
Lauffenburger & Horwitz (1996). They proposed that the mechanism is initiated by cell 
polarization and a modification of the cell shape induced by protein interaction and 
signalling. Briefly, actin polymerization leads to a change in cell shape into a cylindrical 
finger-like shape (pseudopod).This change in cell shape pushes the cell membrane 
outwards, increasing contact with the adjacent ECM (extracellular matrix), and eliciting 
adhesion molecules and integrins. This stage of migration recruits various signalling 
pathways, both inside and outside the cell. Proteolysis is induced to degrade the ECM 
components,  actin filaments bind to active myosin and form actomyosin contraction and the 
trailing edge of the cell detaches and allows the cell to move (Lauffenburger & Horwitz, 
1996; Friedl & Wolf, 2003). The integrin-ligand interactions, integrin-ligand binding affinities, 
integrin levels, and ligand levels are all important for the migration speed (Palecek et al., 
1997). 
Clearly, cell migration in our depletion model needs to be conducted using other 
methods. We propose that in further studies in this area we would adopt a method which 
gave a precise scratch or wound. For example, an electrical fence (Applied Biophysics) or a 
silicon stopper (Platypus Technologies Inc.) may be used, to create a standardised cell 
exclusion zone. This approach not only gives a similar size and shape of wound, but also 
avoids cell damage from the mechanical scraping. 
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6.6 Summary 
 There was no significant effect of methyl donor depletion on cell migration, using the 
scratch assay. However, it proved difficult to avoid a large deviation around the mean for 
each treatment and it is proposed that further work be carried out using alternative methods.  
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Chapter 7 Discussion and Conclusion 
7.1 Conclusion 
It was hypothesized that methyl-donor deficiency influenced the characteristics of the 
cervical cancer cell lines, C4-II, and SiHa cells. The research to investigate this hypothesis 
can be considered in four parts: development and validation of methyl donor depleted 
cervical cancer cell lines; investigation of the effects of methyl-donor status on global DNA 
methylation, DNMT expression and activity; global gene expression; and determination of 
altered phenotype in terms of cell migration.  
The C4-II and SiHa cell models of methyl donor depletion were characterised by: 
1. A fall in intracellular folate and methionine (measured in C4-II cells only). 
2. Growth retardation in response to folate depletion alone and folate and methionine 
depletion. This occurred earlier in the depletion of C4-II cells than SiHa cells. 
3. An increase in the accumulation of homocysteine in the extracellular medium, in 
response to folate depletion alone or folate and methionine depletion. 
4. Global DNA hypomethylation in C4-II cells in response to depletion of folate and 
methionine.   
5. A decrease in mRNA for DNMT3a and 3b in response to folate depletion and folate 
and methionine depletion in C4-II cells. This effect was reversed following repletion with 
folate and methionine. Effects on DNMT1 are equivocal but folate and methionine depletion 
led to a similar fall in DNMT1 mRNA but this effect was not consistent.  
6. Total DNMT activity was increased in response to folate and methionine depletion in 
C4-II cells, but uncertainties about the quality of the assay temper the interpretation of these 
findings. 
7. A high number of changes in gene expression occurred in response to folate and 
methionine depletion in C4-II cells. This included an upregulation of genes important for cell 
death, cell motion, protein kinase cascade, signal transduction, cell communication, blood 
vessel development, and focal adhesion. Genes were down regulated in clusters important 
for regulation of the cell cycle, condensed chromosome, cytoskeleton organization, DNA 
metabolic process, lipid biosynthesis, and chromosome organization. 
8. Folate and methionine depletion of C4-II cells did not show an effect on cell migration 
this may be due to limitations of the method used.  
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7.2 Discussion 
Methyl donor depleted model of cervical cancer cells 
Two cell lines were selected to develop a methyl donor depletion model. Although 
C4-II is reported to be the most similar to cervical cancer biopsies, in terms of gene 
expression, the C4-II cervical cancer cell line has rarely been used in research. A lot of effort 
and time were spent to cope with the unique characteristics of C4-II cells in order to develop 
the model, and for this reason alone the research described here makes a unique 
contribution to our understanding of cervical cancer. Both C4-II cells and SiHa cells grew 
more slowly as a result of methyl donor depletion, is compatible with the role of folates in 
DNA synthesis and cell proliferation (Jackson et al., 1997), albeit at odds with the high 
proliferative state of cancer cells.  The accumulation of homocysteine in the extracellular 
medium is a reflection of disturbance to the methyl cycle and validation of the functional 
effects of methyl donor depletion (Svardal et al., 1986; Nakano et al., 2005), in both cell 
lines. This meant that further investigations were truly in cells in which methyl donor 
deficiency was shown to have a metabolic impact. Importantly, although the intracellular 
concentration of folate was markedly reduced in response to growth in a folate-deplete 
medium, the concentration of folate in the medium was quite comparable to that in the 
plasma of a moderately deficient person (Ruston et al., 2004), and therefore the model is 
considered to be of moderate deficiency and not severe deficiency.  
Effects of methyl donor depletion on global DNA methylation 
Three approaches were used to determine global DNA methylation. In our 
experience only the flow cytometry approach generated results which were reproducible. 
Inconsistences in the findings of other groups interested in effects of folate or other methyl 
donor depletion on global methylation may be partly due to effects of the different methods 
used (Dahl & Guldberg, 2003). Using the flow cytometry method folate depletion alone led to 
a modest effect on global DNA methylation, on the other hand, folate and methionine 
depletion led to a significant lowering of global DNA methylation level in C4-II cells, but not 
SiHa cells. Results suggest that only folate deficiency alone might not be sufficient to affect 
global DNA methylation (Liu et al., 2010), particularly when the methyl donor choline was 
available in a high concentration, which we found, retrospectively, to be the case in our 
studies. Nonetheless, the modest, but not significant, global DNA hypomethylation did not 
mean that there was no alteration of DNA methylation level in specific genes (Crider et al., 
2012). 
Regarding epigenetic effects, histone methylation is another process known to be 
important for the control of gene expression (Fuks, 2005; Cedar & Bergman, 2009). Even 
160 
 
though we have not investigated the effect of methyl donor deficiency on histone 
methylation, we cannot exclude the possibility of an alteration of histone methylation status. 
It has been reported that dietary methyl donor may influence histone methylation status. For 
example, a study in rats found that choline supplementation during embryogenesis E11-E17 
(embryo age day 11-17) led to an increase in global DNA methylation, DNMT1 gene 
expression, and mRNA and protein expression of histone methyltransferase (Davison et al., 
2009). Moreover, a study in cervical specimens from the pre- and post-fortification period of 
folic acid in USA reported a higher level of Lys-9 histone methylation in high grade cervical 
lesions than low-grade, and, that high-grade stage cervical lesions have a higher level of 
Lys-9 histone methylation in the post-fortification than in the pre-fortification period. This 
suggested that histone methylation effect may be adversely affected  by folic acid fortification 
(Piyathilake et al., 2009).  
Effect on DNA methyltransferase gene expression 
In order to investigate the DNA methylation machinery, DNA methyltransferase 
expression and activity were determined by qRT-PCR and ELISA-based enzyme activity 
assay, respectively. Although this result was not validated, more than 4-independent 
experiments were conducted and the result were very consistent. Furthermore, the findings 
were compatible with microarray data. Folate and methionine depletion affected de novo 
DNA methyltransferases (DNMT3a and 3b) expression more than the maintenance DNA 
methyltransferase (DNMT1). The decrease in gene expression of DNMTs may be causally 
associated with the decrease in DNA methylation level observed in this study. However, the 
higher activity of total DNMTs is not in concordance with the lower gene expression. This 
may be the consequence of post-translational modification to compensate for the lower 
mRNA expression (Jiang et al., 2007a), or may be explained by altered gene expression of 
other components involved in DNMTs function (Robertson, 2001). Finally, the method used 
to measure total DNMT activity has important limitations which may have influenced the 
findings. 
The effects of changes in DNMT expression and/or activity on cancer progression 
are not understood. Cheray et al. (2013), in a mouse glioma model by generating global 
DNA hypomethylation phenotype, suggested that inhibition of DNMT1 by 5-aza-2-
deoxycytidine enhanced tumourigenesis (Cheray et al., 2013). Similarly, Gao et al. who 
studied the effect of DNMT3a on lung tumourigenesis in a mouse model, and Hlady et al. 
who studied the effect of DNMT3b on lymphomagenesis, both suggested that loss of the 
DNMT3 family promotes cancer progression (Gao et al., 2011; Hlady et al., 2012). On the 
other hand, some studies have suggested that the loss of DNMTs inhibited cancer 
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progression. In their study of cervical cancer cell lines, Zhang et al. proposed that silencing 
of DNMT1 could reduce carcinogenesis/cancer progression by re-activation of tumour 
suppressor genes (Zhang et al., 2011).  
Even though animal studies may be more relevant to human carcinogenesis than in 
vitro studies, it is difficult to draw an informed conclusion about the effect of DNMTs 
expression on cancer progression, and more research in this field is warranted. 
Effect on gene expression profile 
Gene expression profiling was investigated using microarray analysis of folate and 
methionine deficient cervical cancer cells compared to replete cells, in order to gain some 
understanding of how phenotype might change in response to methyl donor depletion. Our 
investigation showed a significant alteration of expression in more than 10,000 probe genes. 
For example, the up-regulation of genes involved in cell death and the down-regulation of 
genes involved in the regulation of the cell cycle, which totally supports the observed growth 
retardation in depleted cells. The up-regulation of genes involved in cell communication, 
particularly in the Wnt signalling pathway and focal adhesion, was associated with a 
plausible change in genes involved in the actin cytoskeleton affecting cell motility, and a 
change in expression of signalling genes affecting cell proliferation and cell survival. This 
further supports the observed low proliferation rate in methyl donor depleted cells. Besides 
the important gene clusters mentioned above, there were several altered genes which play a 
role in cancer pathways, such as an up-regulation of Myc, p15, Bcl2, and SMAD3, and a 
down-regulation of E2Fs and JUN. These genes should be investigated further to 
understand overall cancer behaviour in a methyl donor-depleted system. 
Effects on cell migration 
Since the gene microarray results showed an up-regulation of genes involved in cell 
motion, cell migration rate was investigated in folate and methionine depleted cells in 
comparison to control cells. Several protocols have been used in the investigation of cell 
migration, but in the first instance, we set up the scratch assy. Although many groups use 
the scratch assay it became clear that this assay has important limitations. For example, the 
assay needs a very precise scratch, which is difficult to reproduce.  The poor reproducibility 
cast doubt on the value of the results. It is difficult to be confident about the null findings of 
an effect of methyl donor depletion on cell migration and this is an area that should be 
investigated further.  
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Effect of methyl donor depletion on cancer progression 
 Folate/methyl donor status is altered by lifestyle factors including dietary/supplement 
intake, medication, and genetic variants in individual one-carbon metabolism enzymes 
(Thuesen et al., 2010). The major methyl donors available from food are methionine 
(~10mmol of methyl group/day), 5-methylTHF (~5-10mmol of methyl group/day), and choline 
(~30mmol of methyl group/day) (Niculescu & Zeisel, 2002). In terms of dietary intake the 
prevalence of isolated deficiencies of methionine or choline is quite rare (Rogers, 1995). 
However, perturbing the metabolism of one methyl donor can affect another, therefore, 
indirect deficiency of methionine and choline may occur.  
Regarding the effect of folate/methyl donor status on cancer, it has been stated that 
folate plays a role as a double edged sword (Kim, 2006; Lucock & Yates, 2009). In normal 
cells, folate deficiency leads to DNA instability and aberrant DNA methylation which is key to 
carcinogenesis. However, once the cancer is developed or in the pre-cancerous stage, folate 
plays a role in an adverse way by promoting cancer cell proliferation. Although our results 
suggest that folate depletion or combined folate and methionine depletion may have benefits 
for the cancer patient by inhibiting cancer cell proliferation, the effect on cancer progression 
is still unclear. As methyl donor depletion led to an up-regulation of genes related to cell 
communication, cell motion, and blood vessel development in our combined folate and 
methionine-depleted model, cancer cells may become more aggressive under methyl donor 
deficiency. This suggests that although the cervical cancer cells we studied showed a 
decreased proliferation rate in response to folate and methionine-depletion, this might not 
stop cell differentiation or metastasis.  
Limitations 
Most of the limitations of the studies are a result of time and cost constraints.  
1. The effect of folate depletion alone could not be investigated in all experiments such 
as in the gene microarray experiment because of cost limitations. This meant that it was not 
possible to diffierentiate the effects of folate deficiency alone from the combined depletion. 
2. DNMTs gene expression using qRT-PCR was not evaluated. In order to understand 
DNA methylation machinery, it will be necessary to validate the mRNA result. The correlation 
between transcriptional level (mRNA) and translational level (protein) are not always straight 
forward (Guo et al., 2008). Therefore, it is important that protein expression is measured 
using Western blotting. 
3. The method used to determine total DNMTs activity is not considered robust, and an 
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alternative method should be sought. The activity of individual DNMTs should be measured. 
4. Since microarray measures a large number of gene expressions, a false positive or 
negative is unavoidable. The gene expression profile from microarray result should be 
validated using RT PCR or any other method in order to confirm whether the microarray 
method worked perfectly. 
 
Future work 
In order to build on the findings of the results described here the following studies are 
proposed.  
1. DNMTs gene expression using qRT-PCR should be evaluated by western blot to 
determine protein expression. 
2. The regulation mechanism of DNMTs should be investigated. For example, the 
expression of activator or repressor of DNMTs may be useful. 
3. Candidate genes could be chosen from the findings of the microarray study to further 
validate effects on gene expression.  qRT-PCR would be used, or another method such as in 
situ hibridization.  
4. Specific methylation of target genes should be examined in order to determine 
whether alteration of gene expression resulted from aberrant DNA methylation.  
5. Effects on gene expression should be interrogated in more depth. For example, 
pathway analysis should be considered in more depth and a proteomic study might be 
considered. 
6. Cell behaviour in the methyl donor depleted model should be examined again 
including the determination of cell migration rate using a more satisfactory protocol. Other 
functional effects in addition to cell migration should also be investigated. 
7. The intracellular choline concentration should be examined since choline is another 
methyl donor and the interaction between folate, methionine, and choline deficiency should 
be determined. 
8. Besides the effect of methyl donor on DNA methylation, histone methylation may be 
another response which would also contribute to changes in gene expression. Therefore, 
determination of histone methylation may be conducted to provide some information about 
the effect of methyl donor on gene expression. 
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